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Chapter 1
The acute ischemic limb
Limb ischemia occurs when blood flow to a limb is not sufficient to meet its demand, 
for instance when a thrombus occurs in an artery. The thrombotic occlusion of the 
artery leads to insufficient blood flow, causing hypoxia of the tissue and in a later 
stage depletion of nutrients necessary to maintain cellular function.
Limb ischemia may be acute or chronic, depending on duration of symptoms before 
presentation. We talk about chronic limb ischemia when symptoms exist for over 2 
week and we classify this according to Fontaine into 4 categories: the mildest being 
asymptomatic and the most severe consisting of loss of tissue (table 1).





Intermittent claudication > 200m
Intermittent claudication < 200m
Stage III Ischemic rest pain
Stage IV Necrosis / gangrene
Limb ischemia is considered acute when symptoms exist for less than 2 weeks. In 
case of acute limb ischemia, tissue loss might not be visible yet. Severe pain in rest 
and loss of function are the most frequently presenting symptoms. Other symptoms 
might include discoloration and / or a lower temperature when compared to the 
contralateral side (table 2). The yearly incidence of acute lower limb ischemia 
varies between 9 and 26 per 100.000 persons3-5. Upper limb ischemia accounts 
for another 1.2-3.5 cases per 100.000 persons6,7.
Although limb ischemia is caused by insufficient blood flow, the severity of it is 
strongly influenced by the duration of symptoms. In ischemic conditions, cells will 
switch to an anaerobic metabolism. Cellular pH will decrease due to production of 
lactate. At the same time, a decrease in ATP will cause a dysfunction in ATPase-
dependent ion transport mechanisms. Fluid will enter the cell, leading to edema 
and eventually rupture of the cell membrane. Another effect of ischemia is an 
increase in intracellular calcium and with it the production of proteases that can 
further damage tissue. The longer ischemia persists, the more tissue will be lost, 
and the more byproducts of ischemic metabolism will be present. After restoration 
of blood flow, reperfusion will initially exacerbate injury to the tissue. This is called 
the ischemia-reperfusion injury. Once blood flow to the limb is restored, reactive 
oxygen species (ROS) will be generated and a cascade of (systemic) inflammatory 
and thrombogenic processes will be triggered. Locally, these processes will cause 
13
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further disruption of the cellular structure and cell death. Endothelial dysfunction 
will cause more leakage of fluid leading to edema and reactive vasoconstriction8.
Table 2. Classification of acute ischemia according to Rutherford2






I Viable Limb not 
immediately 
threatened
None None Audible Audible
II Threatened
























Acute peripheral arterial occlusion leads to loss of the effected limb in 10-30% 
of cases9. And not just limb-threatening, ischemia is also life threatening. Thirty-
day mortality in acute lower limb ischemia is reported to be between 15 and 
20%10. Detrimental factors are both the ischemia and the reperfusion, but also 
complications of treatment and time to intervention. In a study by Kendrick et al, 
mortality rates increased from 15 to 48% when surgical treatment was delayed 6 
hours11.
Current standard of care
There is a trend in etiology of acute limb ischemia. Where earlier reports, from 
the 1980s, show an embolic origin of the arterial occlusion in up to 81% of cases, 
this pathology has decreased in later studies to 14%12-14. In the remaining 86% 
of cases, acute limb ischemia is caused by thrombosis occurring in arteries with 
pre-existing peripheral arterial disease, in bypasses or in a peripheral arterial 
aneurysm. With the changing etiology of acute limb ischemia and advancing 
medical technology, comes a paradigm shift in standard of care. More and more, 
traditional surgical treatment is reserved for patients with an acute embolic event, 
whereas less invasive endovascular interventional techniques are used for acute 




IIa and b, showed that only 13% of patients had received traditional open surgical 
revascularization15. In comparison, a study by Eliason et al in treatment of acute 
lower extremity ischemia between 1992 and 2000, showed 47.3% of patients 
received surgical embolectomy16.
The most frequently used endovascular intervention for acute peripheral arterial 
thrombosis is intra-arterial catheter directed thrombolysis. First introduced by 
Verstraete et al in 1963, catheter directed intra-arterial thrombolysis became part 
of standard care during the 1990s17. A catheter is placed at -or through- the site of 
the arterial occlusion and fibrinolytic medication is continuously infused locally in 
order to dissolve the thrombus (fig. 1). Repeated angiography shows the status of 
the lysis and possible underlying pathology. This therapy has the benefit of being 
minimally invasive with less or no surgical trauma. The fibrinolytic medication 
can reach even the smallest vessels, minimizing loss of outflow. There is no need 
for general anesthesia and once the clot has dissolved, angiography shows the 
underlying pathology which can then be addressed in the same session.
Figure 1. Intra-arterial catheter-directed 
thrombolysis.
The skin is punctured and a sheath (teal) is 
placed in the right common femoral artery. 
The intra-arterial catheter (dark blue) guides 
the infusion of the fibrinolytic agent to the 
site of the occlusion. After the clot (dark red) 
has dissolved, the underlying atherosclerotic 
lesion (yellow) can be addressed.
15
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Although thrombolytic therapy is minimally invasive, it still requires puncture of the 
skin and artery for placement of the intra-arterial catheter. Furthermore, it takes 
time to dissolve a clot using a fibrinolytic agent, while prognosis is strongly related 
to time. During treatment, patients must adhere to a hospital bed, adding to the 
burden for the patient. The therapeutic aspect of fibrinolytic agents, to dissolve 
clots, also carries risks. Major bleedings occur in 8,9% of patients and the most 
feared complication, intracranial hemorrhage, occurs in 1-2.8% of patients18,19. 
There is a strong correlation between the risk of complications of thrombolysis 
and the duration of infusion. In a summary of evidence by van den Berg, the risk of 
complications was 4% if fibrinolytic therapy had a maximum duration of 8 hours. 
This increased to 34% at a duration of 40 hours19.
Possibilities for improvement of current standard of care
Minimal invasive techniques for revascularization in acute peripheral arterial 
occlusion have clear benefits for the patients, however, there is still ample room 
for improvement. A better prognosis for both limb and life can be expected, should 
we be able to decrease time to reperfusion of the limb. The burden of treatment 
for patients with acute limb ischemia is another factor that might be improved. 
If we can negate the need for an intra-arterial catheter, patients would not have 
to be bedridden during treatment and skin puncture would only be necessary 
for placement of an intravenous catheter. Reducing risks of fibrinolytic therapy, 
especially risk of hemorrhage, is another possible improvement.
In 1995, Tachibana et al introduced the use of ultrasound contrast agents and 
ultrasound for thrombolysis20. They found that the presence of ultrasound 
contrast agents induced acceleration of thrombolysis by ultrasound in an in-vitro 
setting. Ultrasound contrast agents consist of gas-filled microbubbles. They are 
approximately 1-5µm in diameter, slightly smaller than an erythrocyte (6-8µm), 
and can freely pass the capillary bed. Under influence of ultrasound, microbubbles 
start to oscillate (fig. 2). When the ultrasound pressure gets high enough, the 
microbubbles will destabilize and eventually burst, causing microstreams in the 
surrounding fluid. When oscillation and/or implosion of microbubbles is induced 
in the vicinity of a clot, this leads to shear stress to the surface of the clot (fig. 3). 
Not only does this directly lead to erosion, but the larger surface area of the clot 




Figure 2. Under influence of positive and negative pressure waves induced by the ultra-
sound beam, the microbubble will start to oscillate: it will be alternatingly compressed and 
stretched. Higher pressure waves will lead to collapse of the microbubble.
17
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 a.  b.
 c.  d.
Figure 3. Mechanics of thrombolysis using microbubbles and US.
a. Thrombus has lodged itself in an artery and microbubbles have been administered; b. An 
US probe is directed at the site of the thrombus; c. High mechanical index US causes the 
microbubbles to burst, leading to erosion of the thrombus surface; d. The thrombus has 
dissolved and blood flow has been restored.
So microbubbles can accelerate thrombolysis when influenced by ultrasound. 
But microbubbles have other interesting properties that could help improve on 
standard catheter directed thrombolysis. They can be used as a vehicle to transport 
drugs such as a fibrinolytic agent. This can be achieved by loading drugs into the 
microbubble or attaching them to its surface membrane. The possibility to attach a 
drug to the surface of the microbubble also gives us the option to give microbubbles 
a target to adhere to. We can target microbubbles to adhere to thrombus by 
attaching Arg-Gly-Asp-Ser, the recognition and binding site of platelet membrane 
glycoprotein 2b/3a receptor, to its outer layer23(fig.4). And in recent years, it has 




Figure 4. Non-targeted vs targeted microbubbles 
a.
Microbubbles follow the blood flow and can be destroyed once they reach the area of the 
clot. If they are not destroyed, they will continue following the flow.
b.
After following the blood flow, microbubbles that are targeted to adhere to the platelet 
membrane glycoprotein 2b/3a receptor will cluster at the site of the clot.
19
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Rationale and aims of this thesis
Thrombolysis using a combination of microbubbles, ultrasound and a fibrinolytic 
agent is called contrast-enhanced sonothrombolysis (CEST). Several studies 
investigated the benefit of CEST in a setting of acute ischemic stroke or myocardial 
infarction, but precious little has been published on the use of CEST for peripheral 
arterial thrombosis. This thesis focuses on different aspects of CEST that might 
improve treatment for patients with an acute ischemic limb. To give an idea of 
the current situation and gain some insight into the extent of the problem, we 
retrospectively reviewed our clinical results with standard intra-arterial catheter-
directed thrombolysis and gave an overview of the current status of CEST in acute 
peripheral arterial thrombosis in a systematic review. We investigated different 
aspects of microbubbles and different protocols for CEST in a laboratory setting: 
Firstly, we added microbubbles and ultrasound to standard catheter directed 
thrombolysis, as this might accelerate thrombolysis. We continued our experiments 
using microbubbles as a carrier for a fibrinolytic agent, as this might one day negate 
the need for an intra-arterial catheter. And thirdly, we investigated CEST using the 
EkoSonic™ Endovascular System (EKOS; Boston Scientific, Marlborough, USA). This 
system uses an intra-arterial catheter that helps to physically disrupt thrombus 
by applying local ultrasound. We tested what effect this catheter might have on 
intra-arterially infused microbubbles and whether the combination of the two 
would improve thrombolysis without a need for external ultrasound. The findings 
of these preclinical trials were translated to a safety and feasibility study on the 
use of microbubbles and ultrasound in standard catheter-directed thrombolysis 




Outline of the thesis
Chapter 1 provides an insight into the clinical problem and the issues accounted 
when treating the condition of acute limb ischemia.
The first part of this thesis focuses on the current situation and what is known 
about CEST in peripheral arterial occlusion, In chapter 2, we investigate protocols 
currently in use for fibrinolytic therapy and explore their risks and benefits. A 
systematic review of the current literature on therapeutic use of microbubbles in 
acute peripheral arterial thrombosis is given in chapter 3.
The second part of this thesis gives the results of our pre-clinical studies.
In chapter 4 we present an animal model for investigating different fibrinolytic 
therapies. This model is implemented in chapters 5, 6 and 7, where we explore 
the therapeutic use of ultrasound contrast agents in fibrinolytic therapy and the 
possible benefits that can be gained when adding these agents to the current 
standard of care.
The third part of this thesis focuses on CEST in a clinical setting. In chapter 8, 
chapters 5, 6 and 7 are translated to a clinical study, where we propose a model 
for microbubble and ultrasound enhanced thrombolysis in setting of peripheral 
arterial thrombosis. In chapter 9 we present the results of this clinical trial.
Chapter 10 summarizes the thesis, provides a general discussion, and reflects on 
the findings in respect to clinical practice as well as gives suggestions for further 
investigations.
Chapter 11 is a Dutch summary of the thesis.
21
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To evaluate the efficacy and bleeding complications associated with a low-dose 
thrombolysis protocol for thromboembolic lower extremity arterial occlusions.
Design
A retrospective cohort study.
Materials and methods
A retrospective analysis was performed using data from all consecutive patients 
who underwent catheter-directed, intra-arterial thrombolysis for thromboembolic 
lower extremity arterial occlusions between January 2004 and May 2013. All 
patients were treated on a standard surgical ward. Endpoints were incidence 
of bleeding complications, duration of thrombolysis, angiographic patency rate, 
30-day mortality rate and amputation-free rate at 6 months.
Results
Of the 171 cases analysed, 129 cases underwent low-dose thrombolysis and 
42 cases underwent high-dose thrombolysis. No major bleeding complications 
occurred in the low-dose group vs. 5% in the high-dose group (P=.01). The median 
duration of thrombolysis was 67h (4-304h) in the low-dose and 49h (2-171h) in the 
high-dose group (P=.027). Angiographic patency was restored in 67% of the cases 
in the low-dose group vs. 79% of the high-dose group (P=.17). The 30-day mortality 
rates were 1% in the low-dose vs. 5% in the high-dose group (P=.09). However, this 
higher mortality rate was not related to bleeding complications. Major amputation-
free rates at 6 months were 81% in the low-dose group and 88% in the high-dose 
group (P=.22).
Conclusions
Based on this data series, low-dose thrombolysis for thromboembolic lower 
extremity arterial occlusions is as effective as high-dose thrombolysis. By contrast, 
the risk of major bleeding complications is substantially lower when using low-dose 
thrombolysis.
31
Low-dose thrombolysis for thromboembolic lower extremity arterial occlusions
Introduction
Prior to the 1990s, the standard treatment for acute leg ischemia was surgical 
thromboembolectomy. The publication of several prospective randomized trials 
in the 1990s showed that thrombolysis might represent an effective alternative to 
primary surgical intervention1-2. Since these landmark trials, a consensus has been 
reached that thrombolysis can be viewed as a first-line treatment for many cases of 
thromboembolic lower extremity arterial occlusion3-5. While a range of fibrinolytic 
agents and a variety of dose protocols have been used for thrombolysis6, most 
studies have reported results of urokinase (UK) at doses of more than 100 000 
IU/h, together with varying doses of heparin. These studies reported major 
bleeding rates ranging from 6% to 13%, including 2% intracranial bleeding, and 
minor bleeding complications in 5% to 17% of patients1,2,7,8. Overall success rates 
for high-dose thrombolysis are reported to be around 70% (Table I).
Before 2011, a low-dose thrombolysis protocol consisting of a 500 000 IU UK 
intra-arterial bolus, followed by continuous infusion of 50 000 IU UK/h and 4 
800 IU of heparin per 24 hours was routinely used in our university hospital. In 
mid-2011 this protocol was replaced by a high-dose protocol (100 000 IU UK/h 
and 9 600 heparin/24h). Two factors triggered this decision: a nationwide survey 
on thrombolysis practice revealed that most Dutch hospitals use high-dose 
protocols, and our successful use of a high-dose protocol during a clinical trial to 
evaluate ultrasound-accelerated thrombolysis compared to standard thrombolysis. 
However, the safety and effectiveness of high-dose thrombolysis was called into 
question in our hospital following two incidents of major bleeding complications in 
rapid succession. This was the rationale underlying our decision to retrospectively 
evaluate thrombolysis success rates and bleeding complications of both our low- 
and high-dose thrombolysis protocols.
Materials and methods
This retrospective analysis included data from all consecutive patients who 
underwent thrombolysis for thromboembolic occlusions of native arteries or 
bypass grafts distal to the aortic bifurcation in the period January 2004-May 2013. 
We have acquired approval of the institutional ethics review board. The results 
for patients treated with low and high-dose protocols were analysed separately.
Clinical and outpatient records, radiological reports, surgeons’ and nurses’ reports 
were all reviewed. Patients were excluded on the basis of a thromboembolic 
occlusion directly caused by an endovascular intervention and when treated 
with an EKOS EndoWave infusion catheter system9, since patency rates, lysis 
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complications are probably influenced by this new thrombolysis technique. We 
followed recommendations in the literature and defined occlusions in patients with 
symptoms of less than 14 days duration as acute and those with symptoms of 14 
days or more as non-acute2.
In our hospital, thrombolysis is only performed as a primary treatment for suspected 
thromboembolic peripheral arterial occlusions in patients with viable extremities, 
i.e. not in immediately threatened limbs (Rutherford IIb/III) or in patients without 
evident pre-existing arterial occlusive disease presenting with hyperacute 
ischemia suggesting an embolic cause. Contra-indications for thrombolysis were 
active internal bleeding, recent (<10 days) surgery or trauma, recent (<1 month) 
peptic ulcer or gastrointestinal bleeding, oesophagus varices, recent (<3 months) 
intracranial bleeding, intracranial tumor, aneurysm or malformation, recent (<1 
month) cardiopulmonary resuscitation, thrombocytopenia (<150×109/L) and 
coagulation disorders. After ipsilateral antegrade puncture or contralateral 
retrograde puncture under ultrasound guidance, an intra-arterial thrombolysis 
catheter (Royal Flush High-Flow, Cook Medical®, Amsterdam, the Netherlands) 
was advanced via a guide wire and placed into the proximal end of the thrombus 
or as close as possible. The standard thrombolysis protocol consisted of a 500 000 
IU UK (Medac GmbH, Hamburg, Germany) lacing dose, followed by continuous 
infusion of 50 000 IU/h UK. A continuous dose of 4 800 IU/24h of heparin was 
infused through the side-port of the sheath to prevent peri-catheter clotting. After 
thrombolysis, patients were routinely heparinized and oral anticoagulant treatment 
was started.
In the second half of 2011, the low-dose protocol was changed to a high-dose 
protocol for reasons mentioned earlier. This protocol consisted of a 500 000 IU 
UK lacing dose, followed by continuous infusion of 100 000 IU/h UK together with 
a continuous heparin dose of 9 600 IU/24h, i.e. a doubling of continuous doses of 
urokinase and heparin. Decisions regarding follow-up angiographies, continuation 
of therapy and additional procedures were made by a dedicated team of vascular 
surgeons and interventional radiologists. The number of follow-up angiographies 
per 24h depended on the severity of ischemia and progression of thrombolysis. 
Patients were routinely treated on a standard surgical ward. All nurses and clinical 
residents involved in treatment underwent extensive training and had both paper 
and electronic access to the thrombolysis protocol at all times.
Haemoglobin (Hb), thrombocytes, Activated Partial Thromboplastin Time (APTT, 
normal range 25-40s), Prothrombin Time measured as International Normalized 
Ratio (INR, normal range 0.80-1.20) and fibrinogen levels (normal range 200-400 
mg/dL) were monitored daily. In cases with a fibrinogen level below 100 mg/dL, the 




level dropped below 50 mg/dL, UK infusion was stopped and the catheter perfused 
with NaCl 0.9%. After a period of 3h the fibrinogen level was checked again and 
therapy was continued if the fibrinogen level had recovered to >100 mg/dL. 
During therapy, aspirin was continued but no coumarines, low molecular weight 
heparins or intravenous heparins were administered. The handing of patients with 
coumarines/warfarin use pre-lysis included pro-thrombin time (INR) monitoring 
at the moment of admission. When pro-thrombin time was supratherapeutic 
(INR>3.5) patients received vitamin K and therapy was initiated when INR<2.5. 
After thrombolysis patients were routinely heparinized and oral anticoagulant 
treatment with coumarines was started concomitantly with a target INR range 
2.5-3.5.
Thrombolysis was considered successful when angiographic patency was restored, 
i.e. restoration of luminal continuity without significant residual thrombus. Intra 
and retroperitoneal bleeding, intracranial bleeding and all bleeding complications 
requiring blood transfusion or invasive procedures were considered potentially 
life threatening and therefore categorized as major bleeding complications. Minor 
bleeding complications were defined as bleeding at any other site not requiring 
blood transfusion or invasive treatment.
The data were analysed using SPSS (IBM Statistics v20, Chicago, IL, USA). A Mann-
Whitney-U test or an unpaired Student’s t-test was used to compare continuous 
variables with (non) parametric distributions. A Chi-square test was used to 
compare proportions between groups. P-values <.05 were considered statistically 
significant.
Results
During the inclusion period, thrombolysis was performed for 276 cases of lower 
extremity arterial occlusions in 199 patients. A total of 171 cases were included, 
129 cases in 103 patients treated with low-dose thrombolysis and 42 cases in 29 
patients treated with high-dose thrombolysis. Reasons for exclusion are described 
in Figure 1. Characteristics of included patients and occlusions are summarized 
in Tables II and III, respectively. Baseline and occlusion characteristics were not 
significantly different between groups.
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Age -(in years, mean ±SD) 64 (±12) 64 (±10) .94
Sex –(% male) 57 67 .29
Vascular history – (%) 77 86 .38
Cardiac history – (%) 35 31 .75
Current tobacco use– (%) 57 61 .70
Hypertension – (%) 77 83 .37
Hyperlipidaemia – (%) 81 86 .47
Diabetes – (%) 23 36 .11
Tissue necrosis at hospital admission– 
(%)
14 10 .12
Duration of symptoms -(in days, mean 
±SD)
8 (±11.8) 8 (±11.9) .29







Acute 102 (79) 31 (74) .48
Non-acute 27 (21) 11 (26)
Native artery 69 (53) 17 (40) .14
 Bypass graft 60 (47) 25 (60)
Venous graft 14 (23) 5 (20) .29
Prosthetic graft 45 (75) 19 (76)
Combined graft 1 (2) 1 (4)
Location occluded 
segment
Aorto-iliac 24 (19) 13 (31) .18
Femoral 73 (56) 23 (55)
Popliteal 24 (19) 3 (7)
Crural 8 (6) 3 (7)
Acute is defined as occlusion with symptoms existing less than 14 days. Non-acute is defined 




Treatment characteristics and results
Treatment characteristics of both groups are summarized in Table IV. The median 
duration of thrombolysis was 67h (range 4-304h) in the low-dose vs. 49h (2-171h) in 
the high-dose group, P=.027, and the median frequency of follow-up angiographies 
was 1.0 (0.3-2.3) vs. 1.5 (1.1-4.0) per 24h, P<.001. Angiographic patency was 
restored in 87 cases (67%) in the low-dose vs. 33 cases (79%) in the high-dose 
group (P=.17). For the low-dose group, success rates increased in the second half 
of the inclusion period: in the period 2004-2007 patency was restored in 57% of 
the cases vs. 77% in the period 2008-2011 (P=.02).






Treatment duration – (in h, median + range) 67 (4-304) 49 (2-171) .03
Total UK dose - (in million IU, mean ± SD) 4.7 (±3.1) 6.1 (±3.8) .02
Angiography frequency – 
per 24h, median + range)
1.0 (0.3-2.3) 1.5 (1.1-4.0) <.001
APTT - (in s, mean ± SD) 59 (±30) 65s (±52) .29
INR - (ratio, mean ± SD) 1.5 (±0.4) 1.7 (±0.6) .04
Fibrinogen - (in mg/dL, mean ± SD) 264 (±114) 204 (±65) .002
Technical success rate – (%) 99 100 .75
Patency rate – (%) 67 79 .17
Major bleeding complications – (%) 0 5 .01
Minor bleeding complications – (%) 5 7 .39
30-day mortality rate – (%) 1 5 .15
6 months amputation-free rate – (%) 81 88 .32
The median period of admission of all patients was 9 days (2-147 days). Patients 
successfully treated with thrombolysis had a significantly shorter in-hospital stay, 
independent of dose regimen, than patients in whom thrombolysis failed; 8 (2-82 
days) vs. 13 days (2-147 days), respectively (P=.001).
Success rates of thrombolysis for all cases were higher (although still non-
significant) for acute compared to non-acute occlusions; 73% vs. 61% respectively 
(P=.14). However, the median duration of symptoms in patients successfully treated 
with thrombolysis compared to non-successfully treated patients was significantly 
shorter at 3 days (0-67 days) vs. 7 days (0-60 days), respectively (P=.006). The 
success rates of thrombolysis for occluded native arteries and bypass occlusions did 
not differ (70% vs. 71%), and thrombolysis of prosthetic bypasses was significantly 
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more successful than thrombolysis of venous bypasses at 77% vs. 53%, respectively 
(P=.04). All of the above outcome parameters were independent of dose regimen. 
Univariate analysis showed that a variety of factors including history of vascular 
interventions, cardiac history, diabetes, smoking, hyperlipidaemia and hypertension 
did not significantly influence thrombolytic success.
Figure 1. Excluded cases; values presented are cases.
Complications
Although no major bleedings occurred in the low-dose group, minor bleeding was 
noted in 6 cases (5%) and included bleeding at the puncture site in 5 cases and 
haematuria in a single case. Two of these six cases developed a groin haematoma, 
which led to the premature abortion of thrombolytic therapy. Other complications 
included delirium (2 cases), compartment syndrome of the leg (2), pseudoaneurysm 
formation (1), ischaemic stroke (1) and temporary kidney failure (1).
Two cases with major bleeding complications occurred in the high-dose group, 
including one case with intracranial bleeding and one with intra-abdominal 
bleeding. These cases resulted in a major bleeding complication rate of 5% in the 
high-dose group vs. 0% in the low-dose group (P=.01). The high-dose group also 
included 3 minor bleedings (7%), with bleeding at the puncture site, vs. 6 cases (5%) 
in the low-dose group (P=.39). Pseudoaneurysm formation of the femoral artery 




Follow-up of low-dose cases
Of the 87 cases successfully treated with low-dose thrombolysis, 42 (48%) 
underwent an additional percutaneous intervention and 8 (9%) underwent 
an additional surgical intervention (revision of bypass anastomosis, lumbar 
sympathectomy, toe amputation or below knee amputation) within the period of 
admission. The causes for unrestored patency in the remaining 42 cases were no 
or marginal lysis in 33, initial lysis followed by direct reocclusion in 4, abortion 
of therapy due to complications in 3 (catheter luxation due to a fall out of bed in 
1 case, groin haematoma in 2 cases), technical failure (not possible to advance 
catheter) in 1 and non-compliance in 1 case. In 21 cases without restored patency, 
surgical revascularization was attempted (thromboembolectomy in 11 and bypass 
surgery in 10 cases; 5 of these cases underwent additional major amputation within 
30 days) and direct major amputation was performed in 12 cases. One patient 
refused further treatment and in the remaining 8 cases, despite lack of restoration 
of patency in the target artery, thrombolysis resulted in clinical improvement and 
the patients could return home without any additional intervention.
Follow-up of high-dose cases
Of the 33 cases successfully treated with high-dose thrombolysis, 11 (33%) 
underwent an additional percutaneous intervention and 3 (9%) underwent an 
additional surgical intervention (revision of bypass anastomosis, toe amputation). 
In the high-dose group, 9 cases showed unrestored patency due to causes including 
no or only marginal lysis in 6, abortion of the procedure due to complications in 2 
and initial lysis followed by direct reocclusion in 1 case. Major amputation followed 
for 4 of these 9 cases, and 2 cases underwent thromboembolectomy. Although 
patency of the target artery was not restored in 2 cases, thrombolysis resulted in 
clinical improvement and the patients could return home without any additional 
intervention. Finally, one patient underwent a second course of thrombolysis 
treatment.
Follow-up comparisons
Rates for 30-day mortality and remaining amputation-free for 6 months were 
not significantly different between low vs. high-dose groups, 1% vs. 5% and 81% 
vs. 88%, respectively (P=.09 and P=.22). In the low-dose group, the death of one 
patient was due to (pre-existing) heart failure, while one patient in the high-dose 
group died from (pre-existing) heart failure and a concomitant refusal of further 
therapy. An additional patient died two weeks after hospital discharge in good 
condition due to a traumatic subdural haematoma complicated by renal failure.
Laboratory values
Although the mean APTT values over the whole treatment period did not differ 
between groups (low vs. high) at 59 seconds (s) (±30s) vs. 65s (±52s) (P=.29), the 
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mean INR in the high-dose group was significantly higher at 1.5 (±0.4) vs. 1.7 (±0.6), 
(P=.04). Mean fibrinogen levels were also significantly higher in the low-dose group 
compared to the high-dose group, 260 (±110) vs. 200 (±60) mg/dL, respectively 
(P=.002). All cases with major and minor bleeding complications showed fibrinogen 
levels >100 mg/dL, and APTT and INR were within normal ranges on the day of the 
bleeding complication.
The APTT exceeded 60s at least once within the treatment period in 67% of the 
cases in the low-dose group vs. 55% in the high-dose group, indicating therapeutic 
treatment ranges despite the low-dose intra-arterial heparin administration. 
Furthermore, 51% of the cases in the low-dose group vs. 48% in the high-dose 
group showed an INR >2.0 at least once within the treatment period, indicating 
that INR levels were also within therapeutic ranges. Fibrinogen levels dropped 
below 100 mg/dL in 12% of the cases in the low-dose group (13 of 16 within the 
first 24h of therapy) and in 21% of the cases (4 of 9 within the first 24h of therapy) 
in the high-dose group. 2% of the cases in the low-dose group showed fibrinogen 
levels of ≤50 mg/dL vs. 7% in the high-dose group.
Discussion
An evidence-based guideline on optimal urokinase and heparin doses for the 
thrombolysis of thromboembolic peripheral arterial occlusions has not been 
produced to date. High-dose urokinase protocols are frequently used but are 
accompanied by high rates of major (6-13%) and minor (up to 17%) bleeding 
complications1,2,7,8. While the success rate of low-dose thrombolysis in the present 
study was comparable to the success rates of high-dose studies published in the 
literature (Figure 2A), the most significant finding in our study was that we achieved 
comparable angiographic patency rates without major bleeding complications 
(Figure 2B). Interestingly, our results using low-dose thrombolysis also improved 
over time, from 61% patency in the period 2004-2008 to 79% in the period 
2009-2013 (P=.03), while baseline and occlusion characteristics remained stable. 
This improvement may be attributable to improved radiological skills. Overall, 
thrombolysis in prosthetic grafts was more successful than in venous grafts (77% 
vs. 53% respectively, P=.04), a finding also reported by several other studies10,11. 
This again raises the question of whether initial thrombolysis is the best therapy 
for occluded vein grafts.
Similar rates of major bleeding complications were observed in our high-dose 
thrombolysis group when compared to literature, once again emphasizing the 
increased bleeding risk associated with treatment with higher doses of fibrinolytics 




the 2% mortality rate reported by Cragg et al. but lower than the 4% reported for 
the STILE trial2,8. The TOPAS trial did not report 30-day mortality rates.
Figure 2. Comparison of results with literature: (A) success rates, amputation-free rates at 
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The low rate of bleeding complications in our low-dose group can be explained by 
the low-dose infusion of urokinase, as well as by the low-dose of the concomitantly 
administered heparin. Which of these factors contributes most to the favourable 
outcome cannot be determined from the present study. Despite the intended 
subtherapeutic intra-arterial administration of heparin to prevent peri-catheter 
clotting, APTT levels were within therapeutic ranges in the majority of patients at 
least once within the treatment period. This may be due to the potential synergistic 
effects of urokinase and heparin12,13. The concomitant use of unfractionated 
intravenous heparin during thrombolysis remains controversial14,15. In the TOPAS 
trial, the use of intravenous heparin (intended APTT 1.5-2 times the control 
value) was aborted after treatment of 62 patients, when the safety monitoring 
committee identified an unacceptably high rate (4.8%) of intracranial bleeding1. The 
initial requirement for therapeutic doses of systemic heparin was abandoned and 
replaced by subtherapeutic amounts of heparin, administered through the arterial 
sheath. This resulted in a drop in the rate of intracranial bleeding to 0.5%, suggesting 
a significant link between the co-administration of intravenous therapeutic doses 
of heparin and the risk of major bleeding. Another drawback of heparin use is the 
possible induction of heparin-induced thrombocytopenia thrombosis (HITT), which 
is rare but is associated with a high morbidity and mortality16. To our knowledge, 
a randomized trial of thrombolysis with and without concomitant heparin 
administration has not been performed. The necessity and safety of concomitant 
heparin infusion, whether intended as therapeutic or as subtherapeutic to prevent 
peri-catheter clotting and potential thrombus propagation, is questionable and 
should be further investigated.
The clinical use of laboratory tests during thrombolysis is controversial17. Although 
fibrinogen depletion was identified in the STILE trial as a risk factor for bleeding 
complications during thrombolysis with urokinase2, a lack of other randomized 
controlled trials in the literature means that this is still an isolated finding. In our 
study, fibrinogen levels of patients with bleeding complications were all >100 mg/
dL on the day of occurrence.
In the present study and in other studies, angiographic patency, i.e. restoration 
of luminal continuity, was used to define success of thrombolysis1,2,7,8,18. However, 
despite restoration of luminal continuity of the target artery, poor distal run-off 
might result in early reocclusion and thus hamper clinical improvement and indicate 
failed treatment. The opposite - clinical improvement without successful lysis of 
the target artery - might also occur and could be explained by lysis of a thrombus in 
important collateral or outflow arteries, leading to relief of ischemia. In 5% of our 
cases angiographic blood flow was restored but no clinical improvement was found, 




or major amputation). By contrast, in 4% of the cases clinical improvement was seen 
without restoration of luminal patency in the target artery.
In our study, thrombolysis was continued as long as progression of lysis was 
observed on follow-up angiographies, without clinical deterioration demanding 
a change of therapy. The median duration of therapy in the low-dose group was 
nearly 3 days. Other studies have described protocols that stop thrombolytic 
treatment at defined points such as 7, 24, 36 or 48h1,2,7,8, although reasons for this 
strict discontinuation of thrombolysis at predefined time points were not reported. 
The relatively long duration of therapy in our study might be partly explained by the 
lower dose of urokinase. Furthermore, the frequency of follow-up angiographies 
might also influence therapy duration, with a higher frequency potentially resulting 
in earlier cessation of therapy. With the protocol change in 2011 with higher 
doses of urokinase we expected faster reperfusion. We anticipated on this with 
more frequent treatment evaluation with angiographies to prevent unnecessary 
overnight continuation of thrombolysis and thereby an unnecessary higher risk on 
haemorrhagic complications. Despite the longer therapy duration in the low-dose 
group, which might also influence limb salvage, the 6-month amputation-free rate 
of 81% comparable to that reported in the literature1,2,7,8 (Figure 2A). ‘
Duration of ischemia is another factor that might influence success of thrombolysis 
and risk of major amputation. The STILE investigators found a non-significant trend 
towards an advantage for surgery compared to thrombolysis in the combined death 
and amputation outcome (9.9% vs. 17.8%; P=.08) in the group with symptoms lasting 
more than 14 days. However, in the group with symptoms of less than 14 days 
duration thrombolysis performed significantly better than surgery, 15.3% vs. 37.5% 
respectively (P=.01)2. This resulted in guidelines advising thrombolysis only for 
recent occlusive events, defined as symptoms lasting for a maximum of 14 days17. 
The patency rates of thrombolysis in the present study were (non-significantly) 
higher for acute compared to non-acute occlusions, 73% vs. 61% respectively 
(P=.14). In addition, patients successfully treated with thrombolysis compared to 
non-successfully treated patients had a shorter history of symptoms, 3 vs. 7 days, 
respectively (P=.006). In our data series, thrombolysis was successful in 5 out of 
8 cases with occlusions with a duration of 1 month or longer. Patients with long-
lasting occlusions who are unfit to undergo surgical intervention might therefore be 
considered candidates for thrombolysis. Additionally, as more than half of patients 
receiving thrombolysis in the STILE trial underwent reduced surgical procedures2, 
thrombolysis might reduce the magnitude of additional interventions.
Potential bias could have been introduced by the comparison of non-
contemporaneous groups. However, as time progressed patency results of low- and 
high-dose thrombolysis became more similar and we do not think the difference 
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in time could influence the higher risk on haemorrhagic complications with higher 
doses of urokinase. Although a limitation of this study remains the retrospective 
study design, we consider this study relevant due to the lack of available evidence 
for an optimal thrombolysis protocol and regimen for peripheral arterial occlusions 
and a high incidence of major haemorrhagic events.
Finally, due to the absence of major bleeding complications, performing low-dose 
thrombolysis on a general surgical ward appears to be safe. With an increasing 
number of patients undergoing thrombolysis, this option could reduce the logistic 
burden on special care units and might also lower the costs of therapy.
Conclusion
Based on our data series, low-dose thrombolysis for thromboembolic lower 
extremity arterial occlusions appears to be as effective as high-dose thrombolysis. 
In addition, low-dose thrombolysis results in a substantially lower risk of major 
bleeding complications.
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Catheter-directed thrombolysis (CDT) for acute peripheral arterial occlusion 
is time consuming and carries a risk of major hemorrhage. Contrast-enhanced 
sonothrombolysis (CEST) might enhance outcomes compared to standard CDT. 
In this study we systematically review all in vivo studies on contrast-enhanced 
sonothrombolysis in a setting of arterial thrombosis. A systematic search of the 
PubMed, Embase, Cochrane Library and Web of Science databases was conducted. 
Two reviewers independently performed the study selection, quality assessment 
and data extraction. Primary outcomes were recanalization rate and thrombus 
weight. Secondary outcome was any possible adverse event. The 35 studies 
included in this review were conducted in 4 different (pre)clinical settings: ischemic 
stroke, myocardial infarction, (peripheral) arterial thrombosis and arterio-venous 
graft occlusion. Due to high heterogeneity among the studies, it was not possible 
to conduct a meta-analysis. In almost all studies, recanalization rates were higher 
in the group that received a form of CEST. One study was terminated early due 
to a higher incidence of intra cranial hemorrhage. Studies on CEST suggest that 
adding microbubbles and ultrasound to standard intra-arterial CDT is safe and 
might improve outcomes in acute peripheral arterial thrombosis. Further research 
is needed before CEST can be implemented in daily practice.
Key words
Peripheral arterial thrombosis, microbubbles, thrombolysis, ultrasound, contrast-
enhanced sonothrombolysis
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Introduction
Peripheral arterial disease represents an affliction in which one or more non-
coronary arteries are partially or completely occluded leading to compromised 
blood flow and eventually ischemia (Morcos et al. 2018). With rare exceptions, 
atherosclerosis remains the most common underlying pathology of this affliction. 
The estimated number of people that are affected ranges from 30-200 million 
worldwide (Morcos et al. 2018; Yurtkuran et al. 2013). Peripheral arterial disease 
in an advanced stage can cause acute limb ischemia (ALI), usually due to a thrombus 
that completely occludes a blood vessel. ALI is a life-threatening condition that 
may result in amputation or even death. Advancing age, chronic kidney disease 
and diabetes are all known risk factors for development of atherosclerosis. With 
an aging world population and a rising incidence of both chronic kidney disease 
and diabetes, peripheral arterial disease - and with it ALI - is likely to dramatically 
increase in the near future (Falluji and Mukherjee 2014). Rapid treatment is 
essential to restore blood flow to the extremity (Santistevan 2017).
In the majority of cases of ALI, treatment will consist of catheter-directed 
thrombolysis (CDT), with only a small percentage of patients (13,1% in a study by 
Davis et al, 2018) still needing primary surgical revascularization. With CDT, an 
intra-arterial catheter is guided to the site of the occlusion and used to administer 
the thrombolytic agent locally. Although CDT has the benefit of being minimally 
invasive, procedures are time consuming, expensive and carry a risk of major 
bleeding (Falluji and Mukherjee 2014). Current thrombolytic therapy is effective 
in many cases, but a simpler, safer and non-invasive treatment is urgently required 
to improve on patient outcomes and lower the burden for both the patient and the 
healthcare system. A new treatment currently being researched, is the addition of 
ultrasound-induced microbubble cavitation to standard CDT (sCDT), i.e. contrast-
enhanced sonothrombolysis (CEST) (Unger et al. 2014). Microbubbles (MB), also 
known as ultrasound contrast agents, oscillate and collapse under the influence of 
ultrasound (US). The oscillations and cavitation cause highly energetic micro flows 
near the thrombus, thereby destructing the (surface) structure of the thrombus. 
This leads to a greater exposure of thrombus surface to the lytic agent and 
consequently can accelerate thrombolysis. Another development in CEST is the 
ability to load the microbubble with a lytic agent, such as tissue plasminogen activor 
(tPA) or urokinase. In addition, the arginine-glycine-aspartic acid-serine peptide 
(RGDS) can be added to the surface of the microbubble as a targeting ligand for 
thrombus (Nederhoed et al. 2017). Both developments might increase the efficacy 
of CEST even further, as the MB will adhere to the surface of the thrombus and 
the lytic agent can be released locally. Moreover, these factors might also reduce 
bleeding risks and cost of the treatment. CEST holds a considerable promise for 




conducted on recanalization using microbubbles and ultrasound, however, their 
therapeutic use in peripheral arterial thrombosis has only been reported in a few 
studies (Ebben et al. 2015; Nederhoed et al. 2017). As very little research has been 
done on CEST in the setting of peripheral arterial thrombosis, we investigated the 
effectiveness and safety of CEST in any setting of arterial thrombosis, excluding 
articles on microvascular arterial thrombosis. The main objective of this systematic 
review is to give an overview of all relevant in vivo studies on the subject of CEST 
in arterial thrombosis and to raise awareness on the possibility of CEST amongst 
specialists treating acute peripheral arterial thrombosis. Our primary outcomes 
are recanalization rate or thrombus weight. Our secondary outcome is any adverse 
event that might be related to the given treatment.
Materials and methods
Search strategy and selection criteria
This study was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA)-statement (Liberatie et al. 2009). 
To identify all relevant publications on the therapeutic use of microbubbles in 
peripheral arterial thrombosis, three authors (one of whom an experienced 
research librarian) systematically searched the bibliographic databases PubMed, 
Embase, the Cochrane Library (via Wiley) and Web of Science for publications 
up to February 3, 2020. Search terms expressing ‘microbubbles’ were used in 
combination with search terms comprising ‘thrombosis’ and both controlled terms 
(MeSH in PubMed and Emtree in Embase) as well as free text terms (The Cochrane 
Library) were used. After the initial search, title and abstract of all citations were 
independently screened by two of the authors. Included were all studies that 
investigated therapeutic use of microbubbles and ultrasound in arterial thrombosis 
in an in vivo setting (human or animal) and that reported the outcome measures 
recanalization rate and / or thrombus weight. There were no limitations on language. 
Articles were excluded if they did not report original data, only consisted of case 
reports or where the full text was not available. As the focus of this review is CEST 
in peripheral arterial thrombosis, we also excluded articles where the therapeutic 
US was not directed at the occluded vessel, but at the outflow territory. All articles 
were screened for statements on approval of a local ethics committee, adherence 
to guidelines for animal care and/or obtaining informed consent. As articles that 
had no such statement might still contain valuable data this was not used as an 
exclusion criterion, but an annotation was added in the results section. For the 
complete search strategy see the appendix.
Quality assessment
Quality assessment of the included studies, was done independently by the two 
previous mentioned authors, using the SYstematic Review Centre for Laboratory 
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animal Experimentation (SYRCLE) tool for animal studies, the Methodological 
Index for Non-Randomized Studies (MINORS) criteria for non-randomized studies 
in humans and the Cochrane Risk of Bias tool for randomized trials in a clinical 
setting (Hooijmans et al. 2014; Slim et al. 2003; Sterne et al. 2019). Disagreements 
between the 2 reviewers were resolved via consensus meetings.
Data extraction
Two authors extracted the data following a pre-defined schedule that included: 
study design, subject studied (human or animal), number of subjects, location and 
duration of arterial thrombosis, type of microbubble used, dosage of microbubbles, 
site of injection (intravenous or intra-arterial), type of fibrinolytic agent used 
including dosage and site of injection, ultrasound settings, duration of therapy given, 
outcomes on recanalization rate and/or thrombus weight as well as on possible 
adverse events. When looking at the recanalization rate (primary outcome), the 
method for determining recanalization was noted as was the definition of successful 
recanalization. Mortality and intracranial hemorrhage (ICH) were scored separately 
in the possible adverse events (secondary outcome), as well as whether or not the 
ICH was symptomatic (sICH). Treatment protocols that combined the use of MB, 





8260 Records identified through 
database searching 
(Pubmed 3018, Embase 2507, 
Cochrane Library 127, Web of 
Science 2608) 
6953 Records after duplicates removed 
6953 Records screened 
on title and abstract 
148 Full-text articles 
assessed for eligibility 
113 Full-text articles excluded 
79 Not an original article 
11 Wrong outcomes 
6 Wrong intervention 
5 Wrong setting 
4 Wrong indication 
7 Duplicate 
1 Wrong study design 
6805 Records excluded 
35 Studies included in 
qualitative synthesis 
0 Additional records identified 
through other sources 
Figure 1. PRISMA flow diagram
Results
After removal of duplicates, 6953 records were identified for screening. Based 
on our inclusion and exclusion criteria, 35 studies were included in this review: 26 
preclinical and 9 clinical trials, 3 of which were randomized. See fig1 for the PRISMA 
flow diagram and table 1 for an overview of the selected studies.
Quality assessment
Table 2 shows the results of the quality assessment. The preclinical studies 
all suffered from risk of bias due to problems in allocation generation and/or 
concealment. Baseline characteristics were unclear in most of these trials and -save 
for 1 study- caregivers and investigators were not blinded to the treatment given. 
Most studies did not report on the housing of the animals, but since these were 
short experiments this would have a minimal impact on the outcomes of those 
studies.
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The preclinical models for arterial thrombosis that were used, were created to 
approximate four different clinical settings: ischemic stroke (n=8), myocardial 
infarction (n=4), arterial thrombosis (n=8) and arterio-venous graft occlusion (n=6). 
The clinical trials comprised 2 clinical settings: ischemic stroke (n=8) and acute 
myocardial infarction (n=2). There was a high heterogeneity in the selected studies. 
They not only varied in type of subject used for the experiments and in location of 
thrombus formation, but also in type of microbubbles used, the injection site of the 
microbubbles (intravenous or intra-arterial), duration of experiments, ultrasound 
settings, whether a fibrinolytic agent was used and if so, which fibrinolytic agent, 
the injection site of the fibrinolytic agent used, the method for monitoring outcomes 
and definition of success. It was therefore not possible to perform a meta-analysis 
on any of the predefined outcomes.
Primary outcomes
Recanalization rate
Definition of successful recanalization varied between the studies. Some defined 
success as (a variation of) any indication of flow in the previous occluded artery 
(10 studies), some used a complete return of flow or used varying degrees of TIMI 
(thrombolysis in myocardial infarction ) /TIBI (thrombolysis in brain ischemia) or 
TICI (thrombolysis in cerebral infarction) scores (table 3) .
In the preclinical trials, twelve studies investigated a combination of microbubbles, 
ultrasound and a fibrinolytic agent (CEST). In 10 of the 12 studies, the rate of 
recanalization using CEST was higher than in any other tested arm (table 4a1). 
In the other 2 studies the recanalization rate was similar to the best results in 
another arm tested. One of these, the study by Tomkins et al. (2015), was the only 
study where no recanalization was found in the 10 occlusions studied with the 
combination of MB, US and a fibrinolytic agent. The investigators used platelet 
rich clots that seem to be highly resistant to thrombolysis in general. The other 
study that showed similar recanalization rates for CEST and the best compared 
alternative, was the study by Laing et al. (2012). They compared the thrombolytic 
effect of CEST to that of thrombus-targeted, tPA-loaded echogenic liposomes and 
found a comparable recanalization rate of 60% in both treatment arms.
The maximum recanalization rate in the groups combining MB, US and a fibrinolytic 
agent (CEST), excepting the study by Tomkins et al, varied between 56 and 100% 
(table4a2). In contrast, studies investigating the possibility of arterial recanalization 
using microbubbles alone (n=2) found 0% (0/6 and 0/10) recanalization rate. The 
effect of ultrasound alone, was investigated in 13 studies. Recanalization rates 
varied from 0% (5 studies) to 63% in the study by Gao et al. (2014 ; 5/8 occlusions, 




pulse duration of 5µS. Ten studies tested the use of a fibrinolytic agent alone. 
The recanalization rate reported in these studies varied between 0% (2 studies) 
and 50% (1 study), with the majority of the studies reporting recanalization rates 
between 40 and 50% (6/10). The combination of US and a fibrinolytic agent, tested 
in 4 studies, showed recanalization rates between 20 and 50%. The combination of 
MB and a fibrinolytic agent, without addition of US, was only tested in the trial by 
Laing et al. (2012), previously mentioned. The protocol that was most frequently 
compared to CEST (17 studies), was the combination of US and MB. Looking at the 
39 different protocols investigated in these 17 studies, recanalization rates varied 
from 0 (2 study arms)to 100% (5 study arms). The best recanalization rates of these 
studies varied between 29 and 100%.
Of the 12 preclinical trials that tested a form of CEST, only 2 administered the 
fibrinolytic agent intra-arterially as is common in sCDT for peripheral arterial 
thrombosis. The first of these was the study by Laing et al. (2012), mentioned 
previously. Their definition of success, was a return to at least 95% of baseline 
flow and they found a recanalization rate of 60% for both the group with echogenic 
liposomes and the high MI US CEST group. Ebben et al. (2015) studied sCDT vs 
CEST in a porcine model of peripheral arterial thrombosis. They found a median 
increase in flow of 27% in the CEST group and 0% in the sCDT group. If the same 
definition of success is used as in the study by Laing et al. (2012), their recanalization 
rate in the CEST group is 33% versus 0% using sCDT.
Clinical trials concerning CEST were performed in patients with ischemic stroke 
(8 studies) and myocardial infarction (1 study) (table 4b). There was a higher 
recanalization rate of the affected artery in the CEST group in all trials where 
CEST was compared to standard care in either another study arm or in previously 
reported data. All clinical trials investigated the use of an intravenous fibrinolytic 
agent as part of their thrombolytic therapy. Only Ribo et al. (2010) investigated 
CEST using intra-arterial tPA when recanalization did not occur with intravenous 
tPA alone (n=7 out of 16 patients) or when there was a contra-indication for 
intravenous thrombolysis (n=2). They found in-procedure recanalization in 7 of 
these 9 patients (2 complete, 5 partial).
Perren et al. (2008) compared the effect of MB combined with a 2-MHz transcranial 
color-coded duplex (TCCD) and intravenous tPA (n=11) vs the TCCD and tPA alone 
(n=15) in patients with acute MCA stroke. They found complete recanalization 
rate in 7 out of 11 patients in the CEST group (64%) at 1 hour treatment, vs 8 out 
of 15 in the control group (53%). They found a significantly greater improvement 
in clinical outcome in the CEST group vs the control (p = 0.05). In the study by 
Dinia et al. (2009), 188 stroke patients that received CEST were compared with 
a historic group of 98 stroke patients that received tPA + transcranial Doppler 
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(TCD). They found significantly higher recanalization rates in the CEST group at all 
measurement windows (p < 0.05) as well as a higher proportion of patients achieving 
independency at 3 months in the CEST group versus the control group (51 vs 37%; 
p=0.052). In the TUSCON (Transcranial Ultrasound in Clinical Sonothrombolysis) 
trial by Molina et al. (2009), the aim was to test the safety, tolerability and activity 
of various doses of perflutren lipid MB combined with TCD and i.v. tPA. It was a 
multicenter randomized trial that was terminated early due to safety issues (see 
secondary endpoint section). A total of 35 patients were randomized: 12 received 
1,4ml of MB with TCD and tPA, 11 received 2,8ml of MB, and 12 received tPA with 
only brief TCD assessment (control group). Sustained complete recanalization at 
the end of the treatment, was 67% for the 1,4ml CEST group, 46% for the 2,8ml 
CEST group and 33% in the control group (p = 0.255). Functional independence 
at 3 months was 75% in the 1,4ml CEST group, 50% in the 2,8ml CEST group and 
36% in the control group (p = 0.167).
One study compared 2 different MB (galactose-based air-filled vs sulphur 
hexafluoride based) combined with tPA and TCD in 138 MCA stroke patients 
(Rubiera et al. 2008). There were no differences in recanalization rate or clinical 
outcome. Slikkerveer et al. (2012) conducted a pilot safety and feasibility study 
of low dose tPA combined with US and MB prior to PCI in patients with acute 
myocardial infarction. All patients (n=10) received a single bolus of 50mg tPA in 
the ambulance. At presentation at the ER, they were randomized to either receive 
1 vial of perflutren-containing lipid MB and high MI, short pulse duration US or a 
placebo. After 15 min, all patients underwent an emergency coronary angiogram 
and - when necessary - intervention. At angiography, 3 out of 5 patients in de CEST 
group had TIMI flow III versus 1 out of 5 in the control group (p = 0.23).
Thrombus weight
Only two studies reported on thrombus weight as outcome of the therapy, Ebben 
et al. in 2015 and Nederhoed et al in 2017. In the first study, standard intra-arterial 
CDT was compared to intra-arterial CDT enhanced with intravenous microbubbles 
and locally applied ultrasound. CEST resulted in a significant lower thrombus weight 
at the end of therapy in this study (1.1g vs 1.6g; p = 0.01). In the second study, the 
microbubbles were loaded with urokinase and targeted to thrombus by adding 
RGDS to the microbubble surface. The targeted, urokinase-loaded microbubbles 
were administered intravenously and high MI ultrasound (MI 1.1) was applied 
at the sight of the occlusion. This form of CEST was compared to intravenously 
administered urokinase, combined with the same regimen of ultrasound. Thrombus 
weight at the end of therapy was significantly lower in the CEST group (0.94g vs 





Out of the 26 preclinical studies, 11 did not report safety outcomes. Of the 15 
studies that did report safety outcomes, only 4 found possible adverse events: 
Ebben et al. (2015) reported 1 distal embolization in the group that received 
microbubbles. Wu et al. (2015) found histologic evidence of focal hemorrhage 
in the infarct area in 3 out of 18 pigs, but there was no difference in incidence 
between the groups. Tomkins et al. (2015) reported 2 incidences of subarachnoid 
hemorrhaging due to incorrect catheter placement and 1 catheter dislodgement. 
Finally, Nederhoed et al. (2017) reported 1 re-occlusion during therapy in the CEST 
group, possibly due to distal embolization.
In the clinical studies, the main adverse event reported was intracranial hemorrhage 
(table 5). Some studies only reported on symptomatic, i.e. clinically important ICH. 
The TUSCON trial was a prospective randomized multicenter phase II trial of MB 
dose escalation combined with systemic thrombolysis in patients with ischemic 
stroke (Molina et al. 2009). The aim was to include 72 patients (48 targets and 24 
controls), but the study was terminated after 35 inclusions due to a higher incidence 
of sICH in the 2,8ml MB dose group (3/11 patients in this group, vs 0/12 in the other 
2 groups; p =0.028). There was no incidence of sICH in the 12 patients receiving 
the first tier of the dose escalation study, i.e. 1,4ml of MB.
The only other adverse events were reported by Slikkerveer et al. (2012), who 
tested the feasibility of treatment with low dose thrombolytics in combination with 
ultrasound and microbubbles prior to primary percutaneous coronary intervention 
in patients with a first acute ST-elevation myocardial infarction. They reported 
2 incidences of minor leakage at the injection site of the catheters, 1 in each 
treatment arm of the study, and 1 non-sustained ventricular tachycardia in each 
treatment arm.
Discussion
This systematic review highlights a number of positive outcomes in terms of 
efficacy and safety of CEST, but a lot still remains unknown. Studies suffer from 
low numbers, lack of randomization, differences in CEST protocols including 
variation in US settings, location of arterial thrombosis, duration of therapy and 
fibrinolytic agent used. Studied outcomes and mode to determine outcome, as well 
as definition of success varied widely across the studies. Therefore, comparisons 
among the studies are challenging, and conclusions on what protocol of CEST would 
be best for our patient with acute peripheral arterial occlusion are difficult to draw. 
Despite the heterogeneity of the included studies, of the preclinical trials only 1 
study showed no recanalization in any of the treatment arms and in 1 study, US did 
not seem to have an influence when thrombus-targeted echogenic liposomes were 
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used. In all other preclinical studies where CEST was investigated, recanalization 
rates were higher than in any of the control arms. All clinical trials that compared 
CEST to standard care, whether in their study or in previously reported data, show 
a higher recanalization rate of the affected artery in the CEST group. Where clinical 
outcomes are reported, they are better than in the standard group. This was even 
true for the study arm of the TUCSON trial that received the 2,8ml dose of MB 
and had a higher incidence of ICH (Molina et al. 2009).
Although there were few adverse events reported that might be attributed to 
the addition of microbubbles and ultrasound to standard thrombolysis in the 
included studies, adverse events have been reported in other studies. Roos et al. 
(2016) reported an unexpected high incidence of coronary vasoconstriction in 
their study on the role of sonolysis for reducing microvascular injury in patients 
with myocardial infarction. In this study, patients with acute myocardial infarction 
received an intravenous infusion of the MB Definity at 1,3ml/min. Diagnostic 
ultrasound (MI=0,18) was used to guide therapeutic high-MI, long pulse duration 
ultrasound (MI=1,3, pulse duration 20µs) to the site of the myocardial perfusion 
defect. The treatment was given for a maximum of 15 minutes prior to PCI, during 
which diagnostic and therapeutic US regimens were alternated at the rate of 
15s per imaging mode. The inclusion target for this safety and feasibility study 
was set at 20, but the trial was aborted after 3 of the first 6 included patients 
showed vasoconstriction unresponsive to nitroglycerine in the affected artery 
on angiography. None of the patients that showed vasoconstriction, suffered any 
lasting noticeable effects. A subsequent study by the authors using a porcine model 
for acute myocardial infarction, showed a decrease in coronary artery diameter 
distal to the injury site after application of ultrasound. The authors conclude that 
long-pulse-duration ultrasound might cause coronary vasoconstriction distal to 
the culprit vessel location. In a study by Mathias et al. (2019), 100 first-STEMI 
patients were randomized to either receive short pulse-duration (<5µs) high MI 
US directed at different myocardial segments combined with infusion of Definity or 
only very low MI diagnostic US combined with Definity. They found a significantly 
higher pre-PCI recanalization of the infarct vessel in the high MI US group (24/50 
vs 10/50; p<0.001) and reported no adverse events. This supports the theory that 
the vasoconstriction found in the study by Roos et al. might have been due to the 
long pulse-duration US. Since affected vessels in peripheral arterial disease have 
a larger diameter and tissues distal to the affected vessels are more resilient to 
ischemic conditions, possible temporary vasoconstriction due to ultrasound is not 
expected to cause a clinical problem in the setting of peripheral arterial thrombosis.
Future perspectives
This systematic review was conducted to assess the safety and efficacy of CEST 




we added all in vivo studies that tested a form of CEST in combination with an 
arterial thrombosis. This lead to the current overview, where most studies are 
conducted in a setting of small cerebral or coronary artery occlusions. Although 
we cannot extrapolate the data directly to patients with peripheral arterial disease, 
this overview gives us direction to where we might go with future studies and 
-hopefully- with improving treatment for our patients. For future clinical studies, 
we would suggest infusing the MB and applying local US during the first hour of 
treatment, as this seems to already achieve success in many of the trials in this 
review. A longer duration of US would burden both the patient and the care system. 
Furthermore we would suggest US with a high MI of around 1 and switching 
between ‘on’ and ‘off’ settings every few seconds, to allow the MB to re-enter the 
area of the thrombus. We have conducted the MUST-trial, a clinical safety and 
applicability trial for contrast-enhanced sonothrombolysis in acute peripheral 
arterial thrombosis, using these settings (Ebben et al. 2017). Inclusion has just 
finished and preliminary data show promising results without major complications 
(Evers et al. 2019). We need to wait for definitive data, however, to draw more solid 
conclusions. Another aspect to take into account when determining US settings 
for clinical use of CEST, is the vasoconstriction mentioned previously when a long 
pulse duration US was used. This might not be a problem with peripheral arterial 
occlusion, but use of a short pulse duration of <5µs can be explored. Depending 
on the definitive results of the MUST trial, a large multicenter randomized trial 
comparing standard intra-arterial CDT and CEST will be set up in the near future. 
End points will include time to reperfusion of the affected limb, major and minor 
amputations, duration of hospitalization and any adverse event with emphasis on 
intracranial hemorrhage. Long term follow up is needed to detect any possible long 
term side effects of the experimental treatment. For the more distant future, aims 
might not only include a better clinical outcome and shorter hospitalization times, 
but also an even less invasive treatment for the patient with the acutely ischemic 
limb. As discussed before, MB can be used as a vehicle for medication. They can be 
targeted to adhere to thrombus and with the most recent developments they can 
now also be directed magnetically (Chen et al. 2019). Combining these attributes, 
it seems a catheter-free intra-arterial form of thrombolysis might very well be 
possible in the future. More research is needed however, before these theories 
can be translated to a clinical setting. As mentioned previously we excluded 
articles where the therapeutic US was not directed at the occluded vessel, but at 
the outflow territory. The reason for not including studies that focused on outflow 
territory, is that the focus of this review is on revascularization of the ischemic limb 
using CEST and it does not seem feasible to treat the arterial occlusion by directing 
therapeutic ultrasound at such a large outflow territory that is also far away from 
the occlusion. Treating the microvasculature in peripheral arterial occlusion with 
a combination of microbubbles and US might still be beneficial though. Several 
studies reported on a better microcirculatory perfusion after using MB, which 
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could help in prevention of no-reflow phenomenon after revascularization of an 
acutely ischemic limb (Leeman et al. 2012; Xie et al. 2009b). We speculate that MB 
might also play a role in diabetic foot ulcers, as a loss of microcirculation is one of 
the main contributing factors for both the development of ulcers and the difficult 
healing process after macro vascular optimization of blood flow.
Conclusion
Studies on contrast-enhanced sonothrombolysis show promising results with 
regard to recanalization rate and clinical outcome in acute arterial thrombosis. It 
was not possible to perform a meta-analysis due to the high heterogeneity among 
the studies. Nonetheless, data suggest that adding microbubbles and ultrasound 
to standard intra-arterial catheter-directed thrombolysis might be a safe way to 
improve outcomes for patients with acute peripheral arterial thrombosis. More 
research on safety and applicability in a clinical setting is needed before it can be 
implemented in daily practice.
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Table 1. Overview of included trials




To investigate the enhancing 
effect of MB on the in 
vivo recanalization rate of 
thrombotically occluded 
rabbit iliofemoral arteries by 
transcutaneous US exposure
DDFP emulsion significantly 
enhances the clot-disrupting 
effect of low frequency US
Birnbaum
 1998*
To examine the efficacy of 
arterial clot disruption by a 
noninvasive, nonlytic approach 
with intravenous administration 
of perfluorocarbon-exposed 
sonicated dextrose albumin 
(PESDA) and transcutaneous 
delivery of US alone
In vivo arterial clot dissolution 
can be achieved with intravenous 




To develop a method to declot 
full-size arteriovenous dialysis 
grafts using intravenous 
perfluorocarbon-exposed 
sonicated dextrose albumin 
(PESDA) MB and low frequency 
ultrasound (LFUS)
Direct injection of PESDA with 
transcutaneous LFUS succeeds 




To examine the effectiveness of 
different ultrasonic frequencies 
in recanalizing thrombosed 
vessels in a simple attenuation 
model
Transcranial and transthoracic 
US in the presence of 
intravenous MB can improve 
flow to ischemic regions
Culp
 2003
To demonstrate utility of FDA-
approved MB for arteriovenous 
graft declotting, establish 
efficacy levels, and assess US 
parameters inclucing intensity 
and wave-mode applications for 
this purpose
LFUS with direct injection of MB 
is effective in lysing moderate-
sized clots and recanalizing 
thrombosed arteriovenous 
grafts. It best succeeds at the 
higher range of intensity settings 
tested in PW mode.
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None X .. X
25 (13)
Rabbit
IFA <30 PESDA None X .. X
26 (3)
Canine
FAVG ≥60 PESDA None X .. X
15 (17)
Porcine
CA (LCX ) <30 PESDA None X .. X
104 (5)
Canine








To demonstrate that 
transtemporal LFUS used with 
MB tagged with a low-dose 
glycoprotein 2b/3a receptor 
antagonist can recanalize acutely 
thrombosed intracranial vessels
Intravenous platelet-targeted 
MB combined with transcranial 





To determine the effectiveness 
of lipid-encapsulated MB and 
US in recanalizing arteriovenous 
graft thrombi and the effect that 
tissue attenuation has on the 
succes rate
US and MB are capable of 
recanalizing acute arteriovenous 
graft thromboses. Higher 
intensities may be needed in the 
presence of tissue attenuation.
Tsutsui
 2006
To determine the added value 
of simultaneous imaging of 
intravenously infused MB that 
are being used to dissolve an 
intravascular thrombus with 
therapeutic US
The use of TUS with intravenous 
MB has a high success rate in 
recanalizing deeply located 
thrombosed arteriovenous 




To determine whether DUS, in 
the presence of MB, would be 
capable of recanalizing deeply 
located intravascular thrombi 
without the need for fibrinolysis 
or systemic anticoagulation
DUS can recanalize thrombosed 
vessels without a fibrinolytic 
agent, high MI US has a higher 




To determine whether a low-MI 
MB sensitive imaging system 
could be used to guide high-
MI impulses from the same 
diagnostic transducer during a 
platelet-targeted MB infusion 
and improve both epicardial and 
microvascular flow in a pig model 
of acute coronary thrombosis.
Intravenous platelet-targeted 
MB combined with brief high-MI 
DUS impulses guided by contrast 
pulse sequencing improve both 
epicardial recanalization rates 
and microvascular recovery.
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PESDA None X .. ..
55 (4)
Canine
FAVG 240 Definity None X .. ..
24 (1)
Canine
FAVG 240 MRX815 None X .. X
24 (2)
Canine
FAVG 240 MRX-801 None X .. ..
45
Porcine












To test whether tPA-loaded 
echogenic liposomes (TELIP) 
with US will confer thrombolytic 
efficacy similar (or superior) 
to that of other clinically used 
or proposed tPA treatment 
modalities for ischemic strokes.
The thrombolytic efficacy of 
tPA-loaded ELIP is comparable 
to other clinically described 
effective treatment protocols, 
while offering the advantages 
of US monitoring and enhanced 




To address whether P1 
polypeptide-loaded MB can 
prolong the 3 h therapeutic 
window in cerebral thrombosis 
and achieve a higher 
recanalization rate with a lower 
risk of cerebral hemorrhage.
TMB/LFUS is an effective and 
safe therapy for thrombolysis in 




To evaluate the efficacy of MB in 
transcranial Doppler ultrasound 
(TCD)-assisted urokinase 
thrombolysis.
The addition of MB enhanced the 





To determine the type of 
cavitation required for 
successfully dissolving 
intravascular and microvascular 
thrombi in acute myocardial 
infarction and whether longer 
pulse duration therapeutic 
impulses (sustaining the duration 
of cavitation) could restore both 
microvascular and epicardial 
flow with this technique.
Although short pulse 
duration guided therapeutic 
impulses from a diagnostic 
transducer transiently improve 
microvascular flow, long pulse 
duration therapeutic impulses 
produce sustained epicardial and 
microvascular re-flow in acute 
myocardial infarction
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tPA X .. X
32
Rabbit
MCA 60 SonoVue Urokinase X .. X
36
Porcine








To examine the enhancing effect 
of thrombus-targeted bubble 
liposomes (BLs) developed for 
fresh thrombus imaging during 
ultrasonic thrombolysis.
TIMI grade 3 flow was present in 
a significantly higher number of 
rabbits with USD and targeted 
BLs than rabbits with USD and 




To determine whether skull 
attenuation would limit the 
ability of US alone to induce 
the type and level of cavitation 
required to dissolve thrombi 
and improve cerebral blood flow 
(CBF) in acute ischemic stroke.
Guided high-MI impulses from 
an US imaging system produce 
sustained improvements in 
ipsilateral and contralateral CBF 
after acute cerebral emboli.
Hua
 2014
To investigate the thrombolytic 
efficacy of a novel type of MB 
carrying tPA which can bind to a 
fresh thrombus via the arginine-
glycine-aspartic acid-serine 
(RGDS) polypeptide in vivo 
under the exposure of US.
Ultrasound-induced targeted 
tPA-loaded MB release is a 
promising thrombolytic method 
with satisfactory thrombolytic 
efficacy, lowered tPA dose 




To investigate the effect of 
additional US and MB on 
standard low-dose intra-arterial 
thrombolysis in a porcine model 
of extensive peripheral arterial 
occlusion.
The addition of contrast-
enhanced US accelerated the 
thrombolytic effect of low-dose 
intra-arterial thrombolysis in 
peripheral arterial occlusions.
73
Microbubbles and ultrasound in acute peripheral arterial thrombosis


























255 Definity None X .. X
70 (40)
Rabbit






tPA X .. ..
10
Porcine








To determine whether guided 
high mechanical index (MI) 
impulses from a diagnostic US 
transducer during an intravenous 
MB infusion could augment 
low-dose fibrinolytic therapy 
in treating acute myocardial 
infarction (ST segment elevation 
myocardial infarction, STEMI).
Guided high MI-induced MB 
cavitation from a diagnostic 
transducer added to lowdose 
tPA can immediately improve 
regional function and reduce 
infarct size in acute STEMI
Tomkins
 2015
To investigate the effect on 
recanalization rates of tPA 
therapy alone or in conjunction 
with US and a new MB 
formulation (BR38) in a model 
with platelet rich clots.
These platelet rich clots were 
highly resistant to tPA with 




To investigate the efficacy of 
transcranial color Doppler 
ultrasound (TCCS) combined 
with MB and rtPA for 
thrombolysis in vivo.
TCCS + MB combined with rtPA 
is a relatively effective approach 
for ischemic arterial thrombosis 




To study the thrombolytic effect 
of low-frequency US combined 
with targeted urokinase-
containing MB contrast agents 
on treatment of thrombosis 
in rabbit femoral artery; and 
to determine the optimal 
combination of parameters for 
achieving thrombolysis in this 
mode
The optimal parameters for 
thrombolysis were determined 
to be 1) an US frequency of 2.2 
MHz and 2) a 90,000 IU/kg 
dose of urokinase. US exposure 
time (30 min vs. 60 min) had 
no significant effect on the 
thrombolytic effects
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CA (LAD) ≥20 MRX-801 tPA X .. X
30
Rodent





SonoVue tPA X .. ..
72
Rabbit













To compare intravenously 
administered targeted MB 
incorporating Urokinase 
and locally applied US, with 
intravenous Urokinase and US 
alone
Minimally invasive thrombolysis 
using i.v. targeted MB carrying 
urokinase combined with 
ultrasound is feasible and 
might accelerate thrombolysis 
compared with treatment with 
urokinase and ultrasound alone.
Porter
 2017
To examine the effect of 
different forms of DUS induced 
cavitation in restoring branch 
flow following carotid artery 
thrombosis in a porcine model 
of common carotid stenosis and 
thromboembolism.
High MI 20usec pulse duration 
impulses during a commercial 
MB infusion can be used to 
recanalize acutely thrombosed 
carotid arteries and restore 
downstream flow without 
anticoagulants. However, this 
effect is only seen with SC 
inducing impulses and not at 
higher mechanical indices, when 
a paradoxical reversal of the 
thrombolytic effect is observed.
Cui
 2017*
To determine whether combining 
TUS with MB could accelerate 
thrombolysis at the in vitro and 
in vivo studies without the use of 
fibrinolytic drugs
Recanalization rates and flow 
scores in TUS + MB group were 
significantly higher than the 
control and TUS group
Chen
 2019
To investigate the feasibility and 
efficacy of magnetically targeted 
MB-mediated sonothrombolysis 
for the treatment of obstructive 
thrombi
The recanalization rate, average 
blood flow velocity, and hindlimb 
perfusion in the red and white 
thromboembolic models were 
all significantly higher in the US 
+ M-MB and US + M-MB + r-tPA 
groups than in the control and 
US + C-MB groups.
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Urokinase X X X
38 (21)
Porcine






None X .. ..
40 (20)
Rodent
IFA 60 Magnetic 
(streptavidin 












To evaluate the effects of 
administration of MB on the 
beginning, speed, and degree of 
middle cerebral artery (MCA) 
recanalization during systemic 
thrombolysis and continuous 
2-MHz pulsed-wave TCD 
monitoring
Administration of MB induces 
further acceleration of US-
enhanced thrombolysis in 
acute stroke, leading to a more 
complete recanalization and to a 




To study whether transcranial 
color-coded duplex ultrasound 




ECA, accelerates i.v. rtPA-
thrombolysis in the acute phase 
of MCA stroke more than TCCD 
ultrasound monitoring alone
ECA enhanced TCCD monitored 
rtPA thrombolysis is superior 
to TCCD monitored rtPA 
thrombolysis in terms of residual 
flow improvement as measured 
by TIBI, especially during the 
first 30 min. It is also superior 
in the immediate (24h) clinical 
improvement as measured by 
NIHSS. The rate of hemorrhagic 
transformation was not different 
between the two groups
Pagola
 2007
To determine the timing 
of recanalization in basilar 
artery occlusion treated with 
systemic thrombolysis, MB, and 
continuous TCD monitoring
Combined treatment with i.v. 
tPA, MB, and continuous US 
in acute BAO leads to early 
recanalization in a significant 
number of patients; this is 
associated with favourable 
outcomes
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111 MCA 156 Levovist tPA X .. X
26 MCA <180 SonoVue tPA X .. X








To test the feasibility and 
safety of novel lipid coated MB 
containing perfultren, that are 
consistent in size (1 to 2 Um) and 
more stable in saline solution
Perflutren MB reached and 
permeated beyond intracranial 
occlusions with no increase 
in sICH after systemic 
thrombolysis, suggesting 
feasibility of further MB 
dose-escalation studies and 
development of drug delivery 




To compare the effect of 
galactose-based air-filled 
MB (levovist) and sulphur 
hexafluoride-filled MB (sonovue) 
on recanalization and clinical 
outcome in sonothrombolysis 
for acute ischemic stroke
MB administration during 
sonothrombolysis is associated 
with a high recanalization 
rate. Recanalization rates, 
clinical course and long-term 
outcome are comparable 
when administering galactose-




To investigate the risk of 
hemorrhagic transformation 
(HT) after MB-enhanced 
sonothrombolysis in acute 
stroke
Microbubble administration 
was associated with early 
recanalization and a high rate of 
hemorrhagic transformation but 
does not seem to increase the 




To study the safety, tolerability, 
and activity of perflutren-lipid 
MB MRX-801 2MHz TCD 
insonation as an adjuvant to iv 
tPA, and conduct a phase I-II 
safety dose escalation study
Perflutren lipid MB can be safely 
combined with systemic tPA and 
US at a dose of 1.4ml. Safety 
concerns in the second dose 
tier may necessitate extended 
enrollment and further 
experiments to determine 
the mechanisms by which MB 
interact with tissues
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15 MCA <180 Perflutren-
lipid MB
tPA X .. X
138 MCA  178 (mean) Levovist & 
SonoVue
tPA X .. X




tPA X .. X












To evaluate safety and efficacy 
on middle cerebral artery 
(MCA) recanalization of local 
MB administration during 
intra-arterial thrombolysis and 
continuous TCD monitoring
The combination of ultrasound 
and i.a. MB and tPA may be 
a strategy to enhance the 




To determine the safety and 
feasibility of treatment with 
low dose thrombolytics in 
combination with ultrasound 
and microbubbles prior to 
PPCI to increase the epicardial 
recanalisation rates in patients 
with a first acute STEMI
No significant difference 
between treatment and control 
group in safety (minor adverse 
events 2/5 vs. 2/5, p = NS) and 
outcome (TIMI III flow 3/5 
vs. 1/5 respectively, p = 0.23) 
was recorded. These results 
demonstrate that the study 
protocol is feasible in the acute 
cardiac care setting and safe 
during treatment and follow-up
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18 MCA 175 
(median)
Levovist tPA X .. X
10 CA (LAD 7, 
RCA 3)
134-177 Luminity tPA X .. X
* No statement was included on adherence to guidelines for animal care or obtaining 
permission from a local ethics committee. ** No statement was given on approval of a local 
ethics committee or obtaining informed consent. *** Approval was given by a local ethics 
committee, but no statement on obtaining informed consent was included in the article.
Abbreviations: IFA = iliofemoral artery, CA = coronary artery, LCX = left circumflex, 
FAVG = femoral arterio-venous graft, APA = ascending pharyngeal artery, LAD = left 
anterior descending, AA = abdominal aorta, CCA = common carotid artery, MCA = middle 
cerebral artery, ICA = internal carotid artery, RCA = right coronary artery, BA = basilar 




Table 2. Results of quality assessment.























Free of other 
problems that 




























































of the study 
size













Molina 2006 2 2 2 2 1 2 0 1 2 1 2 1
Perren 2007 2 0 2 2 1 0 0 1 2 2 1 0
Pagola 2007 2 2 2 2 1 2 0 1 - - - -
Rubiera 2008 2 2 2 2 1 2 0 1 2 1 2 0
Dinia 2009 2 2 2 2 2 2 0 1 2 1 2 2
Ribo 2010 2 2 2 2 1 2 0 1 - - - -
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Table 3. Overview of classifications for flow and recanalization
Grade Definition
TIMI* 0 No perfusion No penetration of contrast past the clot in the 
obstructed artery.
(angiography) 1 Penetration without 
perfusion
Contrast passes the occlusion, but there is no 
perfusion of the target area.
2 Partial perfusion Contrast passes the obstruction and reaches 
the target area, but slower than adjacent normal 
vessels.
3 Normal perfusion Normal flow through obstructed artery in 
comparison to adjacent vessels.
TIBI** 0 Absent Lack of regular pulsatile flow signals despite varying 
degrees of background noise.
(transcranial 
Doppler)
1 Minimal Systolic spikes of variable velocity and duration, 
absent flow during all cardiac cycles, reverberating 
flow.
2 Blunted Flattened systolic flow acceleration of variable 
duration compared to control, positive end diastolic 
velocity and pulsatility index <1,2.
3 Dampened Normal systolic flow acceleration, positive end-
diastolic velocity, decreased mean flow velocities 
(MFV) by >30% compared to control.
4 Stenotic MFV>80cm/sec and velocity difference of >30% 
compared to control OR if both affected and 
comparison sides have MFV<80cm/sec due to low 
end-diastolic velocities: MFV>30% compared to the 
control side and signs of turbulence.
5 Normal <30% mean velocity difference compared to 
control, similar waveform shapes compared to 
control.
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Table 3. Overview of classifications for flow and recanalization (continued)
Grade Definition
TICI*** 0 No perfusion No antegrade flow beyond the point of occlusion.
(angiography) 1 Penetration with 
minimal perfusion
The contrast material passes beyond the area of the 
obstruction but fails to opacify the entire cerebral 
bed distal to the obstruction for the duration of the 
angiographic run.
2 Partial perfusion The contrast material passes beyond the 
obstruction and opacifies the arterial bed distal 
to the obstruction. However, the rate of entry of 
contrast into the vessel distal to the obstruction 
and/or its rate of clearance from the distal bed 
are perceptibly slower than its entry into and/or 
clearance from comparable areas not perfused by 
the previously occluded vessel, eg, the opposite 
cerebral artery or the arterial bed proximal to the 
obstruction.
2a. Only partial filling (<2/3) of the entire vascular 
territory is visualized.
2b. Complete filling of all of the expected vascular 
territory is visualized, but the filling is slower than 
normal.
3 Complete perfusion Antegrade flow into the bed distal to the 
obstruction occurs as promptly as into the 
obstruction and clearance of contrast material from 
the involved bed is as rapid as from an uninvolved 
other bed of the same vessel or the opposite 
cerebral artery.
* Thrombolysis in Myocardial Infarction. Adapted from: the TIMI Study Group, 1985. 
** Thrombolysis in Brain Ischemia (Demchuk et al. 2001). *** Thrombolysis in Cerebral 




Table 4. Recanalization rates for CEST vs best alternative arm in same study










Xie 2009b prourokinase i.v. vs 
low-MI US guided 
high-MI pulses + 
prourokinase i.v. + 
tMB i.v. vs low-MI US 
guided high-MI pulses 
+ prourokinase i.v. + 
ntMB i.v.
45 low MI (0.2) 
1,5MHz pulsed; 
high MI (1.9) 
1.5MHz pulsed
≥20 30 (+ 60 
follow up)
Laing 2011 i.a. saline vs i.a. free tPA 
vs i.a. tPA mixed with 
Definity vs tPA-loaded 
echogenic liposomes; 
randomization within 
these groups for high vs 
low MI US or no US
59 6MHz pulses 
high MI (0.4) 
2min vs 6MHz 
intermittently low 
MI (0.2) 30min
10 2 vs 30
Lui 2012 urokinase i.v. + US vs 
urokinase i.v. + MB i.v. 
+US
32 2MHz pulse 
0,252W/cm2
60 20 (+ 100 
follow up)
Xie 2013 rtPA i.v. vs rtPA i.v. + MB 
i.v. + high MI short pulse 
US vs rtPA i.v. + MB i.v. 
+ guided low MI long 
pulse US
36 1.6MHz long 
pulses; high MI 
(2.0), pulse length 
5µs vs low MI (1.0), 
pulse length 20µs
≥20 30 (+ 60min 
follow up)
Hua 2014 no treatment vs tPA i.v. 
vs TUS vs TUS + tPA i.v. 
vs TUS + ntMB i.v. + tPA 
i.v. vs TUS + tPA-loaded 
tMB i.v. vs DUS + tPA-
loaded tMB i.v.
70 2 MHz, intensity of 
1.8 W/cm2 TUS; 2 
MHz, MI 1.4 DUS
30 30
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recanalization Best result CEST Best alternative arm p
angiography Evidence of contrast 
flow through the site of 
occlusion and normal 
runoff of flow distal to the 
occlusion.
60% (tMB) 20% NS
pulsed spectral 
doppler







TCD If blood flow velocity 
was improved >30% or 
waveform improvement 
was greater than 1 grade 
according to the TIBI 
grading system
56% 31% 0.154

















4a1. Preclinical (part 1) (continued)
Author Design Number of 
occlusions








urokinase i.a. vs 
urokinase i.a. + MB i.v. 
+ US
10 1.6MHz, high MI 
(1.2) pulses (5sec 
off, 1 sec on)
100 60 UK 
+/- MB 
followed 
by 120 UK 
alone
Wu 2015 1/2 dose tPA i.v. vs full 
dose tPA i.v. vs 1/2 dose 
tPA i.v. + MB iv + high 
MI US vs MB iv + high 
MI US
32 intermittent high 
MI (2.0)




tPA i.v. vs tPA i.v. + US + 
MB i.v. vs saline i.v.
30 3MHz, continuous, 
MI 1.7
>480 60 (+ 70min 
follow up)
Ren 2015 no treatment vs rtPA 
i.v. vs TCCS + MB i.v. 
vs TCCS + MB i.v. + full 
dose rtPA i.v. vs TCCS 
+ MB i.v. + 1/2dose 
rtPA i.v.
30 1MHz transcranial 





Zhu 2016  urokinase-loaded tMB 
i.v. in different settings: 
A 3 × 2 × 2 factorial 
table was applied 
to create different 
combinations of 
ultrasonic frequencies 
(Factor A: 1.6 MHz, 2.2 
MHz, 2.8 MHz), doses of 
urokinase i.v. (Factor B: 
90,000 IU/Kg, 180,000 
IU/Kg) and ultrasound 
exposure time (Factor 
C: 30 min, 60 min).
72 1.6 MHz vs. 2.2 
MHz vs. 2.8 MHz
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Changes in flow (ml/min) 
as percentage of baseline 
(=flow after creating 
stenosis; formula: change 
in flow/baseline flow 
x100%)
27%* 0% NR
angiography Not defined 83% 50% (in 2 arms: 





Return to ≥ 100% of 






Not defined, but based on 
result section any grade 
≥1 in author created 
grading system
100% (full dose 
tPA)
50% (tPA alone) 0.046
pulsed Doppler 
flowmetry









4a1. Preclinical (part 1) (continued)
Author Design Number of 
occlusions









i.v. + US vs urokinase 
i.v.+US




100 60 (+ 
120min 
follow up)
Chen 2019 saline i.v. vs. US + MB i.v. 
vs US + magneticMB i.v. 
vs US + magneticMB i.v. 
+ rtPA i.v.
40 2 MHz, MI 1.9 60 30
4a2. Range of recanalization rates for different study arms
Study arm
(number of studies)
Range of recanalization rate (%)
CEST (12) 56-100
Placebo & no ultrasound (7) 0-10
Microbubbles alone (2) 0
Ultrasound alone (13) 0-63
Fibrinolytic agent alone (10) 0-50
US & MB (17) 0-100
US & Fibrinolytic agent (4) 20-50
MB & Fibrinolytic agent (1) 50
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Best result CEST Best alternative arm p
ultrasonic flow 
probe
Any recanalization 80% 25% NR
Doppler US 
(mechanical 
index [MI], 0.18; 
frequency, 14 
MHz)
Not defined 100% 95% (magnetic MB; 









* If success was defined as ‘any recanalization’, the result would be 67% for CEST, 25% for 
the alternative arm. If defined as ‘recanalization over 15% of baseline flow’, the result would 




4b. Clinical (part 1 )
Author Indication














tPA i.v. +US + MB 
i.v.(38) vs tPA i.v. + 
US (37) vs tPA i.v. 
(36)







tPA i.v. + US + MB 
i.v. (9) vs tPA i.v. + 
US (15)









tPA i.v. + MB i.v. + 
US (20)







tPA i.v. + US + MB 
i.v. (12) vs tPA i.v. + 
US (3)*
MB vs no MB, 
ratio 3:1
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TCD Partial when blunted 
or dampened 
signals appeared in 
a previously absent 
or minimal flow and 
complete if the end-
diastolic flow velocity 
improved to normal or 
elevated values





tPA i.v. + 
US)
0.65
TCCD Partial when the TIBI 
grade evolved from 0–1 
to 2–3 and complete 
with a final TIBI grade 
of 4 or 5






TCD Partial when dampened 
signals appeared 
in a previously 
demonstrated absent 
or minimal flow, 
complete if the end 
diastolic flow velocity 
improved to normal or 
elevated values
20% after 1 hour 
(10% complete), 
50% after 24hrs (all 
complete)
NA
TCD Partial if the affected 
MCA segment with 
the worst residual flow 
grade pretreatment 
showed an 
improvement by 1 TIBI 
grade or more to TIBI 
grade 2 or 3, complete 
if TIBI flow grades 
recovered to grade 4 or 
5 within 2 hours









4b. Clinical (part 1 ) (continued)
Author Indication














tPA i.v. + Levovist 
MB i.v. + US (91) vs 
tPA i.v. + Sonovue 
MB i.v. + US (47)
Not randomized 1.97 MHz 
pulsed-wave, 









Dinia 2009 Ischemic 
stroke
tPA i.v. + MB i.v. 
(188) + US vs tPA i.v. 
+ US (98; historical 
control group)










tPA i.v. (12) vs tPA i.v. 
+ 1.4ml MB i.v. (12) 
vs tPA i.v. + 2.8ml 
MB (11) i.v. vs tPA i.v. 
+ 5.6ml MB i.v. (0) vs 
tPA i.v. + 11.2ml MB 
i.v. (0)**
MB + US vs no 
MB + US, ratio 
2:1
continuous 
2 MHz TCD, 
maximum 
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TCD Partial when TIBI 
2 or 3 appeared 
in a previously 
demonstrated TIBI 
1 pattern, complete 
if TIBI 4 or 5 were 
achieved
32.2% LV/35.6% 
SV after 1hr, 50.0% 
LV/46.7% SV 
after 2hrs, 63.8% 
LV/54.5% SV after 
6hrs. (% complete not 
specified)
NA
TCD Partial when blunted 
or dampened 
signals appeared 
in a previously 
demonstrated absent 
or minimal flow, 
complete if the end-
diastolic flow velocity 
improved to normal or 
elevated values
32.2% after 1hr, 
50% after 2 hrs, 
63.8% after 6hrs, 
74.3% after 12 hrs 












TCD Partial if abnormal 
signals were still 
seen at the distal 
portion (TIMI grade 
II flow equivalent), 
complete when a 
normal waveform or a 
low-resistance stenotic 
signal appeared at 
the selected depth of 
insonation (TIMI grade 
III flow)
84% 1.4ml group 
after 2 hrs (67% 
complete), 45% 2.8ml 











4b. Clinical (part 1 ) (continued)
Author Indication










Ribo 2010 Ischemic 
stroke
tPA i.v. + US (16) 
vs tPA i.a. +MB 
i.a. + US (7 after 
first receiving 
tPA i.v. with no 
improvement of 
flow, 2 direct i.a. )















MB i.v. + US + tPA i.v. 
+/- PCI (5) vs saline 
i.v. + tPA i.v. +/- PCI 
(5)
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Partial if TICI II, 
complete if TICI III
78% after i.a. 
treatment (22% 






angiography TIMI grade III in culprit 
vessel at PCI***
60% 20% 0.23
* Study was terminated early for administrative reasons, thus not reaching a predetermined 
sample size of 40; ** Study was terminated early due to a high rate of ICH in the 2.4ml MB 
dose group; ***No documentation of TIMI grade previous to intervention
3
Chapter 3
* All sICH occurred in the 2,8ml dose MB group. ** Two of these ICH occurred in the 1,4ml 
dose group (17%) and one in the 2,8ml dose group (9%). *** All 3 deaths were in the 2,8ml 
dose group (30%).
Table 5. Adverse events in clinical trials (part 1)
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.. 2 (5,5) 1
(16)
.. .. .. .. 3 months
1 (6,7) .. .. .. .. .. .. .. .. 15 days
.. .. .. .. .. .. .. .. .. 3 months
0 1 
(33)
1 (33) .. .. .. .. .. .. 3 months
.. .. .. .. .. .. .. .. .. 3 months
3 (2,1) 17 
(19)
15 (15) .. .. .. .. .. .. 24 hours
.. .. .. 0 0 0 .. .. .. 3 months
.. .. .. NR NR NR .. .. .. 3 months
.. .. .. 0 .. 0 .. .. .. 4 months
Two deaths were attributed to sICH, 1 to progression of the ischemic stroke. a Thrombolysis 
was given intravenously in 16 out of 18 patients, 7 of whom then proceeded to intra-arterial 
CEST as there was no recanalization . The remaining 2 patients had a contra-indication for 
IV thrombolysis and received primary intra-arterial CEST. NR = not reported.
3
Part II
Pre-clinical in-vitro and animal studies

Chapter 4: Contrast-enhanced sonothrombolysis in a 
porcine model of acute peripheral arterial thrombosis 
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Acute peripheral arterial thrombosis can be threatening to life and limb. Dissolution 
of the thrombus by local catheter-directed intra-arterial infusion of fibrinolytic 
agents such as urokinase, is the standard therapy for thrombosis; however, this 
method is time-intensive, and amputation of the affected limb is still needed in 
10–30% of cases. Furthermore, thrombolytic therapy carries the risk of bleeding 
complications. The use of small gas-filled bubbles, or ultrasound contrast agents 
(UCAs), in combination with ultrasound has been investigated as an improved 
thrombolytic therapy in acute coronary and cerebral arterial thrombosis. The 
authors describe a porcine model of acute peripheral arterial occlusion to test 
contrast-enhanced sonothrombolysis approaches that combine ultrasound, UCAs 
and fibrinolytic agents and recommend a strategy for preventing severe allergic 
reactions to UCAs in the pigs.
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Introduction
Acute peripheral vascular disease is most often caused by a thrombus blocking an 
artery. This can lead to acute lower limb ischemia, which is associated with high 
mortality rates, and with amputation of the affected limb within 30 d after hospital 
admission in ~10–30% of patients1. Dissolution of the thrombus, for example, by 
catheter-directed intra-arterial infusion of fibrinolytic agents such as urokinase 
proximal to the thrombus site, can restore blood flow to the limb. However, this 
technique is invasive and time-consuming, requires repeated angiography and 
carries the risk of major hemorrhagic complications, resulting in high morbidity 
and mortality rates2. Improved therapies are therefore needed.
Sonothrombolysis is a promising technique for the treatment of acute peripheral 
arterial occlusion that combines thrombolysis with ultrasound3,4. The efficacy of 
sonothrombolysis in small vessels can be further enhanced with the addition of 
ultrasound contrast agents (UCAs)5–7. UCAs consist of small gaseous microbubbles 
(1–10 µm) with lipid shells that oscillate under the influence of low-intensity 
ultrasound and even collapse at higher intensities. These oscillations result in 
mechanical forces on the clot surface, making the thrombus more susceptible 
to thrombolytics8. These particles therefore have been broadly investigated to 
improve thrombolytic therapy9.
A therapeutic approach that combines the use of ultrasound, UCAs and fibrinolytic 
agents has not been described previously in subjects with acute thrombotic 
occlusion of large peripheral arteries. To assess the efficacy of contrast-enhanced 
sonothrombolysis (CEST) for the treatment of acute peripheral arterial occlusion, 
an appropriate animal model is needed. Because porcine and human coagulation 
and fibrinolytic systems have similar components10, we developed a porcine model 
of CEST by modifying a previously described model of intra-arterial thrombolysis11. 
Here, we describe a technique for inducing acute peripheral arterial occlusion 
in pigs for the investigation of different CEST protocols and for preventing 
anaphylactic shock after administration of UCAs.
Technique
All procedures were done at the Animal Laboratory of the VU Medical Center 
under the direct supervision and support of a licensed veterinary staff. All 
procedures were done in accordance with both the Dutch national guideline for 
humane animal treatment (Code Of Practice Welzijnsbewaking van proefdieren, 
2004) and the European Directive 2010/63/EU on the protection of animals used 
for scientific purposes. The VU Medical Center Animal Ethics Committee approved 




Twenty-three adolescent female Yorkshire pigs, weighing between 58 kg and 90 
kg, were housed at the research facility for acclimatization and quarantine for 1 
week before initiation of the experiments.
Anesthesia
We sedated the pigs with an intramuscular injection of 28 mg per kg body weight 
ketamine (Alfasan, Woerden, The Netherlands), 0.5 mg per kg body weight 
midazolam (Actavis bv, Baarn, The Netherlands) and 1 mg atropine (Pharmachemie, 
Haarlem, The Netherlands). We then induced anesthesia with intravenous (i.v.) 
injection of 20 mg etomidate (B. Braun, Melsungen, Germany), after which the 
pigs were intubated. When necessary for cannulation of the airway, we repeated 
the administration of etomidate. During the procedure, we maintained anesthesia 
with 1.5–2.0% isoflurane (Pharmachemie, Haarlem, The Netherlands) administered 
endotracheally and with i.v. 50 µg/h fentanyl (Hameln Pharmaceuticals, Hameln, 
Germany), 50 mg/h midazolam and 20 mg/h pancuronium (Organon, Oss, The 
Netherlands). We also administered i.v. 5 ml per kg body weight per h 0.9% NaCl. 
Tidal volumes were set at 10ml per kg body weight, with a frequency of 15–18/min, 
and were adjusted depending on capnography to maintain the CO2 concentration 
between 35 mmHg and 40 mmHg. We assessed arterial blood gases regularly for 
pH, partial pressure of CO2 (pCO2) and partial pressure of oxygen (pO2) using 
the IRMA TruPoint blood analysis system (ITCmed, Edison, NJ). We also measured 
blood pressure, heart rate, oxygenation and body temperature (Solar 8000 patient 
monitor, Marquette, GE Medical Systems, Milwaukee, WI) as well as temperature 
and microcirculation of the affected limb (laser Doppler probe; Periflux 4001 
Master, Perimed AB, Järfälla, Sweden) during the entire procedure.
Creation of a stable thrombus
Via a midline laparotomy, we identified the left common and external iliac arteries 
and ligated the internal iliac artery. We measured blood flow in the iliac artery 
using an ultrasonic flow probe (Transonic-Systems Inc., Ithaca, NY). We created a 
stenosis in the external iliac artery by reducing the diameter of the vessel with a 
vascular tourniquet, decreasing the flow in the iliac artery by 50 ± 10% (Fig. 1). To 
promote adhesion of a thrombus to the vessel wall, we damaged the endothelium by 
clamping and declamping the iliac artery with a straight Kocher clamp (Heljestrand, 
Eskilstuna, Sweden) over a length of 4 cm. We then occluded the artery with the 
same clamps proximally and distally and injected 100 units of freshly prepared 
bovine thrombin (Calbiochem, EMD Millipore, Darmstadt, Germany) intraluminally. 
We removed the proximal clamp after 1 h and the distal clamp after 90 min. When 
persistent flow in the iliac artery was present, we once again occluded the vessel 
and administered another 100 units of thrombin. Once a thrombus formed, we left 
it to stabilize for 30 min.
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In the first pig, time to creation of thrombus (TCT) was 295 min, after which the 
iliac vessel still was not completely occluded. TCT diminished during the study 
period, however, to 95 min in the last of the four subjects. The main reason for this 
shortening of TCT may be that we adjusted our technique to increase the amount 
of endothelial damage given; we increased the force applied to the vessel by fully 
closing the clamp ratchet when clamping and we increased the amount of time 
spent causing the endothelial damage. Another adjustment in the procedure was to 
release the proximal clamp for a short time after injection of the bovine thrombin 
to allow for extra blood to mix with the thrombin; this prevented the thrombin 
from replacing some of the blood when it was injected into the vessel, which might 
originally have made the thrombin less effective.
Figure 1. Diagram of the iliac artery. A stenosis was created, the endothelium was damaged 
and the artery was occluded. Illustrated by H.P. Ebben.
CEST procedure
To perform sonothrombolysis, we used a Philips Sonos 7500 ultrasound machine 
with a diagnostic S3 transducer (Philips Healthcare, Eindhoven, The Netherlands). 
We placed a balloon filled with saline between the probe and the arterial wall to 




the vessel was made, the probe would be too close to the thrombus to allow for 
visualization and treatment. The resulting distance between the ultrasound probe 
and the occluded vessel was 3 cm. We set the mechanical index (MI) to 1.1 with a 
focus of 3 cm and a frequency of 1.6 MHz.
From this point on, a variety of CEST protocols could be initiated. The UCA 
that we used was SonoVue (Bracco Imaging SpA, Milan, Italy), which consists of 
microbubbles with a phospholipidic monolayer shell containing sulfur hexafluoride. 
UCAs can be administered i.v. or intra-arterially , one vial per several minutes until 
the UCAs diminished from circulation, which can be controlled by ultrasound. The 
fibrinolytic agent that we used was urokinase (Lamepro bv, Breda, The Netherlands). 
Pigs received urokinase either i.v. or intra-arterially in a dosage regularly used in 
clinical setting: a bolus injection of 500,000 U followed by continuous infusion 
of 50,000 U per h. Microbubbles were administered i.v. and local ultrasound was 
applied to the occluded vessel. Because of the allergenic effects of the UCAs, 
therapy time varied from 0 to 180 min and all animals were terminated at the end 
of the experiment.
In the first pig that was administered UCA, systemic blood pressure dropped less 
than 2 min later, severe bradycardia occurred and ventilation was no longer possible 
owing to high airway resistance. We performed external cardiac compressions 
to no avail, and the pig died within 3 min. Differential diagnosis consisted of 
pulmonary embolism, anaphylaxis or severe hemorrhage elsewhere in the body. At 
autopsy there were no signs of pulmonary embolism. There was some intracranial 
hemorrhage, though not enough to be a likely cause of death. In the second, third 
and fourth pigs, similar reactions occurred a few seconds after each bolus of UCA, 
and external cardiac compressions were necessary in all pigs. Symptoms could not 
be prevented by administering i.v. methylprednisolone (Pfizer, Capelle a/d IJssel, 
The Netherlands) and tavegyl (Novartis, Breda, The Netherlands) 30 min prior 
to injection of the UCA, but the second, third and fourth pigs did respond to i.v. 
epinephrine (Pharmachemie, Haarlem, The Netherlands) in various doses (0.1–0.5 
mg) and recovered. In these four pigs, severe hemodynamic changes and cardiac 
arrhythmia were caused by the anaphylactic shock, and the surviving pigs were 
excluded from further testing. We did not observe any cutaneous symptoms of 
allergic reaction in the pigs, and a literature search identified no previous reports 
of allergic reactions to UCAs in pigs. Allergic reactions to liposomes have been 
mentioned previously12,13; Szebeni et al.14 recently stated that “nanoparticulate 
materials in pigs could lead to acute cardiopulmonary, hemodynamic, hematological, 
biochemical and dermatological changes within minutes, mimicking the human 
infusion (or anaphylactoid) reactions” and cited compliment activation-related 
pseudoallergy as a possible cause. Therefore, we found it necessary to premedicate 
the pigs prior to injection of the UCA to prevent possible allergic reactions to the 
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liposome outer layer of the microbubbles. Thirty minutes before injection of 
UCA in the remaining pigs, we administered 40 mg i.v. methylprednisolone and 
500 mg indomethacin (Pharmachemie, Haarlem, The Netherlands) via rectal 
suppository. Because it takes time to obtain adequate blood levels of indomethacin 
when administered rectally, we also administered 2.5 g of i.v. acetylsalicylic acid 
(Sanovi-Aventis, Gouda, The Netherlands) in three doses, each given 5 min prior to 
administration of a dose of UCA in increments of 15 min. After introduction of the 
premedication step to the protocol, none of the remaining pigs (n = 19) experienced 
anaphylactic reactions.
Conclusions
Experiments to evaluate different protocols of CEST are currently being 
conducted using our porcine model, and results from these protocols are being 
analyzed. In view of our experience, we recommend that such experiments include 
premedication to prevent anaphylactic reactions to the lipid shell of the UCA. Our 
premedication approach was based on recommendations of other researchers in 
this field, who used an i.v. combination of 40 mg methylprednisone and 5 mg per kg 
body weight indomethacin. Since the cost of i.v. indomethacin (~$600 per 1-mg vial) 
is high, we instead used a suppository form of the drug (~$2 per 100 mg). Although 
this is not a new treatment in itself, indomethacin via suppository has not previously 
been described for this purpose to our knowledge. Using i.v. aspirin (~$190 per 
500 mg) in a dose of 10 mg per kg body weight is another option with a lower cost 
than i.v. indomethacin and has previously been described as an effective method 
of preventing adverse reactions to liposomes13. Because aspirin has antiplatelet 
activity, there might be a slight effect on the outcome in a model of thrombolysis; 
however, patients with peripheral arterial vascular disease will almost always be 
taking antiplatelet medication. When comparing different methods of thrombolysis, 
the same systemic medications, including aspirin, should be used in both methods.
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Chapter 5: Therapeutic application of contrast-
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thrombolysis in a porcine model of acute peripheral 
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The addition of local ultrasound with contrast agents to standard intra-arterial 
thrombolysis has been promising in the setting of stroke and myocardial infarction. 
In this study, we investigated the effect of additional ultrasound and microbubbles 
on standard low-dose intra-arterial thrombolysis in a porcine model of extensive 
peripheral arterial occlusion.
Methods
In ten pigs, extensive arterial thrombosis was induced in the external iliac artery. 
The ‘urokinase only’ group (UK) (n=4) received standard thrombolytic therapy: 
intra-arterial bolus injection of 500,000 International Units (IU) followed by 
continuous low-dose urokinase (50,000 IU/h) infusion via an intra-arterial catheter 
and local intermittent application of ultrasound to visualize vascular patency. The 
‘urokinase + bubbles’ group (UK+) (n=6) received the same urokinase therapy 
with concomitant infusion of microbubbles (5x 5mL vials during the first hour) 
intravenously and local intermittent application of ultrasound. After three hours 
of therapy the animals were terminated. End points were thrombus weight, arterial 
flow and microcirculation, representing reperfusion.
Results
Mean thrombus weights were 1.1 vs. 1.6 grams in the UK+ group and in the UK 
group, respectively (P=.01). Arterial blood flow increased in four out of six pigs 
in the UK+ group by a mean 61% versus one out of four in the UK group with 1%. 
Microcirculation and lower limb arterial pressure levels improved after start of 
therapy in the UK+ group, contrary to a trend of decline in the UK group. No signs 
of bleeding complications were observed in either group.
Conclusions
In this experimental pilot study, the addition of contrast-enhanced ultrasound 
improved low-dose intra-arterial thrombolytic therapy in extensive peripheral 
arterial occlusions. Further clinical studies are warranted.
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Introduction
Acute peripheral arterial occlusions are limb- and potentially life-threatening. In 
western countries the incidence of patients with acute limb ischemia is around 
140 per million per year, and rises every year1. In spite of rapid development of 
new endovascular techniques, in approximately 10-30% of the patients presenting 
with acute lower limb ischemia amputation follows within 30 days after hospital 
admission2. Since its introduction, intra-arterial thrombolysis has altered the 
treatment of acute peripheral arterial thrombosis. Randomized trials published in 
the 1990s showed that thrombolysis with urokinase might be a good alternative 
for primary surgical intervention3,4. Nevertheless, thrombolysis using fibrinolytic 
agents is time consuming and patients are confined to bed for days, which 
increases patients’ burden. In the Netherlands we use the fibrinolytic urokinase, 
however, no standard protocol exists and different fibrinolytic agents with various 
dose protocols have been used throughout the years worldwide. Furthermore, 
thrombolytic therapy is accompanied by major bleeding complications in up to 
9% of the cases with up to 3% intracranial bleeding5, depending on dosage and 
length of treatment. However, low-dosed thrombolysis could be used to minimize 
bleeding complications. A disadvantage is that this regimen increases therapy time. 
Therefore improvement of thrombolytic therapy with low-dose fibrinolytics is 
needed to minimize bleeding complications and concomitantly reduce therapy time.
Thrombolysis can be enhanced by ultrasound (US), especially in the early phase 
of therapy6. In turn, the thrombolytic effect of fibrinolytics combined with US 
can be amplified with ultrasound contrast agents7. These encapsulated gas 
filled microbubbles (1-5µm) can pass freely through capillary systems without 
extravasation into the interstitial fluid. During exposure to high-intensity US, 
these bubbles tend to cavitate and collapse leading to formation of free radicals 
and microjets, causing mechanical stress, erosion of the clot and the formation of 
small holes in the clot surface8. These mechanical effects cause destabilization of 
the clot structure, making it more susceptible to fibrinolytics. Nowadays second-
generation contrast-agents such as SonoVue (Bracco, Switzerland) and Definity 
(Lantheus Medical Imaging, MA, USA) are EMEA/FDA approved and safely used 
in clinical practice for diagnostic purposes. For therapeutic purposes such as 
thrombolysis, it has been applied in patients in clinical trials for the treatment of 
myocardial infarction and stroke9,10.
The therapeutic application of microbubbles in thrombolysis has been investigated 
in animal models of myocardial infarction and stroke11,12. However, it has never 
been investigated in large peripheral arterial occlusions. We aim to improve 
the thrombolytic therapy of patients with peripheral arterial occlusions by 




concomitantly shorten the therapy time with the use of microbubbles. Therefore 
in the present study we investigated the in-vivo application of this thrombolysis 
protocol in a porcine model of large peripheral arterial occlusion. End points 
were thrombus weight, arterial flow and microcirculation. We hypothesized that 
contrast-enhanced ultrasound can enhance low-dose thrombolysis in-vivo.
Methods
General protocol and anesthesia
Approval of the Animal Ethics Committee was obtained before initiation of the 
study.
Ten female adolescent Yorkshire pigs were housed at the research facility for 
a minimum of at least one week before initiation of the experiment to allow for 
quarantine and acclimatization. Animals were randomized (random choice of an 
animal by the animal caretaker) to either the control group (intra-arterial UK, 
designated as the UK group, n=4) or the intervention group (intra-arterial UK with 
intravenous microbubbles and local application of ultrasound, designated as UK+ 
group, n=6). The pigs are numbered in chronological order.
At the start of procedure, the animals were sedated with an intramuscular injection 
of ketamine 28mg/kg, midazolam 0,5mg/kg and atropine 1mg. Anesthesia was 
induced with 20mg of etomidate intravenously, after which intubation followed. 
Where necessary, the administration of etomidate was repeated to allow for 
cannulation of the airway. During the procedure, anesthesia was maintained with 
isoflurane 1,5-2,0% endotracheally, and fentanyl 50µg/h, midazolam 50mg/h and 
pancuronium 20mg/h intravenously. Furthermore 5 ml/kg/h of NaCl 0.9% were 
administered intravenously. Tidal volumes were set at 10ml/kg with a frequency 
of 15-18/min and adjusted depending on capnography, maintaining the CO2 
concentration between 35-40mmHg. These initial parameters were modified after 
serial blood gas measurements to keep the pCO2 between 25 and 35 mmHg and 
the pH within normal limits.
All pigs (control group and intervention group) received 40mg methylprednisolone 
and 500mg indomethacin premedication and 2500mg acetylsalicylic acid in three 
doses during the procedure to prevent allergic reaction to the microbubbles13.
An overview of the experimental protocol can be found in Figure 1. A catheter was 
placed in both the right carotid and femoral artery to measure blood pressure. 
Thermometers were placed in the esophagus and between the toes of both 
hind legs to measure core- and limb temperature. The electrocardiogram, blood 
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pressure, blood gases, urine output, transcutaneous oxygen saturation, and body 
temperature were monitored throughout the entire procedure.
Experimental surgical protocol
Via a midline laparotomy, the left common and external iliac arteries were 
identified and the left internal iliac artery was ligated. A stenosis was created in 
the left external iliac artery by reducing the diameter of the artery with a ligature, 
decreasing the flow in the iliac artery by 50%±10%. Proximal from the stenosis 
the endothelium of the arterial wall was mechanically damaged by clamping and 
declamping over a length of 4 centimeters of the external iliac artery in order to 
damage the endothelium and promote thrombus formation. Subsequently this 
artery was then clamped proximally and distally over a total length of 4 cm and 
100 units (U) of bovine thrombin (Calbiochem, EMD/Merck, Germany) was injected 
intraluminally in order to create a thrombus. The proximal clamp was removed 
after one hour and the distal clamp was removed 30 minutes thereafter (Figure 
1B). In case of persistent flow in the external iliac artery, the thrombus induction 
procedure was repeated by reclamping and additional injection of bovine thrombin. 
If necessary, small side branches were coagulated and large side branches 
were ligated. Blood flow in the external iliac artery distal to the occlusion was 
measured using an ultrasonic perivascular flow probe (T106, Transonic Systems 
Inc). A Laser Doppler probe (PeriFlux 4001 Master, Perimed Instruments) was 
placed transcutaneous on the affected limb in order to measure subcutaneous 
microcirculation.
After thrombus induction (see above) and 10 minutes of thrombus stabilization, 
a thrombolysis catheter (Royal Flush High-Flow, Cook Medical®, Amsterdam, 
the Netherlands) was placed intra-arterially just proximal to the occlusion and 
thrombolysis was initiated. The catheter was placed using an antegrade approach 
via the common iliac artery in analogy to the standard intra-arterial thrombolytic 
treatment of peripheral arterial occlusions in patients. The control group, i.e. ‘ the 
UK group’ received an intra-arterial bolus injection of 500,000 International Units 
(IU) of UK via the catheter, followed by the continuous low-dose infusion of 50,000 
IU UK per hour. A diagnostic ultrasound probe (Philips Sonos 7500, 1.6 Mhz., 
focus: 3cm, MI: 1.2, S3 transducer, Philips, Best, the Netherlands) was directed at 
the external iliac artery at the site of the thrombus to visualize vascular patency 
during the procedure. To mimic transcutaneous application, the probe was placed 
on a balloon filled with saline resulting in a distance between the probe and the 
treatment artery of 3cm. In the ‘UK+ group’, the same UK infusion regimen was 
administered as in the UK group and the ultrasound probe was placed following the 
same protocol. However, in addition 5 vials (25mL) of microbubbles (SonoVue 5mL, 
Bracco, Switzerland, prepared following the manufacturer’s manual) were infused 




during 10 minutes, after an additional 5 minutes a new vial was infused. To ensure 
replenishment of the microbubbles in the treatment area, ultrasound impulses 
were applied intermittently (5 seconds off, 1 second on) until all microbubbles were 
destroyed at the site of the occlusion.
After 3 hours of thrombolytic therapy the pigs were terminated and autopsy was 
performed. Brains, kidneys, liver, lungs, heart and spleen were cut in thin slices and 
macroscopically inspected for potential (hemorrhagic) adverse events and tissue 
samples were taken. The left external iliac artery was excised and the persisting 
thrombus and 4 cm surrounding external iliac artery to which it adhered were 
weighed together. As control, four centimeters of the untreated right external iliac 
artery were excised and weighed.
The data were analyzed with SPSS (IBM Statistics v20, Chicago, IL, USA). A Mann-
Whitney-U test or an unpaired Student’s t-test was used to compare continuous 
variables with (non-) parametric distributions. A Chi-square test was used to 
compare proportions between groups. A P-value of 0.05 or less was considered 
statistically significant.
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Figure 1. Overview of experimental protocol
A. Diagram of experimental setting with pig lying supine with site of occlusion highlighted. 
Location of microcirculation-, limb pressure and flow measurements shown in figure.
B. Experimental protocol over time (mins). Each small vertical line on the x-axis represents 
a measurement point. The arrow corresponds to t=0 i.e. the moment of initiation of therapy 
after which immediate measurement followed.
Abbreviations: B = Baseline, S = Stabilization period (10 minutes).
Symbol legend:
= creating stenosis,  = thrombus induction,  = release of the proximal clamp, 





Baseline and thrombus induction before start of therapy
Baseline parameters at the start of the experiments of all pigs and per subgroup 
are presented in Table I. Thrombus induction varied between pigs in duration and 
amounts of thrombin needed (Table II).
123
Contrast-enhanced ultrasound and low-dose urokinase for thrombolysis

















































































































Abbreviations: n= number, kg = kilograms, MAP= Mean Arterial Pressure, ml/min = milliliters 
per minute, mmHg = millimeter of mercury, PU = Perfusion Units, T = Temperature. Values 
presented are medians (range). Baseline parameters were measured after creation of the 
















































































































































































































































































































































































































































































































































































































































































































































Contrast-enhanced ultrasound and low-dose urokinase for thrombolysis
Changes during the experiment after start of therapy
Flow
After induction of the stenosis the median (baseline) flow was 100 ml/min (range 73-
289). After execution of the occlusion protocol complete occlusion of the external 
iliac artery was reached in 7 out of 10 pigs. In three pigs some flow persisted, i.e. 
29% (=84/289; UK+ group), 26% (=27/102; UK+ group) and 54% (=135/250; UK 
group) of their baseline flows.
After 3 hours of treatment, revascularization was regained in the UK+ group in 
4 out of 6 pigs, with a median of 27% (range 0-96) of baseline flow and a mean 
increase of 61% (±42%). However, two of them already regained some flow during 
the stabilization period, as can be observed in Figure 2; right panel. Nevertheless, 
despite incomplete occlusion at the moment of initiation of therapy, arterial flow 
levels in these pigs showed marked increases during the rest of the procedure 
(up to 42% (=121/289) and 96% (=98/102) of baseline flow respectively). Of the 4 
pigs with no arterial flow at the start of therapy, one (b2) showed higher flow, one 
showed temporary increase of flow (b6, reocclusion by embolization) while the 
other two (b4, b5) did not. Changes in flow are presented per pig in Table II. In the 
UK group, no increase in flow was observed in three out of 4 pigs within 3 hours 
of therapy (Figure 2; left panel). One pig had little increase in flow, although the 
occlusion of this pig’s external iliac artery was partial at the time of release of the 
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Figure 3. Microcirculation
Mean microcirculation curves. The two main groups, i.e. based on therapy, are each divided 
in 2 subgroups depending on whether there was total or partial occlusion at the moment 
of initiation of therapy. Unfilled symbols depict pigs treated with urokinase; filled symbols 
depict pigs treated with urokinase + bubbles. The large arrow corresponds to the moment 
of initiation of therapy. Continuous line depicts pigs with total occlusion, dashed line depicts 
pigs with partial occlusion at the moment of initiation of therapy.
Microcirculation
At the start of the experiments the median (baseline) microcirculatory flow was 44 
Perfusion Units (PU, range 28-63). After execution of the occlusion protocol the 
median microcirculatory flow was 21 PU (range 11-31). The microcirculation partly 
remains because of the presence of existing collateral circulation.
In Figure 3 microcirculation levels are depicted for the different treatments 
and stratified for total- or partial occlusion at the moment of initiation of 
therapy. Microcirculation levels reflect a trend towards increase in pigs treated 
with urokinase + bubbles. Changes in microcirculation due to therapy (ΔMC, 
microcirculation at t=180 vs. microcirculation after stabilization thrombus) per 
pig are presented in Table II. They show an increase in microcirculation in 3 out of 




in 2 out of 4 pigs in the UK group (5% and 12%), median change = -22% (-52 – 12) 
in the whole UK group.
Pressures and temperature
Mean arterial limb pressures fluctuated amongst groups during the procedure 
showing a trend to increased pressures in the UK+ group (Figure 2, values at the 
top). Changes in mean arterial limb pressures (Δ limb pressure) per pig as presented 
in Table II show increased limb pressures in 4 out of 6 pigs in the UK+ group, median 
increase of 46% (-6–104), and decreased limb pressures in 3 out of 4 pigs in the UK 
group, median change in limb pressures of -13% (-19–0) in the whole UK group.
Systemic temperature of nearly all pigs (except b1) rose during the procedures 
(overall median increase in systemic temperature: 0.6ºC (-0.1–2.2). There were 
slight temperature changes during the procedure in the affected limbs (Δ T affected 
limb) of all pigs (Table II), however none significant. Temperature of the control 
limbs (Δ T control limb) of all pigs remained the same (Table II).
In one animal of the UK+ group the pig was terminated before the experiment was 
ended after 135 minutes of therapy because of cardiac arrhythmias.
Thrombus weights and absence of bleeding complications at the end of the experiment
Thrombus weights were significantly lower in the pigs of the UK+ group when 
compared to the UK group, median 1.1g (0.8-1.3) vs. 1.6g (1.3-1.9) (P=.01; Figure 
4). The weights of the 4 cm excised right external arteries varied with a maximum 
of 0.03g. Note that all the pigs in the UK+ group had lower thrombus weights 
post-mortem if compared to the pigs in the UK group; the exception in the latter 
group (pig a1) that showed already high flow at the moment of initiation of therapy. 
Importantly, no signs of hemorrhagic complications were observed during the 
procedures or in any of the organs investigated at autopsy.
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Figure 4. Thrombus weights post-mortem
A  B 
Thrombus weights post-mortem grouped and of all individual pigs. Asterisks mark pigs 
in which only partial occlusion was reached before initiation of therapy. NB: note the 
difference in y-axis between grouped (Figure 4A) and individual (Figure 4B) figures. Dark 
columns: UK group, light columns: UK+ group.
Discussion
In this study we investigated the therapeutic application of contrast-enhanced 
ultrasound with low-dose urokinase to enhance thrombolysis in order to lower 
the required doses of urokinase and to shorten therapy duration, both aiming at 
reducing complications. From a clinical perspective, thrombolytic therapy with 
urokinase for peripheral arterial occlusion takes one or more days at average to 
regain vascularization and ensure relief of symptoms5. In the present study we 
observed that in 3 hours of therapy-time, thrombus weights were on average 30% 
lower in animals treated with urokinase + bubbles. Furthermore we observed 
increases in arterial flow, microcirculation and limb arterial pressures in the 
experimental group, whereas in the UK group an increase in arterial flow was 
observed in only one out of four pigs and deterioration of microcirculation and 
limb arterial pressures. This raises the potential for contrast-enhanced ultrasound 
to enhance thrombolysis and shorten therapy duration in humans.
The most feared adverse events during thrombolytic therapy are bleeding 
complications, especially the occurrence of intracranial bleeding. During the 
performed procedures with low-dose urokinase, no signs of bleeding complications 
were observed. Although no conclusions regarding the incidence of (intracranial) 




dose of urokinase lowers the risk of bleeding complications. Furthermore, shorter 
therapy duration could lower the risk of occurrence of other complications as 
well and most importantly lowers patient burden. In the present study the total 
therapy time was unfortunately limited to a maximum of 3 hours, due to ethical and 
practical reasons. However, in 3 hours marked improvement of reperfusion was 
observed in the group with microbubbles without any hemorrhagic complications.
In this study we used pigs for their resemblance to human cardiovascular anatomy 
and coagulation parameters. However, pigs are known to be allergic to nanoparticles‘ 
lipid shell, so we needed to provide medication to prevent allergic reactions13,14. To 
the best of our knowledge, no previous studies have been performed regarding 
thrombolysis with additional contrast-enhanced ultrasound in large animal models 
of peripheral arterial occlusion. In the setting of myocardial infarction Xie et al. 
showed improvement in epicardial recanalization rates as well as improvement in 
microvascular flow to the risk area with contrast-enhanced ultrasound and pro-
urokinase-induced thrombolysis after acute coronary thrombotic occlusion in 
pigs12. This supports the results of our feasibility study. Importantly, treatment 
with contrast-enhanced ultrasound in addition to the administration of fibrinolytics 
could benefit the microcirculation as well. Clinically this could indicate potential 
improvement in the disease management of a patient’s leg microcirculation. A 
potential explanation for the beneficial effects of contrast-enhanced ultrasound 
on the microcirculation could be a NO-dependent mechanism, as opted in the 
coronary setting15.
The potential role of contrast-enhanced ultrasound in thrombolysis has also been 
shown in smaller animal models (rabbit iliofemoral arteries): Nishioka et al.16 and 
Birnbaum et al.17 showed dissolution of in-vivo thrombus after treatment with 
contrast-enhanced ultrasound solely, thus without the use of a thrombolytic drug. 
The (non-targeted) microbubbles were administered intra-arterially (Nishioka 
et al.) and intravenously (Birnbaum et al.), the latter importantly without loss 
of effectiveness compared to intra-arterial infusion. A drawback of treating 
thrombotic occlusions without fibrinolytics is the possible occurrence and 
persistence of distal emboli. The rabbit iliofemoral arteries treated with contrast-
enhanced ultrasound showed no (0 out of 17, Nishioka et al.) or few cases (1 out of 
10, Birnbaum et al.) of distal embolization. Distal emboli can occur during standard 
urokinase therapy, however, the continuous infusion of fibrinolytics dissolves them. 
In our study we also used continuous infusion of low-dose urokinase as part of the 
experimental treatment with microbubbles, which likely dissolves any distal emboli.
The therapeutic application of contrast-enhanced ultrasound and thrombolysis in 
humans is still in pilot stage. In a clinical pilot setting microbubbles in combination 
with ultrasound have shown a trend toward higher early recanalization and 
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clinical recovery rates in acute stroke patients when used as an adjunct to 
standard intravenous tPA therapy9. Despite limitations regarding sample size 
and deployment of operator-dependent techniques this trial shows promising 
results and the authors warrant continuation of clinical trials with contrast-
enhanced thrombolysis. However, in the setting of acute stroke the safety in terms 
of intracranial hemorrhage and micro-embolization of this therapy needs to be 
established first, before evaluating its efficacy in a phase-II clinical trial setting. 
In the acute cardiac care setting a thrombolysis protocol with microbubbles was 
feasible and safe during treatment and follow-up10. In the latter, a trend toward 
a higher epicardial recanalization rate in patients treated with ultrasound and 
microbubbles seems present, although group sizes were too small in that pilot study 
to provide conclusions regarding patency rates. Patient inclusion of this trial is still 
ongoing. Contrast enhanced ultrasound combined with thrombolysis has not been 
applied in patients with critical limb ischemia.
For acute peripheral arterial occlusions in the limbs we recommend more studies 
on the optimization of contrast-enhanced ultrasound techniques for therapeutic 
thrombolytic use: different microbubbles and fibrinolytics as well as different 
infusion protocols could be used to enhance thrombolysis and minimize bleeding 
complications. In this study we were limited to our own low-dose urokinase 
thrombolysis protocol for translational purposes and we used a contrast agent 
that is clinically available and used in our current practice. However, utilization 
of other fibrinolytic agents such as tPA and other market-approved lipid-based 
contrast agents such as Definity (Lantheus Medical Imaging, MA, USA) have also 
proven feasible9,11. Furthermore we used freshly formed thrombus in our model, 
whilst the duration of ‘acute’ formed thrombus in patients at the moment of 
presentation with symptoms can vary from a few hours- to a few days. In addition 
we applied acute damage and induction of thrombotic occlusion in an otherwise 
‘normal’ artery without atherosclerosis. Although we used a standardized thrombus 
induction protocol, in three out of 10 pigs limited flow persisted after release of the 
distal clamps. This variation can most likely be attributed to individual differences 
in coagulation profile. However, resembles the clinical situation of patients: a 
major reduction in flow only could lead to clinical symptoms and requirement of 
thrombolysis. Furthermore, changes in parameters due to therapy remain relevant 
(Table II).
Conclusion
In conclusion, we observed beneficial effects of contrast-enhanced ultrasound on 
thrombolysis with urokinase in extensive peripheral arterial occlusions: a significant 
reduction in thrombus weight was reached in the pigs receiving additional 
contrast-enhanced ultrasound. Moreover, iliac blood flow, microcirculation and 




seems that time to thrombus resolution could be likely shortened. No hemorrhagic 
complications occurred during these experiments. Contrast-enhanced ultrasound 
has the potential to improve thrombolytic therapy in large peripheral arterial 
occlusions: this technique could result in faster revascularization and lowering 
of thrombolytic dose and therefore minimize complications. Our data warrant 
prospective studies in patients with peripheral arterial occlusions.
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Standard therapy in acute peripheral arterial occlusion consists of intra-arterial 
catheter guided thrombolysis. As microbubbles may be used as a carrier for 
fibrinolytic agents and targeted to adhere to the thrombus, we can theoretically 
deliver the thrombolytic medication locally following simple intravenous injection. 
In this intervention-controlled feasibility study, we compared intravenously 
administered targeted microbubbles incorporating Urokinase and locally applied 
ultrasound, with intravenous Urokinase and ultrasound alone.
Materials and methods
In 9 pigs a thrombus was created in the left external iliac artery, after which animals 
were assigned to either receive targeted microbubbles and Urokinase (UK+tMB-
group), or Urokinase alone (UK-group). In both groups, ultrasound was applied at 
the site of the occlusion. Blood flow through the iliac artery and microcirculation 
of the affected limb were monitored and the animals were euthanized one hour 
after treatment. Autopsy was performed to determine the weight of the thrombus 
and to check for adverse effects.
Results
In the UK+tMB-group (n=5), median improvement of arterial blood flow was 5ml/
minute (range 0-216). Improvement was seen in 3 out of these 5 pigs at conclusion 
of the experiment. In the UK-group (n=4), median improvement of arterial blood 
flow was 0ml/minute (-10-18), with slight improvement in 1 out of 4 pigs. Thrombus 
weight was significantly lower in the UK+tMB-group (median 0.9383g (range 0.885-
1.2809) versus 1.5399g (1.337-1.7628; P=0.017). No adverse effects were seen.
Conclusion
Based on this experiment, minimally invasive thrombolysis using intravenously 
administered targeted microbubbles carrying Urokinase combined with local 
application of ultrasound is feasible and might accelerate thrombolysis compared 
to treatment with Urokinase and ultrasound alone.
Key words
Targeted microbubbles, thrombolysis, arterial occlusion, ultrasound contrast 
agents
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Introduction
Acute peripheral arterial thrombosis is a condition threatening both limb and life. 
Treatment of acute peripheral arterial thrombosis with intra-arterial catheter 
guided thrombolysis is successful in many cases, reducing need for (redo) surgery1,2. 
However, thrombolysis takes time, while success of therapy greatly depends on 
duration of ischemia, i.e. time between onset of symptoms and reperfusion3. And, 
albeit minimal, intra-arterial thrombolysis remains invasive, as a catheter is needed 
for local administration of the fibrinolytic agent. Due to a possible longer duration 
of ischemia when using thrombolysis compared to surgical intervention, combined 
with the fact that the procedure still has an invasive aspect, further optimization 
of thrombolytic therapy is needed.
In patients with stroke as well as patients with coronary artery disease, clot lysis 
can be accelerated by local application of ultrasound (i.e. sonothrombolysis) and 
interesting results have been found in patients with peripheral arterial occlusive 
disease4-6. An even further acceleration of clot lysis can be achieved when 
ultrasound contrast agents (UCA’s) are used7-11. In a previous study in a porcine 
model, we found promising results of combining intravenously administered 
microbubbles with standard intra-arterial catheter delivered Urokinase and locally 
applied ultrasound in acute peripheral arterial occlusion12.
UCA’s, or microbubbles, can be used as a vehicle for drug delivery: drugs can either 
be incorporated in the microbubble or attached to the outer layer13-15. Furthermore, 
by attaching Arg-Gly-Asp-Ser (RGDS), the recognition and binding site of platelet 
membrane glycoprotein 2b/3a receptor (GPIIb/IIIa), microbubbles can be targeted 
to adhere to the surface of a thrombus16,17 (Figure I).
In combining incorporation of a fibrinolytic agent in targeted microbubbles 
(tMB) and destroying the tMB with high-intensity ultrasound once attached to a 
thrombus, we theoretically have a less invasive way of applying (local) intra-arterial 
thrombolysis, as placement of an intra-arterial catheter is no longer necessary. Hua 
et al showed promising results of targeted tPA loaded microbubbles in regards to 
efficacy and dosage of tPA needed in a rabbit model of small arterial occlusion. This 
model resembled small occluded arteries in ischemic stroke18. To objectively assess 
the feasibility of this less invasive treatment in large occluded arteries, as is the 
case in acute peripheral arterial occlusion in humans, we designed an intervention-
controlled study using a porcine model. The hypothesis of the study was that 
systemically administered tMB with incorporated urokinase and locally applied 
ultrasound will enhance thrombolysis compared to systemic sonothrombolysis 
alone. To our knowledge, no previous studies have been published exploring the 




loaded microbubbles with ultrasound therapy in an in-vivo model of acute 
peripheral arterial thrombosis.
Figure 1. Schematics of targeted microbubble
SonoVue microbubbles which contain urokinase. The RGDS on the surface of the targeted 
microbubble binds to the glycoprotein 2b/3a receptor of the platelet membrane, keeping the 
microbubble at the site of the occlusion until it is destroyed with a high pressure ultrasonic 
wave and releases its contents locally.
SF6 = Sulphur hexafluoride, UK= Urokinase, RGDS = Arg-Gly-Asp-Ser, GPIIb/
IIIa = glycoprotein 2b/3a receptor
Materials and methods
Approval of the Animal Ethics Committee was obtained before the start of the 
study and all procedures were done in accordance with the Dutch national guideline 
for humane animal treatment (Code Of Practice Welzijnsbewaking van proefdieren, 
2004) as well as the European Directive 2010/63/EU on protection of animals used 
for scientific purposes.
Nine female Yorkshire pigs, 6 to 8 months old and with a median weight of 68kg 
(range 63-75), were housed at the research facility during one week before 
initiation of the protocol to allow for quarantine and acclimatization. Animals were 
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randomly assigned to either the intervention group: intravenously administered 
RGDS targeted microbubbles (tMB) combined with urokinase and local ultrasound 
(UK+tMB-group; n=5) or the control group: intravenously administered urokinase 
and local ultrasound (UK-group; n=4).
Before start of the procedure, all pigs received premedication with 40 milligrams 
(mg) of methylprednisolone and 500mg of indomethacin to prevent potential 
allergic reactions to the microbubbles. Pigs can be allergic to the lipids of the 
microbubble shell. Therefore, this protocol was developed in an earlier study, 
when 4 pigs showed severe allergic reactions to the SonoVue microbubbles19. In the 
same study, our protocol for inducing and maintaining anesthesia was described. 
In short, the pigs were sedated with an intramuscular injection of 28 mg per kg 
body weight ketamine (Alfasan, Woerden, The Netherlands), 0.5 mg per kg body 
weight midazolam (Actavis bv, Baarn, The Netherlands) and 1 mg of atropine 
(Pharmachemie, Haarlem, The Netherlands). Induction of anesthesia followed 
with an intravenous (i.v.) injection of 20 mg etomidate (B. Braun, Melsungen, 
Germany), followed by airway cannulation. During the procedure, we maintained 
anesthesia with endotracheally administered isoflurane, 1.5-2.0% (Pharmachemie, 
Haarlem, The Netherlands) and with 50 µg/h fentanyl (Hameln Pharmaceuticals, 
Hameln, Germany), 50 mg/h midazolam and 20 mg/h pancuronium (Organon, 
Oss, The Netherlands) intravenously. A catheter was placed in the right carotid 
artery to allow for regular arterial blood gas determination and to continuously 
monitor systemic blood pressure. Furthermore, heart rate, oxygenation and 
body temperature were measured during the entire procedure. Thermometers 
were placed between the toes of both hind legs and the left femoral artery was 
cannulated to monitor blood pressure of the affected limb. A laser Doppler probe 
(periflux 4001 master, Perimed, Järfälla, Sweden) was placed transcutaneously 
on the affected limb to measure microcirculation. As described previously12,19,20, 
the left external iliac artery was identified via a midline laparotomy and the 
circumflex iliac artery was ligated. This to provide an adequate vessel length of at 
least 4 cm for our experiment. Blood flow in the iliac artery was measured using 
an ultrasonic flow probe (Transonic-Systems Inc, Ithaca, USA). A stenosis was 
created in the distal external iliac artery to more closely mimic a clinical situation, 
as well as to prevent dislocation of a fabricated clot. The diameter of the vessel 
was reduced with a vascular tourniquet, decreasing the flow in the iliac artery by 
40-60%. To promote adhesion of thrombus to the vessel wall, the endothelium was 
damaged over four centimeters by clamping and declamping the iliac artery. The 
vessel was then clamped proximally and distally and 100 units of bovine thrombin 
(Calbiochem) were injected intraluminally. The proximal clamp was removed after 
60 minutes, the distal clamp after 90 minutes. In case of persistent flow in the iliac 





Once a thrombus was created, it was left to stabilize for another 10 minutes. 
After stabilization, an ultrasound probe (Philips Sonos 7500) with a diagnostic S3 
transducer (Philips, Best, the Netherlands) was directed at the site of the thrombus 
in the iliac artery. In a human setting, the ultrasound probe would be placed on 
the skin directly over the target vessel. As closure of the abdominal wound would 
prevent adequate flow measurements through the iliac vessel, we simulated the 
clinical setting by placing a balloon filled with saline over the occlusion site. The 
ultrasound probe was placed on the balloon, resulting in a distance between the 
probe and the treatment vessel of 3cm. The mechanical index (MI) was set to 1.1 
with a focus of 3cm and a frequency of 1.6 MHz.
The pigs in the UK+tMB-group (intervention group) now received an intravenous 
bolus injection of 500 000 units of urokinase combined with 2 vials of targeted 
microbubbles (10cc all together, containing 8µl of microbubbles per cc), followed 
by three repeated gifts of 50 000 units urokinase combined with 1 vial of targeted 
microbubbles every fifteen minutes (5cc), leading to a total treatment period of 
1 hour. The ultrasound contrast agent used was SonoVue (Bracco Diagnostics 
Inc, Milan, Italy), which contains sulphur hexafluoride (SF6) encapsulated by 
phospholipids (Macrogol 4000, DSPC, DPPG, Palmitic acid). As described by Mu 
et al, RGDS adheres to components of the SonoVue microbubble outer layer via 
ionic bonds or physical adsorption17. To create the targeted microbubbles, we 
followed the same direct conjugation method, wherein the urokinase and RGDS 
peptide (Tocris bioscience, Bristol, UK) were added to 5ml of normal saline. The 
SonoVue powder was diffused in this solution and shaken for 1 minute to create the 
urokinase loaded targeted microbubbles. Before each injection, heart rate (BPM), 
blood pressure (mmHg) and temperature of the pig (°C) were measured, as well 
as blood flow through the vessel (ml/min), microcirculation in the affected limb 
(Perfusion Units; PU) and temperature of both limbs (°C). For the UK-group (control 
group), the same protocol was adhered to, with exclusion of the microbubbles. As 
UCA’s are visible on ultrasound, the investigators were not blinded to the type of 
treatment given.
Ultrasound treatment was initiated during the start of infusion of the urokinase. 
In order for the microbubbles in the UK+tMB-group to satiate the treatment area, 
ultrasound impulses were applied intermittently (5 seconds off, 1 second on) until 
all microbubbles were destroyed. With a pulse duration of 3µs, the pulse repetition 
frequency was 24kHz, with a total exposure time of less than 10 minutes. One 
hour after last injection of urokinase, the pigs were euthanized and autopsy was 
performed. All organs were macroscopically inspected for possible (hemorrhagic) 
adverse events and tissue samples were taken. The weight of persisting thrombus 
in the iliac artery was measured. Primary endpoints were flow through the affected 
vessel and weight of thrombus at termination of the procedure. Secondary 
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endpoints were microcirculation, blood pressure and temperature of affected limb 
as well as any adverse events.
Data were analyzed with SPSS (IBM Statistics v20, Chicago, IL, USA). An unpaired 
Student’s t-test or a Mann-Whitney-U test was used for comparison of continuous 
variables with (non-)parametric distribution and a Chi-square test was used to 
compare proportions between groups. A P-value of 0.05 or less was defined as 
statistically significant.
Results
Baseline characteristics were similar in both groups with regard to weight, core 
temperature, blood pressure both systemic and in the affected limb, flow through 
the iliac artery after creation of stenosis (= baseline flow) and percentage of flow 
reduction due to creation of the stenosis (Table I).
Median time to creation of thrombus was 170 minutes (range 93-200) in the 
UK+tMB-group versus 120 minutes (89-220) in the UK-group (P=0.524) and 
median units of thrombin needed for creation of the thrombus was 200 (range 
100-225) in the UK+tMB-group and 163 (100-350) in the UK-group and (Table II). 6
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Abbreviations: n= number, kg = kilograms, MAP= Mean Arterial Pressure, ml/
min = milliliters per minute, mmHg = millimeter of mercury, PU = Perfusion Units, 
T = Temperature, ns = not significant. Values presented are medians (range)
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A complete occlusion was reached in 6 out of 9 pigs. There was some residual flow 
through the iliac artery in 3 pigs, respectively 49% (51/104ml/min; UK+tMB-group), 
38% (=50/131ml/min; UK-group) and 4% (9/213ml/min; UK-group) of baseline flow.
In the UK+tMB-group, 4 out of 5 pigs showed increase in arterial blood flow during 
the experiment. One pig showed a complete return to baseline flow (216/207ml/
min =104%) at the end of the procedure. Of the other 4 pigs in the UK+tMB-group, 
2 more showed improvement in arterial flow at conclusion of the experiment. 
One of these had a partial occlusion at start of therapy and showed an increase in 
arterial flow of 5ml/min. The second had complete occlusion at initiation of therapy 
and showed an increase of 97ml/min, returning to 86% of baseline flow. Of the last 
2 pigs in the UK+tMB-group, 1 showed a temporary increase in flow (49/130ml/
min = 38% of baseline flow) followed by re-occlusion, most likely due to peripheral 
embolization (Figure 2a).
In the UK-group, 2 out of 4 pigs had a partial occlusion at start of therapy. One of 
these showed slight improvement of arterial flow at the end of the experiment 
(18ml/min) and one showed a decrease in blood flow of 10ml/min; the 2 pigs with 
a complete occlusion at the start of treatment did not show any improvement with 
UK therapy (Figure 2b).
Figure 2. Arterial blood flow
A
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B
Arterial blood flow of individual pigs in the intervention group (Figure 2a) versus the control 
group (Figure 2b). Group mean systemic- and limb arterial pressures are shown at the top 
of both graphs. Unfilled symbols depict partial occlusion at start of therapy; filled symbols 
depict complete occlusion. The arrow corresponds to the moment of initiation of therapy, 
i.e. t=0. S = thrombus stabilization period.
= Administration of:  = 500 000U Urokinase,  = 50 000U Urokinase, 
 = 1 vial of microbubbles
Microcirculation
Median baseline microcirculatory flow was 36 PU (range 20-149), 39 in the 
UK+tMB-group and 32 in the UK-group (Table I). After stabilization of thrombus, 
median microcirculation in the entire group decreased to 27 PU (range 9-35). In 
Table II, differences in microcirculation at initiation of therapy versus at the end 
of the experiment are shown per individual pig. Out of the 5 pigs in the UK+tMB-
group, 4 showed increase in microcirculation (range -13-139 PU); median difference 
43%. In the UK-group, 2 out of 4 pigs show a slight increase in microcirculation 
(range -4-3 PU) with a median difference of -4%. In figure III, mean microcirculation 
curves of the 2 treatment groups are shown, divided in 2 subgroups depending on 





Mean microcirculation curves of the two groups, divided in 2 subgroups depending on total 
or partial occlusion at the start of therapy. Unfilled symbols depict partial occlusion at start 
of therapy; filled symbols depict complete occlusion. The arrow corresponds to the moment 
of initiation of therapy, i.e. t=0. S = thrombus stabilization period.
 = Administration of UK with or without microbubbles
Blood pressure and temperature
Mean systemic arterial pressures dropped 15% in both groups during the 
experiment. In both the UK+tMB-group and UK-group mean limb arterial pressures 
varied only slightly. There was no significant difference between mean limb arterial 
pressures at the start of therapy versus at the end of the experiment (ΔMAP limb) 
in either group, nor was there a difference noticeable between the groups (Table 
II/Figure 2).
During the procedure, systemic temperatures of all but 1 pig (b1) rose, with a 
median increase of 1.2°C (range -0.7-2.9). All pigs showed slight temperature 
changes in the affected limb from baseline temperature to end of procedure (ΔT 
affected limb), but there were no significant differences between both groups. The 
same was true for temperatures of the control limb (Table II).
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Thrombus weight
The median thrombus weight at the end of the procedure was 0.9383g (0.885-
1.2809) in the UK+tMB-group and 1.5399g (1.337-1.7628) in the UK-group 
(P=0.017) (Figure 4). All pigs in the UK+tMB-group had a lower thrombus weight 
at autopsy than pigs in the UK-group. In the UK+tMB-group, thrombus weighed 
between 0.89 and 0.98g in 4 out of 5 pigs. The last pig in the UK+tMB-group (a5) 
however, had a markedly higher thrombus weight of 1.28g.






Thrombus weights post-mortem grouped (a) and of individual pigs (b). NB: there is a 
difference in y-axis between grouped and individual figures.
UK = Urokinase, tMB = targeted Microbubbles
 UK + tMB group,    UK + tMB group, partial   
 complete occlusion   occlusion at start of therapy
 UK group    UK group, partial    
 complete occlusion   occlusion at start of therapy
Adverse events
Apart from possible embolization in 1 pig (a5), no adverse events were encountered 
during the experiments and no signs of adverse effects were found at autopsy, 
especially no signs of hemorrhage.
Discussion
Outcome of acute peripheral arterial thrombosis varies from complete recovery 
to amputation and greatly depends on duration of ischemia3. Optimization of 
therapy is needed to increase limb survival. The combination of fibrinolytic therapy, 
ultrasound and UCA’s (ultrasound contrast enhanced sonothrombolysis) shows 
promising results regarding time to reperfusion in both cerebral and myocardial 
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infarction4,9,21, as well as in our earlier study in a porcine model of acute peripheral 
arterial occlusion12. Further optimization of thrombolysis might be achieved by 
avoiding use of intra-arterial catheters and by accelerating lysis.
UCA’s can be loaded with a drug and targeted to adhere to a specific site. Once 
attached to this site, they can be destroyed with high-intensity ultrasound, releasing 
the preloaded drug at the designated location14. In this study, we used UCA’s as 
a vehicle for the fibrinolytic agent, thus avoiding placement of an intra-arterial 
catheter. The use of the carrier function of thrombus targeted microbubbles to 
create a form of minimally invasive local intra-arterial thrombolysis has -to our 
knowledge- not been described before in an in vivo model of acute peripheral 
arterial occlusion.
At the end of this short experiment, we observed an increase in arterial blood flow 
in 3 out of 5 pigs in the UK+tMB-group, whereas only 1 out of 4 pigs in the UK-group 
had a slight increase in arterial blood flow. Only partial occlusion was reached in 3 
out of 9 pigs at start of therapy. Two of the pigs with only partial occlusion at start of 
therapy were treated in the UK-group. One of these showed further deterioration 
during the experiment and the other showed only minor improvement. Therefore, 
reaching only partial occlusion in 3 out of the 9 pigs does not bias our experiment in 
favor of the UK+tMB-group. Thrombus weights at autopsy were significantly lower 
in the UK+tMB-group versus the UK-group. Interestingly, one pig in the UK+tMB-
group (a5) had a markedly higher thrombus weight of 1,28g compared to other pigs 
in this group. This was the same pig that had a temporary increase in arterial blood 
flow during the experiment, after which the iliac artery re-occluded. The temporary 
increase in blood flow as well as the higher thrombus weight might be explained 
by embolization occurring during therapy. We did not find sufficient evidence to 
prove or disprove this theory at autopsy. Apart from possible distal embolization 
in this one case, there were no signs of adverse events during the experiments or 
at autopsy. Based on this experiment, a less invasive manner of sonothrombolysis 
seems feasible for acute peripheral arterial occlusion.
We realize there are some limitations to this study. Duration of therapy was shorter 
than is usual in a clinical setting and we did not examine possible long term effects 
of the tMB combined with urokinase and ultrasound on local tissue. However, based 
on ethical considerations of animal welfare, longer duration of the experiment was 
not justified. Study population was kept small based on the same ethical principles.
Although some promising results were found in this experiment, further research 
on biomechanical properties of the microbubbles is necessary. More information 
is needed towards the exact concentration of incorporated Urokinase in the 




and the therapeutic effect of the RGDS, before this therapy can be investigated in 
patients. We will conduct in-vitro studies and investigate the targeted microbubbles 
on their stability, dose response- and temporal efficacy in order to assess their 
optimal configuration.
Conclusion
This study showed that minimal invasive thrombolysis is feasible using 
intravenously administered targeted microbubbles carrying urokinase combined 
with local application of ultrasound. This technique is effective and might accelerate 
thrombolysis, which is potentially beneficial in patients with acute peripheral 
arterial thrombosis. Further research regarding stability, dose response- and 
temporal efficacy is needed to assess optimal configuration of the microbubbles.
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To evaluate the feasibility of combining microbubble infusion with ultrasound 
catheter directed thrombolysis for peripheral arterial occlusions.
Methods
The effects of the ultrasound (US) catheter (EkoSonic Endovascular Device) on 
microbubble survivability were investigated in an in-vitro model in which the 
ultrasound catheter was placed into a vascular phantom. Microbubble infusion 
was done either through the drug delivery lumen of the ultrasound catheter (DDC, 
n=10 without US, n=10 with US) or through the lumen of the vascular phantom 
(intravascular infusion, n=10 without US, n=10 with US). Microbubble survivability 
was assessed by measuring bubble samples pre- and post-infusion and corrected 
for dilution. Two groups (n=5 per group) were defined for each of the infusion 
methods: the ultrasound catheter was either OFF or continuously ON.
In a second experiment, the thrombolytic efficacy was investigated in-vivo in 
a porcine model (n=5) with a 4 cm peripheral arterial occlusion. The treatment 
consisted of microbubble infusion through the drug delivery lumen of the 
ultrasound catheter during the first hour of continuously ON ultrasound assisted 
thrombolysis with a low-dose urokinase protocol (50.000 IU/hour) for 3 hours. 
The measured determinants for lytic effect were thrombus weight and remaining 
length of thrombus post-mortem.
Results
The ultrasound setting significantly influenced microbubble survivability between 
the OFF vs. ON groups (P<.001) with a relative decrease in concentration of 
42% when the ultrasound setting was ON. Microbubble survivability was not 
significantly influenced by mode of infusion through the DDC or tube lumen of the 
vascular phantom. In the porcine model, the median thrombus weight post-mortem 
was 1.02 grams (0.96-1.43). The median length of the remaining thrombus after 
3 hours of treatment was 2.25 cm (1.5-4.0). These are significantly lower median 
thrombus weight and shorter median thrombus length as compared to our historic 
control group.
Conclusion
Microbubbles can be combined with an ultrasound catheter and could potentially 
accelerate thrombolytic treatment of peripheral arterial occlusions. Future studies 
are warranted to investigate how best to combine the microbubbles with the 
ultrasound catheter before clinical application.
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Introduction
Catheter directed thrombolysis (CDT) has been an effective treatment for patients 
with non-threatening acute limb ischemia for the last two decades.1 Limitations 
of this treatment include bleeding complications in up to 13% of patients and an 
extended time needed for revascularization, which places a heavy burden on the 
patient.2,3 Therefore, acceleration of thrombolytic treatment is needed to minimize 
risks and limit patient burden.
Recently, several studies have investigated ultrasound (US) as an accelerator 
of thrombolytic treatment for peripheral arterial occlusions.4-7 The potential 
effects of ultrasound on clot dissolution include mechanical and chemical effects 
such as acoustic cavitation, microstreaming, mechanical erosion, intracellular 
microcurrents, thermal warming and increased clot permeability. The only 
randomized controlled clinical trial (RCT) comparing ultrasound accelerated 
thrombolysis (n=18) to conventional catheter directed thrombolysis (n=32) 
showed that therapy time for thrombolytic treatment is significantly reduced with 
ultrasound accelerated thrombolysis vs. conventional thrombolysis (17.7 vs. 29.5 
hours, respectively, P=.009).8 However, this decrease came at the cost of major 
bleeding complications in both treatment arms (11 vs. 6%, respectively) including 2 
cases of intracranial bleedings. Potentially this is due to the high dose of fibrinolytic 
agents administered (100,000 International Unit per hour), since several RCTs from 
the 1990s report similar bleeding rates with a high dose protocol.9,10
Another technique to potentially accelerate thrombolysis is contrast-enhanced 
ultrasound, utilizing micro sized gas-filled bubbles (i.e. microbubbles (MBs)) that 
collapse when exposed to high-intensity US and augment the effects of ultrasound 
on clot dissolution.11 This technique has been evaluated in a porcine model of 
peripheral arterial occlusion and accelerated catheter-directed thrombolysis with 
a low-dose urokinase protocol.12 Limitations include the external application of 
US, which has inter-operator variability and the safety, feasibility and application 
of this technique has yet to be investigated in clinical studies. In addition, the 
administration of microbubbles in this technique is intravenous, whereas intra-
arterial administration of microbubbles theoretically could result in a higher local 
dosage of microbubbles and therefore more clot dissolution effect.
A treatment using an ultrasound catheter in combination with intra-arterial 
infusion of microbubbles through its drug delivery lumen could increase efficacy 
of thrombolysis without inter-operator variability of ultrasound application. This 
concept has recently been illustrated with in-vitro data combined with an in-vivo 
model of inferior vena cava thrombosis treated with a custom-designed ultrasound 




for models of peripheral arterial occlusion and furthermore the effects of clinically 
available ultrasound catheters on FDA/EMEA allowed microbubbles are as yet 
unknown.
The aim in the present paper is twofold: to assess whether microbubbles can be 
used in combination with an ultrasound catheter, and to assess the lytic efficacy 
of microbubble accelerated low-dose thrombolysis using an ultrasound catheter 
in a validated porcine model of peripheral arterial occlusion.14
Methods
In-vitro model
In an in-vitro set-up (Figure 1) an ultrasound catheter (EKOS EkoSonic System, EKOS 
Corp, Bothell WA, USA,) was placed into a vascular phantom.15 Two infusion pumps 
(Perfusor FM, B. Braun, the Netherlands) were attached to the catheter system 
to infuse saline at a rate of 0.3 mL/min through the drug delivery lumen of the 
catheter (DDC) and at a rate of 50 mL/hour through the coolant lumen. A third 
pump infused saline into the tube lumen of the vascular phantom to mimic blood 
flow at a rate of 1 mL/min. All pumps were validated for exact flow rates to correct 
small deviations in flow.
SonoVue microbubbles (Bracco International B.V., Amsterdam, the Netherlands, 
clinically approved for diagnostic use in Europe) were 1000x or 100x diluted with 
saline to a concentration in the range of 107/ml or 108/ml and used to replace the 
saline infusion through the drug delivery lumen of the catheter or through the 
vascular phantom lumen.
The pumps ran for 5 minutes before the start of the experiments to fill the dead 
spaces in the in-vitro setup. Immediately after the 5 minutes of priming the pumps 
ran for 10 minutes per experiment at constant flow rates. The part of the vascular 
phantom which contained the catheter treatment area was submerged in a 37˚ 
Celsius water bath. The mix of drug delivery flow and vascular phantom flow was 
collected in a glass column. The saline that was infused through the coolant lumen, 
was collected separately.
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Figure 1: in-vitro set-up with ultrasound catheter in vascular phantom
Bubble survivability
Bubble survivability of the SonoVue microbubbles was measured by comparing 
microbubble concentrations pre- and post-infusion through the catheter system. 
For the microbubble concentration pre-infusion an average of two samples 
at t=0 min and t=10 min was used to correct for differences through time. The 
microbubble concentration post-infusion was corrected for dilution by tube flow 
based on the total infused- and collected volumes. Microbubble samples were 
analyzed using a MultiSizer 3 Coulter counter (Beckman Coulter Nederland B.V., 
the Netherlands) using a 50 um aperture (detection limits 1.0-30.0 um) and 0.9% 
saline buffer (100 uL sample volume, 100 mL electrolyte volume, 500 uL analytic 
volume). Different groups (n=5 per group) were evaluated based on the ultrasound 
catheter settings, i.e. either OFF or continuously ON.
Microbubble infusion was either through the drug delivery lumen of the ultrasound 
catheter (DDC) to simulate intra-arterial infusion nearby the thrombus, or into the 
tube lumen of the vascular phantom directly proximal to the catheter treatment 
area, to simulate systemic intravenous microbubble infusion.
Porcine model of peripheral arterial occlusion
The lytic efficacy was evaluated in a porcine model (n=5) of peripheral arterial 
occlusion. Approval of the Animal Ethics Committee (AEC) was obtained before 
initiation of the study (local registration number FYS 10-11). Five Yorkshire pigs 
with a median weight of 67 kg (64-74) were used. The porcine model of peripheral 
arterial occlusion was used as previously described (Lab Animal 2014). After 
creation and stabilization of a 4cm thrombus in the external iliac artery, this 
experimental treatment group was treated for 3 hours with an ultrasound catheter 
(continuously ON) and 4 vials of SonoVue microbubbles infused through the DDC 
during the first hour. A low-dose thrombolysis protocol was used with 50,000 




The measured determinants for lytic effect were thrombus weight and remaining 
length of thrombus post-mortem.
Statistics
Data was analyzed using SPSS (IBM Statistics v20, Chicago, IL, USA and presented 
as medians (range) in case of non-parametric distribution or as means ±SD in case of 
a parametric distribution. A Mann Whitney-U test was used to compare continuous 
variables with non-parametric distributions between groups. A bonferroni 
correction was used in the case of multiple comparisons to decrease the likelihood 
of a Type I error. A P value less than .05 was considered statistically significant.
Results
Microbubble survivability
Data from the experiments are presented in Table I, included are pre- and post-
infusion microbubble characteristics and survivability.
Table I: Microbubble survivability results of the different experimental groups
A: 50um aperture used, n=5 each group

















































































Microbubble accelerated low-dose thrombolysis using an ultrasound catheter
B: 30um aperture used, n=5 each group
US OFF US ON
pre post Δ% pre post Δ%














































































Presented are median pre- and post-infusion diameters and concentrations of the 
experimental groups with either infusion through the Drug Delivery lumen of the Catheter 
(DDC, n=10) or tube lumen (n=10) with the UltraSound (US) core either switched OFF (n=10) 
or ON (n=10). Survivability is presented based on the pre- and post-infusion concentrations 
of samples corrected for dilution based on the total infused and collected volumes.
Abbreviations: DDC = Drug Delivery lumen Catheter, US = ultrasound, MB = microbubble, 
diam = diameter, conc = concentration, ∆% = relative difference post vs. pre-infusion MB 
diam expressed in %, %survival = MB post-conc/MB pre-conc expressed in %.
Mode of infusion: DDC vs. tube lumen
The mode of infusion of microbubbles through the DDC (simulating intra-arterial 
infusion ) or into the tube lumen of the vascular phantom (simulating systemic 
intravenous infusion) did not significantly influence the bubble survivability. This 
is illustrated by the small differences between the DDC (blue) and tube lumen (red) 
bars within the two US setting groups (Figure 2). Nor did it significantly influence 
the size of the microbubbles.
Ultrasound setting: OFF vs. ON
Whether the ultrasound was OFF or ON influenced microbubble stability 
significantly. For DDC infusion with ultrasound OFF (50um aperture, 1000x 
dilution), a median 94% (70-99) of the microbubble concentration was measured 
post infusion, decreasing to a median 58% (37-81) in the ON group, (P<.001). For 
the 30um aperture measurements with 100x dilution a median 81% (69-99) of the 
microbubble concentration was measured post infusion, decreasing to a median 




For tube lumen infusion with ultrasound OFF (50um aperture, 1000x dilution), 
a median 81% (72-91) of the microbubble concentration was measured post 
infusion, decreasing to a median 46% (35-60) in the ON group, (P<.001). For the 
30um aperture with 100x dilution a median 73% (55-93) of the microbubble 
concentration was measured post infusion, decreasing to a median 42% (28-47) 
in the ON group, (P<.001). This illustrates a relative decrease in concentration of 
41% and 35% (50um aperture, 1000x dilution) and 13% and 31% (30um aperture, 
100x dilution) when the ultrasound setting is ON in the DDC- and tube lumen 
infusion groups, respectively.
In addition, ultrasound application influenced the median size of the microbubbles 
significantly. For DDC infusion with ultrasound OFF (50um aperture, 1000x 
dilution), a median change in size of the microbubbles of +6.5% (3.6-16.2) was 
measured between pre- and post-infusion, vs. a change of -7.9% (-13.9;-0.2) with 
ultrasound ON, (P=.014). For the 30um aperture with 100x dilution a median 
change in size of the microbubbles of -10.2% (-20.0;3.79) was measured between 
pre- and post-infusion with ultrasound OFF, vs. a change of -22.5% (-25.6;-21.2) 
with ultrasound ON, (P=.008).
For tube lumen infusion with ultrasound OFF (50um aperture, 1000x dilution), 
a median change in size of the microbubbles of +3.8% (-2.1;5.5) was measured 
between pre-and post-infusion, vs. a change of -9.4% (-21.2;-6.1) with ultrasound 
ON, (P=.014). For the 30um aperture with 100x dilution a median change in size 
of the microbubbles of -6.3% (-14.0;-1.4) was measured between pre-and post-
infusion, vs. a change of -19.7% (-19.0;-22.5) with ultrasound ON, (P=.008).
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Figure 2: Microbubble survivability after infusion in a vascular phantom, 
50um aperture (2A), 30um aperture (2B) and all experiments combined (2C)
Depicted are medians (range) of groups with n=5. Microbubbles were infused either 
through the drug delivery lumen of the catheter (DDC, simulating intra-arterial infusion) 
or directly into the vascular phantom (simulating intravenous infusion). Bubble survivability 
is measured by the microbubble concentration ratio post/pre infusion. The post infusion 
concentration was corrected for dilution by the tube flow following from the infusion rates 
and collected volumes.
Abbreviations: DDC = Drug Delivery lumen Catheter, US = ultrasound n = amount of 
experiments, ∆=relative difference between groups, ** = 2 outliers (100, 100).
Lytic efficacy
In a series of different experiments in a porcine model as described in the methods 
section of this manuscript, the lytic efficacy was evaluated. The median thrombus 
weight post-mortem was 1.02 grams (0.96-1.43). The median length of the 
remaining thrombus after 3 hours of treatment was 2.3 cm (1.5-4.0). In previous 
experiments of conventional catheter-directed thrombolysis in the same model, 
these were 1.6 grams (1.3-1.9) and 4 cm (2.5-4.0), respectively. [Ebben JVS 2014] 
Four out of five experiments were completed and treated with microbubble infusion 
through the ultrasound catheter. Unfortunately, one of five pigs died before the 
start of the experiment due to cardiac and respiratory failure, probably caused 
by hypersensitivity to the anaesthesia. Since 1 dropout was accounted for in our 
AEC protocol the experiment was not repeated. In two experiments arrhythmias 
occurred despite a preventive protocol as previously described [Lab Animal]. One 
of these experiments was therefore prematurely terminated 15 minutes before 
the planned end of the experiment.
Discussion
The present manuscript showed that in an in-vitro model the mode of infusion 
(simulated intra-arterial infusion through the catheter vs. simulated intravenous 
infusion through the tube lumen of the vascular phantom, see Figure 2) did not 




the impact of the ultrasound of this catheter on microbubble survivability allows 
for either intravenous- or intra-arterial infusion of microbubbles to accelerate 
thrombolytic treatment. In addition, the size of the drug delivery lumen and the 
side holes in the catheter are adequate for intra-arterial infusion of Sonovue 
microbubbles at a rate of 0.3 mL/minute.
Regarding ultrasound settings, microbubble survivability was significantly different 
between US settings groups (P<.001) with relative decreases in concentration of 
13-41% and 31-35% when the ultrasound setting is ON in the DDC- and tube lumen 
infusion groups, respectively.
For DDC infusion with ultrasound OFF, a median 94% (70-99, 50um aperture 
1000x dilution) and 85% (69-99, 30um aperture, 100x dilution) of the microbubble 
concentration was measured post infusion. This suggests that microbubbles are 
able to pass through the ultrasound catheter side holes. For tube lumen infusion 
with ultrasound OFF, a median 81% (72-91, 50um aperture 1000x dilution) and 
74% (55-93, 30um aperture, 100x dilution) of the microbubble concentration 
was measured post infusion. This loss in concentration could be attributed to 
mechanical loss, residual concentration in the in-vitro model or measurement error. 
Nevertheless, the concentration is significantly higher than the concentration of 
microbubbles which survived in the ultrasound ON group.
If the ultrasound was continuously ON, medians of 58% (37-81, 50um aperture 
1000x dilution) and 62% (49-70, 30um aperture, 100x dilution) of microbubble 
concentration were measured post infusion in the DDC group and medians of 46% 
(35-60, 50um aperture 1000x dilution) and 42% (28-47, 30um aperture, 100x 
dilution) in the tube lumen groups. These are significantly lower concentrations 
compared to the OFF setting (P<.001). This suggests that the effect of continuous 
ultrasound application results in a median decrease in microbubble concentration 
after infusion of 41% and 35% (50um aperture, 1000x dilution) and 23% and 32% 
(30um aperture, 100x dilution) as compared to an OFF setting in the DDC and tube 
lumen groups, respectively. Additionally, this drop in microbubble concentration 
with the application of US could indicate potential for a therapeutic effect if 
the microbubbles were destroyed at the site of interest, i.e. after infusion into a 
thrombus near the surface of the catheter.
Additionally, the median size of microbubbles changed significantly in the 
experiments post- vs. pre-infusion with the ultrasound ON setting measured with 
the 50um aperture (DDC -7.9%, tube lumen -12.7%) and with the 30 um aperture 
(DDC -22.5%, tube lumen -19.7%). This could imply that ultrasound has more impact 
on larger microbubbles than smaller ones, with larger microbubbles collapsing and 
smaller more stable microbubbles forming simultaneously, causing a shift in the size 
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distribution. Some of the smaller microbubbles sizes measured post infusion may 
have been debris from the destruction of larger microbubbles rather than actual 
small microbubbles since the MultiSizer 3 Coulter counter does not distinguish 
between small bubbles and debris. Nevertheless, the decrease in median size is 
small and it may not have any clinical significance.
In the present manuscript, we have focused on the feasibility of the combination 
of microbubbles and an ultrasound catheter for accelerated thrombolysis of 
peripheral arterial occlusions. As described above, we demonstrated the efficacy 
of the combined US and microbubbles thrombolytic process in our porcine model. 
Since we had already performed functional experiments in our porcine model of 
peripheral arterial occlusion with conventional low-dose CDT we chose to not 
include the same control group for comparison in the US and microbubble study 
for ethical reasons. We will, however, compare the results in this discussion section.
The median thrombus weight post-mortem in the present in vivo study was 1.02 
grams (0.96-1.43); whereas the median thrombus weight in the conventional 
low-dose CDT group (n=4) in the previous study was 1.59 grams (1.27-1.90). The 
median thrombus weight in the experimental group in the previous study (US + 
intravenous microbubbles, n=6) was significantly lower than its controls at a median 
1.12 grams (0.83-1.25, P=.01). Regarding remaining thrombus length after 3 hours 
of treatment, the median length was 2.3 cm (1.5-4.0) in the present study vs. 4.0 
cm (2.5-4.0) in the conventional low-dose CDT group of the previous study and 
2.5 cm (1.5-4.0) in the experimental group. Although the weights and remaining 
thrombus lengths of the present and previous experiments cannot be compared 
directly, these results suggest that treatment with microbubble accelerated low-
dose thrombolysis using an ultrasound catheter could potentially accelerate 
thrombolytic treatment of peripheral arterial occlusions.
The present manuscript is the first study to report experiments utilizing the 
combination of a clinically used ultrasound catheter and microbubbles approved for 
administration in humans. It shows both in-vitro data on microbubble survivability, 
as well as data on the lytic efficacy of this concept in an in-vivo model of peripheral 
arterial occlusion.
Recently, Gao et al. reported that combining intra-clot microbubble mediated 
ultrasound cavitation with catheter-directed techniques can significantly improve 
the efficacy of thrombolysis, both in-vitro and in a rabbit inferior vena cava 
thrombosis model [ref Gao]. Treatment duration resembled a bolus technique of 
microbubbles for 10 minutes and thrombolysis up to 60 minutes. Nevertheless, 
significant lytic effects were observed compared to the controls in this model. 




on microbubble survivability were not reported in the latter study, nor were the 
effects of clinically available ultrasound catheters on microbubbles approved 
for clinical use evaluated to this end. In our porcine model of peripheral arterial 
occlusion, microbubble treatment was performed for 60 minutes and thrombolytic 
treatment continued for a total of 3 hours.
In the present in-vitro study we used the EKOS ultrasound catheter system that 
is approved for clinical use and has been shown to accelerate thrombolysis of 
peripheral arterial occlusions compared to a conventional thrombolysis catheter 
[DUET 2015]. However, no data is available yet about the effects of this catheter 
on microbubble survivability when used for microbubble accelerated thrombolysis. 
The in-vitro data of this study shows that the combination of this catheter and 
microbubbles is feasible.
The lytic efficacy in our porcine model was evaluated after 3 hours of treatment. 
This is shorter than the clinical situation of patients with peripheral arterial 
occlusions with average treatment durations of 2 or 3 days. Significantly longer 
treatment durations are not practical for ethical and logistic reasons in a porcine 
model [ref Creager NEJM]. Despite this shorter treatment duration, its effects 
are significant: median thrombus weights and median lengths of the thrombi 
post-mortem were significantly lower and shorter compared to the results of 
conventional catheter-directed thrombolysis in the same model in previous 
experiments [Ebben JVS 2014].
Limitations of this study
Since this study represents in-vitro and in-vivo models to simulate a clinical 
technique it is limited by several factors: in the in-vitro setting the tube flow rate 
(1.0 mL/min) was low compared to arterial flow in order to measure reliable and 
reproducible concentrations with the coulter counter. However, the lower flow rate 
resembles a low flow state in a thrombosed artery of a patient. In addition, we didn’t 
account for the influence of blood on the microbubble survivability when they exit 
the catheter side holes in the in-vitro model. Moreover, this manuscript focuses on 
feasibility and used small group sizes, which renders preliminary data that doesn’t 
show normality and has variability. Our study warrants future studies to validate 
these results and to focus on more mechanistic detail. However, our study indicates 
that microbubble infusion combined with an ultrasound catheter shows significant 
decrease in microbubble survivability. However, sufficient microbubbles survived 
to support the feasibility of using this combination to accelerate thrombolysis of 
peripheral arterial occlusions.
The in-vivo model also has several limitations as previously reported including 
hyper acute thrombosis, which might influence thrombus composition, and a 
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shorter treatment time compared to the clinical situation [JVS 2014]. Despite these 
limitations we believe the set aims of this study were reached and we are able 
to continue on to the next step of evaluating microbubble accelerated low-dose 
thrombolysis of peripheral arterial occlusions using an ultrasound catheter.
In conclusion, it is feasible to combine microbubbles with an ultrasound catheter 
in-vitro and the combination can accelerate thrombolytic treatment of peripheral 
arterial occlusions in an in-vivo model. However, our study indicates that 
microbubble infusion combined with an ultrasound catheter shows significant 
decrease in microbubble survivability. Therefore, future studies are warranted to 
investigate how to combine the microbubbles with the ultrasound catheter before 
clinical application.
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Acute peripheral arterial occlusions can be treated with intra-arterial catheter-
directed thrombolysis as an alternative to surgical thromboembolectomy. Although 
less invasive, this treatment is time-consuming and carries a significant risk of 
hemorrhagic complications. Contrast-enhanced ultrasound using microbubbles 
could accelerate dissolution of thrombi by thrombolytic medications due to 
mechanical effects caused by oscillation; this could allow for lower dosages of 
thrombolytics and faster thrombolysis, thereby reducing the risk of hemorrhagic 
complications. In this study, the safety and practical applicability of this treatment 
will be investigated.
Methods and analysis
A single-arm phase-II trial will be performed in 20 patients with acute peripheral 
arterial occlusions eligible for thrombolytic treatment. Low-dose catheter-
directed thrombolysis with urokinase will be used. The investigated treatment 
will be performed during the first hour of thrombolysis,consisting of intravenous 
infusion of 4 Luminity vials (1.5 mL each, diluted with saline 0.9% to 40 mL total) 
of microbubbles with the use of local ultrasound at the site of occlusion. Primary 
endpoints are the incidence of complications and technical feasibility. Secondary 
endpoints are angiographic and clinical success, duration of thrombolytic infusion, 
treatment-related mortality, amputations, additional interventions, and quality of 
life.
Ethics and disemmination
Ethical approval for this study was obtained in 2015 from the Medical Ethics 
Committee (METC) of the VU University Medical Center, Amsterdam, the 
Netherlands. A statement of consent for this study was given by the Dutch 
national competent authority. Data will be presented at national and international 
conferences and published in a peer-reviewed journal.
REGISTRATION Dutch National Trial Registry: NTR4731; European Clinical Trials 
Database (EudraCT) of the European Medicines Agency: 2014-003469-10.
Strenghts and limitations
• This will be a first in man study to examine the safety and technical feasibility 
of therapeutic microbubbles, combined with the application of ultrasound and 
catheter-directed thrombolysis in peripheral arterial occlusions.
• This is a ‘single arm’ trial. The data will be used to inform a future large 
multicentre randomised controlled trial comparing conventional catheter-
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directed thrombolysis with microbubble and ultrasound accelerated 
thrombolysis
• The present study is a non-randomized Phase II-trial, therefore the results 
cannot confirm benefit of sonothrombolysis for peripheral arterial occlusions, 
only safety and feasibility is analyzed.






Acute limb ischemia can be caused by a thrombus occluding an artery in an arm 
or leg. This is an emergency situation that can result in amputation or death if not 
treated successfully.1 Intra-arterial infusion of thrombolytic agents, i.e. catheter-
directed thrombolysis, can restore blood flow by dissolving the clot, as a less 
invasive alternative to surgical thromboembolectomy.2 In comparison with the 
lysis of small arterial occlusions in patients with myocardial infarction, larger 
peripheral arterial occlusions require higher doses of lytic agents and infusion over 
a longer period of time. Inevitably, such treatment is accompanied by a risk of major 
hemorrhagic complications, such as hemorrhagic stroke, in up to 8% of patients.3 
Furthermore, this technique is time-consuming (several days of bed rest is usually 
required) and repeated angiography for treatment monitoring is needed, putting 
patients at risk for contrast-induced nephropathy. As a result, this leads to high 
morbidity rates and a significant patient burden. Methods to improve this therapy 
are therefore highly sought after.
A potential accelerator of thrombolytic therapy is contrast-enhanced ultrasound. 
Contrast agents, consisting of 5-10 µm gas-filled particles (microbubbles), have 
initially been used as diagnostic ultrasound contrast-enhancers. A new field of 
research investigates these agents for potential therapeutic purposes such as 
targeted drug delivery and thrombolysis.4 The proposed mechanism of action in 
thrombolysis is that microbubbles can oscillate under the influence of ultrasound. 
At high intensities, this oscillation can lead to microbubble collapse and the 
production of mechanical forces on the clot surface, making the thrombus more 
susceptible to thrombolytics, thus accelerating thrombolysis.5
In early stages of clinical research, this technique has been shown to be efficient as 
treatment for acute cerebral stroke and acute myocardial.6,7 Although the safety 
of their clinical administration in treating smaller arteries in the heart has been 
a topic of discussion in the past, post-marketing data for diagnostic indications 
showed continued safety after extensive research in more recent years.8,9,10 For 
therapeutic thrombolytic purposes, this technique has been shown to be effective 
and safe in a porcine model of large peripheral arterial occlusions.11 In this study, 
we will investigate the therapeutic application of microbubbles with ultrasound 
in combination with catheter-directed thrombolysis for patients with peripheral 
arterial occlusions. An illustrative video regarding our research project is available 
as supplementary video.
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Methods and analysis
Study objectives
To investigate the safety and practical applicability of the therapeutic application of 
microbubbles and ultrasound in combination with catheter-directed thrombolysis 
for patients with peripheral arterial occlusions.
Design
The Microbubbles and UltraSound accelerated Thrombolysis (MUST) trial is a 
single-arm phase-II trial.
Primary study parameters
Main endpoints will be the safety and technical feasibility of the experimental 
treatment. Safety will be determined by treatment-related mortality, the 
occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected 
Unexpected Serious Adverse Reactions (SUSARs). AEs will be defined as any 
undesirable experience occurring to a subject during the experimental treatment 
period, whether or not considered to be related to the investigational drug or 
intervention. SAEs will be defined as any untoward medical occurrence or effect 
that at any dose results in death; is life threatening (at the time of the event); 
requires hospitalization or prolongation of existing in-patients’ hospitalization; 
results in persistent or significant disability or incapacity; is a new event of the 
trial likely to affect the safety of the subjects, such as an unexpected outcome of 
an adverse reaction. SUSARs, which are related to the microbubble infusion and 
ultrasound application, are the formation of micro embolisms resulting in occlusion 
of the microcirculation, hemorrhages, hypotension, heart rhythm disorders and 
anaphylaxis. See the paragraph adverse events for detailed handling procedures 
of AEs, SAEs and SUSARs. Hemorrhagic complications related to thrombolytic 
therapy will be reported according the Standardized Bleeding Definitions for 
Cardiovascular Clinical Trials proposed by Mehran et al.12
Technical feasibility will be defined as accomplishment of the experimental protocol 
during the first hour of thrombolysis.
Secondary study parameters
Angiographic success will be defined as dissolution of >95% of the thrombus 
with outflow to at least 1 crural artery. Clinical change/success will be reported 
according to Rutherford’s recommended scale for gauging changes in clinical 
status (Table I). Amputations will be defined as either major (above or below knee 
amputation) or minor (metatarsal or toe amputation). Additional interventions 
will be categorized as either surgical (for example thromboembolectomy, bypass 




placement) and as either required for restoration of patency or necessary for 
correction of underlying lesions. We will also determine microcirculation of the limb 
(by Laser Doppler measurements, Perimed Instruments, Järfälla, Sweden), 30-day 
mortality, conversion to surgery, serum fibrinogen concentrations measured during 
thrombolytic treatment on a daily basis, pain by Visual Analogue Scale (VAS) and 
quality of life by SF-36 questionnaires. The duration of thrombolysis will be defined 
by the time-span between initiation and completion angiography.
Table I. Rutherford’s recommended scale for gauging changes in clinical status
+3
Markedly improved: No ischemic symptoms, and any foot lesions completely 
healed; ABI essentially “normalized” (increased to more than 0.90)
+2
Moderately improved: No open foot lesions; still symptomatic but only with 
exercise and improved by at least one clinical chronic ischemia category; ABI not 
normalized but increased by more than 0.10
+1
Minimally improved: Greater than 0.10 increase in ABI* but no categorical 
improvement or vice versa (i.e., upward categorical shift without an increase in 
ABI of more than 0.10)
0 No change: No categorical shift and less than 0.10 change in ABI
−1
Mildly worse: No categorical shift but ABI decreased more than 0.10, or 
downward categorical shift with ABI decrease less than 0.10
−2 Moderately worse: One category worse or unexpected minor amputation
−3
Markedly worse: More than one category worse or unexpected major 
amputations
*In cases where the ABI cannot be accurately measured, an index based on the toe 
pressure, or any measurable pressure distal to the site of revascularization, may be 
substituted.
Adapted from: Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. 
Recommended standards for reports dealing with lower extremity ischemia: revised 
version. J Vasc Surg. 1997;26(3):517–38.
Abbreviations: ABI=Ankle Brachial Index
Patients and eligibility criteria
The present feasibility and safety study is a non-randomized Phase II trial, to be 
conducted in our university hospital in Amsterdam, the Netherlands. Usually in 
a phase-II trial, 10-20 patients are investigated to confirm an occurrence of toxic 
effects or serious adverse events <20%. We chose a sample size of 20 to assess 
the safety of the investigational treatment. Eligibility criteria are listed in Table 
II. Inclusion of 20 eligible patient is expected within 1.5 years. Written informed 
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consent will be acquired by a member of the Research Team after information 
about the study has been provided by the treating doctor.
Table II. Eligibility criteria
Inclusion 
criteria
• Men and women older than 18 and younger than 85 years old
• Patients with a maximum of 2 weeks of symptoms for lower limb ischemia due 
to thrombosed/occluded iliofemoral, femoropopliteal or femorocrural native 
arteries or iiliofemoral, femoropopliteal or femorocrural venous or prosthetic 
bypass grafts
• Patients appropriate for thrombolysis i.e. with acute lower limb ischemia class I 
and IIa according to the Rutherford classification
• Patients who understand the nature of the procedure and provide written 
informed consent before enrollment in the study
Exclusion 
criteria
• Patients with clinical complaints of acute lower limb ischemia due to thrombosis 
of iliofemoral, femoropopliteal or femorocrural native arteries, or iliofemoral, 
femoropopliteal or femorocrural venous or prosthetic bypass grafts for more 
than 2 weeks
• Patients with thrombosed popliteal aneurysms
• Patients with absolute contraindications for administration of antiplatelet 
therapy, anticoagulants or thrombolytics
• History of recent (less than 6 weeks) ischemic stroke, cerebral hemorrhagic or 
myocardial infarction
• Patients with recent (less than 6 weeks) surgery
• Severe hypertension (diastolic blood pressure greater than 110 mm Hg, systolic 
blood pressure higher than 200 mm Hg)
• Current malignancy or severe co-morbid condition with a life expectancy of less 
than 6 months
• Patients with uncorrected bleeding disorders (gastrointestinal ulcer, 
menorrhagia, liver failure)
• Women with childbearing potential not taking adequate contraceptives or 
currently breastfeeding
• Pregnancy
• Patients who are currently participating in another investigational drug or device 
study
• Patients younger than 18 years or older than 85 years
• Patients with contraindications for Luminity microbubbles i.e.:
• Hypersensitivity to perflutren or to any of the components of Luminity
• Recent acute coronary syndrome or clinically unstable ischemic cardiacdisease, 
including: evolving or ongoing myocardial infarction, unstable angina at rest 
within the last 7 days, significant worsening of cardiac symptoms within the last 
7 days, recent coronary artery intervention or other factors suggesting clinical 
instability (for example, recent deterioration of ECG, laboratory or clinical 
findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm 
disorders
• Patients known to have right-to-left cardiac shunts, severe pulmonary 
hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic 
hypertension and in patients with GOLD Stage IV COPD, diffuse interstitial 
fibrosis or adult respiratory distress syndrome





We will keep an electronic log of patients who fulfill the eligibility criteria, patients 
who are invited to participate in the study, patients recruited and patients who 
withdraw from the study. Reasons for non-recruitment will also be recorded. We 
will attempt to collect reasons for non-participation from patients who decline to 
take part. During the course of the study, we will document reasons for withdrawal 
from the study and loss to follow-up. Data will be stored electronically in Case 
Report Forms software with audit trail functionality and will be audited by the 
institutional Clinical Research Bureau (CRB). Only anonymized information will 
be stored and participants will only be identifiable by their unique study number, 
which will be kept in a separate file. Data will be securely stored on these servers 
for 15 years according to national guidelines. The principal investigator will have 
access to the final trial dataset. No independent Data Management Committee 
was instated according to local ethics committee guidelines since the present study 
was not classified as a high-risk clinical study. This classification was approved by 
the local ethics committee based on the risk assessment form of the Netherlands 
Federation of University Medical Centres.
Study procedures
Intervention
A flow chart of the patient work-up after presentation in our hospital is presented 
in Figure 1. Low-dose thrombolytic treatment with urokinase will be initiated 
following our standard institutional protocol: a catheter is placed intra-arterially 
in the affected artery and a bolus injection of 500,000 International Units (IU) 
of urokinase (Medacinase Urokinase, Medac GmbH, Hamburg, Germany) will be 
followed by the continuous infusion of 50,000 units of UK per hour and 9,600 
IU of heparin per 24 hours. The experimental treatment consists of (in addition 
to the standard thrombolytic therapy) the use of local 1.8 Mhz transdermal 
ultrasound (Philips iE33 Ultrasound Machine, Eindhoven, the Netherlands), and 
the intravenous infusion of 4 Luminity vials (total 6 mL, diluted with saline 0.9% 
to 40 mL total, Lantheus MI UK Limited, Newbury, Berkshire, United Kingdom) 
during the first hour of thrombolysis with urokinase. An ACIST VueJect (Bracco 
Imaging Europe B.V., the Netherlands) infusion pump will be used to infuse the 4 
vials continuously. Ultrasound will be intermittently activated (3 seconds manual 
flash to burst microbubbles with Mechanical Index (MI) 1.08 (pulse duration 20 
microseconds, frequency 1.8 Mhz, framerate 39 Hz), 7 seconds of visualization of 
inflow of the microbubbles at MI±0.11, at the site of occlusion during the first hour 
of thrombolysis. Criteria for discontinuation of the experimental treatment during 
the first hour will be the occurrence of any adverse events potentially related to 
the experimental treatment such as bleeding and allergic reactions.
183
Protocol for the MUST trial
 Figure 1. Flow chart of patient work-up after presentation
Assessments
Diagnostic measurements
Additional diagnostic measurements during admission including ECG, duplex 
ultrasound, angiography and microcirculation measurements (by Laser Doppler 
flowmetry) will be performed as depicted in Figure 1.
A duplex ultrasound will be performed every 6±2 hours to monitor for signs of 
revascularization. When resumption of flow is visualized by duplex ultrasound, 




least once daily as standard procedure. Outside of routine hospital working hours, 
angiography will only be performed in emergencies as per standard care.
A standardized pain score (Visual Analogue Scale, 1-10), and Pain Catastrophizing 
Scale will be recorded every 3 hours by a nurse practitioner, research fellow or 
surgical resident to assess pain.
Fibrinogen monitoring
Following our standard institutional thrombolysis protocol, fibrinogen 
concentration will be checked during thrombolysis with the following criteria for 
treatment modification: If <1.0 g/L, the urokinase infusion rate will be lowered to 
25,000 IU/h; if <0.5 g/L, thrombolysis must be aborted temporarily and replaced by 
normal saline infusion. Three hours following treatment modifications, fibrinogen 
concentration will be reevaluated and when >1.0 g/L thrombolysis will be restarted 
at an initial low dose urokinase of 50,000 IU/h.
Post-procedural anticoagulation
After successful thrombolysis, the patient will be heparinized with low-molecular 
weight heparin (fraxiparine) dosed based on body weight: <50 kg: 2 times a day 
3,800 IU (= 0.4 mL), 50-80 kg: 2 times a day 5,700 IU (= 0.6 mL), >80 kg: 2 times a 
day 7,600 IU (= 0.8 mL).
Concomitant therapy with coumarin derivatives will also be started at that time. 
Activated partial thromboplastin time (aPTT) will be measured daily during heparin 
treatment. The target range international normalized ratio (INR) will be 2.5 to 3.5; 
if this value is reached, heparinization will be stopped and coumarin treatment will 
be continued.
Follow-up
Outpatient follow-up will take place at specific time points for a total duration of 
1 year, measurements performed during follow-up visits are depicted in Figure 1.
Adverse events
Adverse events will be recorded in detail in the electronic patient record. Any 
serious adverse events that occur after joining the trial will be reported to the 
accredited Medical Ethics Committee of our institution according to national and 
institutional guidelines. All adverse events will be followed up until they have 
abated, or until a stable situation has been reached. Depending on the event, follow 
up may require additional tests or medical procedures as indicated, and/or referral 
to a general physician or medical specialist. An interim analysis after 10 patients 
will be performed and if serious adverse events have occurred, we will discuss the 
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continuation of the study. The study will be prematurely terminated if 2 or more 
intracranial bleedings occur or more than 5 allergic reactions.
Statistical analysis
Categorized epidemiologic/descriptive patient variables are summarized with 
frequencies and will be analyzed with Fischer’s exact test or the Pearson Chi-
squared test. To avoid possible violations of the assumptions for parametric testing, 
such as a normal distribution pattern, we will employ non-parametric methods such 
as a Spearman rank correlation and a Mann-Whitney U test in the case of a skewed 
distribution or log transformation. For associations of two outcome measurements, 
we will use a correlation (Spearman rank) or single regression analysis. We will 
analyze the following outcomes by means of Kaplan-Meier curves: patency rate, 
amputation-free rate, and intervention-free rate. We will assess heterogeneity in 
prognostic factors as a secondary analysis by means of Chi-squared tests. All tests 
will be performed two-sided, and a p<0.05 will be considered to be statistically 
significant.
Ethics and disemmination
The study will be conducted according to the principles of the Declaration of 
Helsinki (Brazil, October 2013), and in accordance with the Medical Research 
Involving Human Subjects Act (WMO). An Investigator Site File will be produced 
in advance of the study conforming to institutional guidelines. Furthermore we will 
create Case Report Forms by using GCP and 21 CFR Part 11 compliant software, 
to handle patient data.
The study has been registered in the Dutch Trial Register, at the Dutch National 
Central Committee on Research Involving Human Subjects (CCMO) and in the 
European Clinical Trials Database (EudraCT) of the European Medicines Agency. 
Any protocol amendments during the study will be communicated and changed 
accordingly in the relevant registries after approval of the institutional Medical 
Ethics Committee. The results of this study will be submitted for publication in a 
peer-reviewed journal, regardless of the outcome of this study, according to the 
CCMO statement on publication policy. Data will also be presented at international 
conferences.
Discussion
The Microbubbles and UltraSound-accelerated Thrombolysis (MUST) trial is 
a phase-II single-arm clinical trial. In this study the safety and feasibility of an 
experimental ultrasound technique will be investigated for the first time in patients 




We believe that this procedure is safe and can accelerate thrombolysis, thereby 
allowing for reduction of thrombolytic dosage, which in turn reduces the risk of 
major hemorrhagic complications.
An experimental bolus therapy with microbubbles and ultrasound could accelerate 
thrombolysis because at high ultrasound intensities microbubbles can collapse, 
resulting in mechanical forces on the clot surface. The formation of small 
channels in the thrombus lead to exposure of a larger total surface susceptible to 
thrombolytics.5
In regard to the therapeutic application of contrast agents, several studies have 
been performed in patients with ischemic stroke and myocardial infarction. A 
systematic review of sonothrombolysis shows that this treatment option improves 
clinical and long-term outcomes, while potentially reducing bleeding risk, in patients 
with ischemic stroke.13 Nevertheless, dose escalation studies show that the safety 
(in terms of bleeding and micro emboli) needs to be further investigated before 
enrolling patients in phase-III trials.14 Few and heterogeneous studies examined the 
therapeutic application of sonothrombolysis in patients with myocardial infarction. 
Although pilot studies affirm safety and feasibility, the application of therapeutic 
ultrasound with longer pulse durations (20 microseconds vs. 5 microseconds) was 
reported to result in unexpected coronary vasoconstriction in a recent clinical 
trial.15
Potential reported mechanisms for this effect are the summative effect of 
myocardial ischemia, reperfusion damage and long-pulse-duration sonoporation 
on endothelial damage, all leading to calcium overload.
However, patients with peripheral arterial occlusions are mostly chronic vascular 
patients who often have received previous treatments in the respective artery, 
for example thrombolytic therapy, percutaneous transluminal angioplasty, 
thromboembolectomy or bypass surgery. The mechanical manipulation of the 
vascular wall during all these treatments is extensive. Furthermore, during standard 
thrombolytic treatment, arteries are manipulated and perforated on purpose to 
insert guide wires and catheters. Hence, vascular spasms during these peripheral 
treatments are normal and non-threatening to the patient, in contrast to spasms 
in small coronary arteries.
The administration of ultrasound contrast agents has been accompanied by 
important discussions regarding safety concerns in the past8,16. As a response to the 
occurrence of SAEs, the US Food and Drug Administration (FDA) issued a labeling 
change and warnings for contrast agents in 2007. Consequently, new studies on 
the risks of contrast agents were performed and these established their safety.17
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In regard to Luminity contrast agent dose regimens, the recommended dose for 
diagnostic indications is 1.3 mL dispersion added to 50 mL of sodium chloride 
9 mg/mL (0.9%) or glucose 50 mg/mL (5%) solution injected over a short time-
period.18 For therapeutic purposes, in large peripheral arteries there are no dose 
studies available. However, in our university hospital the Sonolysis study has been 
performed by our Cardiology department to treat acute ST elevation myocardial 
infarction patients with Luminity microbubbles and high mechanical ultrasound.19 
The dose used was one flacon Luminity of 1.5 mL which contains 225 microliter 
perflutren diluted with 48.5 mL of saline 0.9% to create a 50 mL suspension. 
Patients were treated with 15 minutes with an infusion rate of 200 mL/h. No 
serious adverse events occurred. In the present study to establish a therapeutic 
effect in large arterial occlusion we will also infuse 1 vial per 15 minutes but we will 
treat patients for 60 minutes. We will use 4 flacons of 1.5 mL Luminity containing 
900 microliter perflutren diluted with saline 0.9% to 40 mL total volume to be 
infused during 1 hour. The clinical consequences of overdose with Luminity are 
not known. Single doses of up to 100 microlitres dispersion/kg and multiple doses 
up to 150 microlitres dispersion/kg were tolerated well in Phase I clinical trials.20 
This equals to the infusion of 12 mL (8 flacons) of Luminity dispersion. We will 
administer a total of 6 mL (4 flacons) of Luminity dispersion. Furthermore, we will 
not administer them as single bolus doses but as low-speed continuous infusion. 
During the experimental protocol with microbubble infusion, patients will be 
continuously monitored.
As with all contrast agents, the risk of anaphylactic reactions to contrast remains. 
Therefore, administration of contrast agents in a center with full resuscitation 
possibilities is mandatory. Furthermore, during the first hours of administration, 
monitoring of vital parameters of patients is important.
In this study, thrombolysis is performed with the fibrinolytic urokinase, which is 
the most used fibrinolytic agent for the treatment of peripheral arterial occlusions 
worldwide and is standard care in the Netherlands. Some countries use tissue 
plasminogen activator for this indication. A Cochrane review on the topic states 
that there is no evidence that (r)t-PA is more effective than urokinase for patients 
with peripheral arterial occlusion.21
If the application of microbubbles and ultrasound concomitant to catheter-directed 
thrombolysis is shown to be safe and technically feasible based on this phase-II trial, 
we anticipate a funding application for a larger randomized controlled trial with a 
comparative group to assess and compare efficacy of this treatment.
Although the efficacy of the currently described protocol cannot be adequately 




control group that had previously received our standard hospital thrombolysis 
protocol.22
Successful thrombolysis is strongly predictive of amputation-free survival with 
vascular patency for at least one year.23 A longer duration of thrombolysis inevitably 
exposes a patient to a higher thrombolytic dose and higher risk of hemorrhage, 
in addition to an already increased patient burden because of prolonged bed 
rest. Therefore ultimately, acceleration of thrombolysis with microbubbles could 
benefit the patient because of a shorter therapy time, a lower risk of hemorrhagic 
complications and a decrease in patient burden.
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Acute peripheral arterial occlusions can be treated by catheter-directed 
thrombolysis (CDT). However, CDT takes time and is accompanied by major 
haemorrhagic complications. The addition of contrast-enhanced ultrasound and 
microbubbles could improve thrombus susceptibility for thrombolytic agents, 
potentially shorten treatment time with less risk of bleeding complications. This 
article reports the outcomes of the safety and feasibility of the use of microbubbles 
contrast-enhanced sonothrombolysis in patients with acute peripheral arterial 
occlusions.
Methods
In this single-arm phase-II-trial, 20 patients with Rutherford I and IIa acute lower 
limb ischemia received CDT combined with an intravenous infusion of microbubbles 
and locally applied ultrasound during the first hour of the standard intra-arterial 
thrombolytic therapy. Primary endpoint was safety, i.e. occurrence of serious 
adverse events (haemorrhagic complications and/or amputation) and mortality 
within 1 year. Secondary endpoints included angiographic and clinical success, 
thrombolysis duration, additional interventions, conversion and quality of life.
Results
The study included 20 patients (16 men; median age, 68.0 (range, 50.0-83.0) 
years and 40% native artery and 60% bypass occlusions). In all patients, the use of 
microbubbles contrast-enhanced sonothrombolysis could be successfully applied. 
No serious adverse events related to the experimental treatment occurred. Duplex 
examination showed flow distal from occlusion after 23.1 hours (range 3.1-46.5) 
with a median thrombolysis time of 47.5 hours (range, 6.0-81.0). The short-term ABI 
and pain-scores significantly improved, however no changes were observed before 
and after thrombolysis in the microcirculation. Overall mortality and amputation 
rates were both 2% within 1-year. The 1-year patency rate was 55%.
Conclusions
The results of the MUST-trial show that treatment of patients with acute peripheral 
arterial occlusions with microbubbles enhanced sonothrombolysis is feasible 
and safe to perform in patients. Further research is necessary to investigate the 
superiority of this new treatment over standard treatment.
Keywords
Peripheral arterial occlusion, catheter directed thrombolysis, microbubbles, 
sonothrombolysis, ultrasound, phase-II-trial
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Introduction
Several studies during the 1990s have revealed that catheter-directed thrombolysis 
(CDT) and surgical interventions were equivalent treatment options for acute 
peripheral occlusions, mostly in terms of amputation free survival in up to one 
year(1). Contrary to surgical intervention, infusion of thrombolytic agents has the 
ability to treat small occluded side branches and, if needed, simplify any required 
procedures to correct unmasked lesions(2). While thrombolysis showed to be a 
good alternative to surgical treatment, this procedure is still accompanied by major 
haemorrhagic complications in up to 8.4%(3). Paradoxically, limb ischemia may 
even worsen during thrombolytic treatment due to distal embolization of the clot. 
Besides the associated complications, this treatment needs monitoring by repeated 
angiography, which entails the risk of nephrotoxicity. In short, optimization of the 
current thrombolytic treatment is needed to minimize complication occurrences, 
limit patient burden and improve outcome.
Microbubbles 1-10 µm in size were initially developed as ultrasound contrast agents 
to improve conventional ultrasound scanning(4). However, several studies have 
addressed the potential of microbubbles combined with ultrasound in thrombolysis. 
The second generation of ultrasound contrast agents consists of a high-molecular-
weight gas encapsulated in a lipid shell, used to improve stabilization and thereby 
making the microbubbles capable of transpulmonary passage into the arterial 
circulation. During continuous intravenous infusion, microbubbles can be visualized 
as an echogenic area for several minutes before their shell is metabolized to free 
fatty acids and the gas is eliminated from the systemic circulation via the lungs(5). 
The generally accepted idea is that low and intermediate acoustic pressure causes 
oscillation of the microbubbles which results in collapse under high acoustic 
pressure. Destruction of these microbubbles can lead to the formation of free 
radicals, causing erosion and small holes in the surface of the clot which weakens 
the fibrin network and eventually increases susceptibility of the clot for the 
fibrinolytic agent(6).
The effectiveness of the therapeutic application of contrast-enhanced 
sonothrombolysis (CEST) has already been demonstrated in clinical trials for 
treatment of acute stroke and myocardial infarction(7). Previous studies in a 
porcine model of large peripheral arterial occlusion, have shown beneficial effects 
of this technique(8). To date, this therapy has never been tested in the setting of 
large peripheral occlusions in humans. The objective of this study is to investigate 
the safety and practical application of intra-arterial infusion of thrombolytic agents 





Study design and patients
The protocol for this trial has been previously described in BMJ open (9). In brief, 
the Microbubbles and UltraSound-accelerated Thrombolysis (MUST) trial, a single-
arm phase II trial, was conducted between July 2017 and November 2019 in the 
Amsterdam UMC location VUmc the Netherlands. Patients were also referred from 
Dijklander Hospital, Hoorn in the Netherlands to be included in the MUST-trial in 
Amsterdam UMC.
A sample size of 20 patients with acute lower limb ischemia Rutherford Classification 
I or IIa was chosen to assess the safety of the novel treatment. A detailed list of the 
eligibility criteria is given in Table 1. All of the patients were informed about CEST 
by the treating physician and written informed consent acquired.
The institutional review board approved the trial protocol and the study was 
performed in accordance with the Declaration of Helsinki. The trial has been 
registered in the Dutch Trial Register, at the Dutch National Central Committee 
on Research Involving Human Subject (registration number: NTR4731) and in the 
European Clinical Trials Database of the European Medicines Agency (registration 
number: 2014-003469-10).
Intervention
In advance of the thrombolysis treatment, unfractionated heparin was given 
systematically to inhibit thrombus propagation and was discontinued when CDT 
was initiated.
Due to market manufacturing problems of Urokinase in May 2018, half of the 
group was treated with Urokinase (UK) until October 2018 and thereafter with 
recombinant tissue plasminogen activator (rtPA). A sheath was inserted in the 
left or right common femoral artery under ultrasound guidance. A McNamara 
catheter was placed intra-arterially in the distal segment of the thrombus. After 
successful positioning of the thrombolysis catheter, the first 10 patients received 
the standard low dose thrombolysis protocol consisting of a bolus injection of 500 
000 International Units (IU) of Urokinase followed by the continuous infusion of 50 
000 IU of UK per hour. The last 10 patients received a bolus of 5 mg of Alteplase, 
followed by the continuous infusion 1 mg rtPA per hour for 24 hours and 0.5 mg 
rtPA after 24 hours. Additionally, a continuous dose of 4800 IU of heparin per 24 
hours was infused through the side-port of the sheath to prevent clot formation at 
the catheter. In addition to the standard thrombolytic therapy, patients received 
continuous intravenous infusion of 4 vials of microbubbles (Luminity, Lantheus 
MI UK, Newburry, Berkshire, UK; total 6 mL, diluted with 0.9% to 40 mL total) 
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Table 1. The eligibility criteria
Inclusion 
criteria
• Men and women older than 18 and younger than 85 years
• Patients with a maximum of 2 weeks of symptoms for lower limb ischaemia due 
to thrombosed/occluded iliofemoral, femoropopliteal or femorocrural native 
arteries or iliofemoral, femoropopliteal or femorocrural venous or prosthetic 
bypass grafts
• Patients appropriate for thrombolysis, that is, with acute lower limb ischaemia 
class I and IIa according to the Rutherford classification
• Patients who understand the nature of the procedure and provide written 
informed consent before enrolment in the study
Exclusion 
criteria
• Patients with clinical complaints of acute lower limb ischaemia due to thrombosis 
of iliofemoral, femoropopliteal or femorocrural native arteries, or iliofemoral, 
femoropopliteal or femorocrural venous or prosthetic bypass grafts for >2 weeks
• Patients with thrombosed popliteal aneurysms
• Patients with absolute contraindications for administration of antiplatelet 
therapy, anticoagulants or thrombolytics
• History of recent (<6weeks) ischaemic stroke, cerebral haemorrhagic or 
myocardial infarction
• Patients with recent (<6weeks) surgery
• Severe hypertension (diastolic blood pressure >110 mmHg and/or systolic blood 
pressure >200 mmHg)
• Current malignancy or severe comorbid condition with a life expectancy of <6 
months
• Patients with uncorrected bleeding disorders (gastrointestinal ulcer, 
menorrhagia, liver failure)
• Women with childbearing potential not taking adequate contraceptives or 
currently breast feeding
• Pregnancy
• Patients who are currently participating in another investigational drug or device 
study
• Patients younger than 18 years or older than 85 years
• Patients with contraindications for Luminity microbubbles, that is:
• Hypersensitivity to perflutren or to any of the components of Luminity
• Recent acute coronary syndrome or clinically unstable ischaemic cardiac 
disease, including evolving or ongoing myocardial infarction, unstable angina 
at rest within the last seven days, significant worsening of cardiac symptoms 
within the last seven days, recent coronary artery intervention or other factors 
suggesting clinical instability (e.g., recent deterioration of ECG, laboratory or 
clinical findings), acute cardiac failure, class III/IV cardiac failure or severe rhythm 
disorders
• Patients known to have right-to-left cardiac shunts, severe pulmonary 
hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic 
hypertension and in patients with Global Initiative for Obstructive Lung Disease 
(GOLD) stage IV chronic obstructive pulmonary disease, diffuse interstitial 
fibrosis or adult respiratory distress syndrome




during the first hour of thrombolysis. An ACIST VueJect (Bracco Imaging Europe 
B.V., Amsterdam, the Netherlands) infusion pump was used to infuse the four 
vials continuously. Transdermal ultrasound (Philips iE33 Ultrasound Machine, 
Eindhoven, the Netherlands) was directed at the site of occlusion during the 
first hour of thrombolysis and intermittently activated (3s manual flash to burst 
microbubbles with Mechanical Index 1.08 (pulse duration 20 µs, frequency 1.8 
MHz, frame rate 39 Hz), 7s of visualization of inflow of microbubbles at MI ±0.11).
Patient were routinely treated on a standard surgical ward where fibrinogen levels 
were monitored following local protocols at that time. A control angiography was 
performed every 24 ± 2 hours to evaluate progression of thrombolysis and to 
determine continuation of therapy with or without additional interventions.
Endpoints and definitions
The primary endpoints were the safety and technical feasibility of the contrast 
enhanced sonothrombolysis. Safety was determined by mortality, the occurrence 
of adverse events (AEs), serious adverse events (SAEs) and suspected unexpected 
serious adverse reactions (SUSARs). The study would have been terminated earlier 
if two or more intracranial bleedings or more than five allergic reactions occurred. 
Technical feasibility was defined as accomplishment of the experimental protocol 
after the first hour of thrombolysis.
Secondary endpoints included clinical change/success according to Rutherford’s 
recommended scale for gauging changes in clinical status (Table 2) (10); additional 
measurements (transdermal microcirculation, serum fibrinogen concentrations, 
pain-scores); duration of thrombolytic therapy needed for complete lysis and 
additional interventions. Complete lysis was defined as complete resolution of the 
thrombosed native artery or bypass graft with restoration of inflow and outflow 
to at least one crural artery.
Measurements
Transdermal microcirculation of the limb was measured every 15 minutes during 
the first hour of treatment and thereafter every 3 hours up until regain of flow was 
visualized, from which point the measurements were performed every day. Every 6 
hours a duplex ultrasound was performed to monitor for signs of revascularization. 
According to standard procedure an angiography was performed at least once a 
day.
199
Outcomes of the MUST trial
Table 2. Rutherford’s recommended scale for gauging changes in clinical status.
+3 Markedly improved: no ischaemic symptoms and any foot lesions completely 
healed; ABI essentially ‘normalised’ (increased to >0.90)
+2 Moderately improved: no open foot lesions; still symptomatic but only with 
exercise and improved by at least one clinical chronic ischaemia category; ABI not 
normalised but increased by >0.10
+1 Minimally improved: >0.10 increase in ABI but no categorical improvement or vice 
versa (i.e., upward categorical shift without an increase in ABI of >0.10)
0 No change: no categorical shift and <0.10 change in ABI
-1 Mildly worse: no categorical shift but ABI decreased >0.10 or downward 
categorical shift with ABI decrease <0.10
-2 Moderately worse: one category worse or unexpected minor amputation
-3 Markedly worse: more than one category worse or unexpected major 
amputations
To document objective change, Ankle-branchial indices (ABIs) of both legs were 
measured preprocedural, postprocedural and every 3 hours during the treatment 
up until reconstitution of flow was visualized, from which point the measurements 
were performed every day to document objective change. Furthermore, a 
standardized pain score (VAS, 1-10) was recorded every 3 hours by a research 
fellow to assess pain.
Follow-up
The follow-up consists of a visit to the outpatient clinic, with clinical examination 
including ankle-branchial indices (ABI), pain-free walking distance, duplex 
ultrasound of the treated limb and questionnaires regarding the quality of life (Fig. 
1). During follow-up, any cases of recurrence of thrombosis, reinterventions or 
amputation on the same limb and mortality of the patients were recorded.
Statistical analysis
The group differences were determined by an independent t-test or a Mann-
Whitney U test in case of a skewed distribution. A Wilcoxon signed rank test 
was used to compare the improvement in continuous variables before and after 
intervention in both groups. Multiple related samples were tested with Friedman’s 
ANOVA and using the Wilcoxon signed rank test for post-hoc analysis. The patency 
rate was analysed by means of the Kaplan-Meier method. A P-value of <.05 (two-
sided) was considered statistically significant. Statistical analyses were performed 




Figure 1. Study flow chart of patient work-up after presentation with acute peripheral ar-
terial occlusion.
ABI: Ankle Branchial Index, IU: International Units, MUST: Microbubbles and UltraSound-
accelerated Thrombolysis, QoL: Quality of Life, UK: Urokinase, rtPA: Alteplase, US: 
ultrasound, VAS: visual analogue scale.
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Results
Contrast-enhanced thrombolysis for thromboembolic obstructions in peripheral 
arteries was performed in 20 patients, of which 10 were treated with UK and 
10 with rtPA. Baseline characteristics of the included patients and occlusions 
characteristics are listed in Table 3.
Primary outcomes
Contrast enhanced thrombolysis was technically feasible in all 20 patients. In 
terms of the primary safety outcome, no major haemorrhagic complications nor 
any events of systemic allergic reactions, in-hospital mortality or 30-day mortality 
related to the microbubbles or ultrasound could be reported.
Secondary outcomes
Secondary outcomes were analysed in 19 patients. One patient was excluded from 
statistical analysis after receiving microbubbles therapy, as the pre-treatment plan 
was to use contrast enhanced sonothrombolysis for rapid restoration of blood flow 
as well as to facilitate an easier access for the surgical procedure of underlying 
vascular lesions. Due to insufficient file documentation, the analysis of the VAS 
scores, microcirculation and ABI measurements of another patient could not be 
performed.
Secondary outcomes regarding treatment characteristics and results are 
summarized in Table 4. Median time until return to flow at duplex ultrasound 
was established after 23.1 hours (range 3.1-46.5 hours). In nine patients (50%), 
return to flow at duplex ultrasound was achieved within 24 hours. Median time 
until revascularisation at angiography was established within 25.5 hours (range 
6.0-81.0 hours). Median duration of total thrombolytic therapy was 47.5 hours 
(range 6.0-81.0 hours).
Angiographic patency was reached in all cases. In 74% of all cases (n=14) additional 
percutaneous interventions were required to treat underlying stenotic lesions (e.g., 
Percutaneous Transluminal Angioplasty (PTA) with or without stent placement). 
In four cases additional surgical interventions were performed, in one case a 
femoral-popliteal bypass and in three cases thromboembolectomy. All patients 
were discharged with a patent treated native artery or bypass graft after additional 
procedures. After thrombolysis, clinical improvement was observed in 85% (n=17) 
of all cases. One case in the UK group had mildly worsened in clinical status due 




Table 3. Baseline and occlusion characteristics.
Total UK patients (n=10) rtPA patients (n=10) p*
Age, year in mean (standard deviation) 69.2±2.1 70.8±7.9 67.6±10.9 .462
Male sex – no. 16 8 8 1.00
SVS/ISCVS risk-factor score – no.
Diabetes 3 0 3 .068
Tobacco use 7 4 3 .834
Hypertension 10 2 8 .131
Hyperlipemia 15 6 7 1.00
Cardiac disease 3 1 2 1.00
Carotid-artery disease 0 0 0 1.00
Renal disease 4 0 4 .029
Pulmonary disease 2 1 1 .942
Sum of SVS/ISCVS-risk-factor scores † 5.05±2.57 4.40±2.01 5.70±2.98 .268
Medication at admission
 Anti-platelets 7 3 4 .473
 Coumarins 5 3 2 .615
 Non-vitamin K oral anticoagulant 5 2 3 .615
 Heparins 0 0 0 1.00
Type of occlusion
 Native 8 5 3 .374
 Bypass 13 5 7 .661
 Venous 1 1 0 .317
 Prosthetic 8 3 5 .374
 Stented native artery 3 1 2 .542
Number of occlusions
 1 occlusion 16 8 8 1.00
 2 occlusions 4 2 2 1.00
Duration of symptoms, days in 
median (range)
6,0 (0-14) 6,5 (0-14) 4,0 (3-14) .593
Rutherford classification
 Rutherford class I 3 2 1 .542
 Rutherford class IIA 17 8 9 .542
Previous revascularization same limb
 PTA and/or stenting 13 6 7 .897
 Thrombolysis 10 5 5 .579
 Bypass 6 3 3 1.00
 Thrombo-embolectomy 5 4 1 .684
Data are presented as n or mean ± standard deviations (SD) or median (interquartile range 
[IQR]). UK=Urokinase, rtPA=Alteplase, PTA=percutaneous transluminal angioplasty.
* p value of difference between thrombolytic agents.
† The Society for Vascular Surgery/International Society for Cardiovascular Surgery 
(SVS/ISCVS) risk-factor score for each of eight domains ranges from 0 (no risk factors) to 
3 (severe risk factors). Total scores can range from 0-24, with higher score indicating more 
risk factors.
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 PTA / stenting 19 7 12 .372
 Thrombo-embolectomy 3 2 1 .542
Rutherford gauging scale of clinical change between admission and at discharge
 Markedly improved – n 8 4 4 1.00
 Moderately improved – n 6 3 3 1.00
 Minimally improved – n 3 2 1 .317
 No change – n 0 0 0 1.00
 Mildly worse – n 1 1 0 .317
 Moderately worse – n 0 0 0 1.00
 Markedly worse – n 0 0 0 1.00
Fibrinogen
(in g/dL, mean ± SD)
2.37 ±.69 2.38 ±.92 2.37 ±.43 .995
APT
(in s, mean ± SD)
46 ±.12.0 46 ±.10.8 46 ±.13.7 .996
PTT
(in INR, mean ± SD)
1.23 ±.34 1.21 ±.29 1.24 ±.41 1.00
Data are presented as n or mean ± standard deviations (SD) or median (interquartile range 
[IQR]). UK=Urokinase, rtPA=Alteplase, PTA=percutaneous transluminal angioplasty; 
APTT=activated partial thromboplastin time; PTT=partial thromboplastin time.




Although no major bleeding complications occurred in any of the groups, minor 
bleeding at the sheath insertion site or groin hematoma was noted in three cases 
(16%). None of these patients required volume substitution or surgical evacuation. 
All cases with minor bleeding complications showed APTT and fibrinogen values 
within normal ranges, whereas in one patient the INR was slightly elevated 1.25 
g/dL on the day of the bleeding complication.
Ankle branchial index increased significantly after treatment in 89% of all patients 
(.27 mL/min (range .0 - .81) vs .82 mL/min (range .29 - 1.20), p=.00; Fig. 2). A non-
significant increase in microcirculation was observed in 61% of all patients (p=.732). 
VAS-scores were significantly lower after treatment in the whole group (p=.005).
Outcomes during follow-up
Median duration of follow-up was 12-months (range 8.9 – 12). One patient died at 
8-months due to (pre-existent) cardiac failure and a concomitant refusal of further 
therapy. The median ABI at discharge was .82 mL/min (range .29-1.20), increased 
to .94 mL/min (range .29-1.23) 6-weeks after the intervention and decreased to 
.84 mL/min (range .46-1.16) at 12-months follow-up (Fig. 2).
During the 12-months follow-up, 11 patients experienced re-occlusions and 2 
stenosis. The primary patency rates at 3-, 6- and 12-months were 75%, 60% and 
55%, respectively (Fig. 3). Among the patients suffering from re-occlusions, 8 
patients underwent thrombolysis with additional percutaneous interventions in 
3 patients. The other 2 patients were treated by surgical interventions (n=1, bypass 
surgery; n=1, thromboembolectomy). Percutaneous interventions were performed 
on the 2 limbs suffering from in-stent or in-bypass-stenosis.
Two patients received at least 2 reinterventions during the follow-up period 
of which one patient who was initially treated by a hybrid approach containing 
CDT and surgical tromboembolectomy and eventually needed a transtibial leg 
amputation. The assisted primary patency rates at 3, 6 and 12 months were 100%, 
95% and 80%, respectively (Fig. 2).
After 1-year follow-up, a significant improvement was observed in the following 
dimensions of the SF-36 questionaries: physical function, role physical, vitality, 
mental health, social functioning and bodily pain (Table 4). However, role emotional 
showed no statistically significant change over time (p=.09), whereas general 
health remained unchanged at 6-months but increased over 1-year of follow-up 
(p=.02). The results of the PCS and its subscales showed a significant decrease after 
6-months which stayed statistically significant after 1-year follow-up.
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Figure 2. Boxplots of changes in ABI at different timepoints during the trial.
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10 with rtPA. Baseline characteristics of the included patients and occlusions 
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Primary outcomes
Contrast enhanced thrombolysis was technically feasible in all 20 patients. In 
terms of the primary safety outcome, no major haemorrhagic complications nor 
any events of systemic allergic reactions, in-hospital mortality or 30-day mortality 
related to the microbubbles or ultrasound could be reported.































































p* .00 .00 .64 .00 .00 .05 .00 .22
p† .00 .00 .09 .02 .00 .01 .00 .02
PCS Total Rumination Magnification Helplessness
Admission 18 
(4-47)
8 (0-16) 3 (0-9) 6.5 (0-22)
6 months 7 (0-21) 1.5 (0-9) 0 (0-6) 4 (0-9)
1 year 5 (0-20) 3.5 (0-8) 0 (0-6) 1 (0-6)
p* .01 .01 .01 .01
p† .01 .01 .00 .00
Data are presented as mean ± standard deviations (SD).
* p value of difference between admission and 6 months.
† p value of difference between admission and 12 months.
Secondary outcomes
Secondary outcomes were analysed in 19 patients. One patient was excluded from 
statistical analysis after receiving microbubbles therapy, as the pre-treatment plan 
was to use contrast enhanced sonothrombolysis for rapid restoration of blood flow 
as well as to facilitate an easier access for the surgical procedure of underlying 
vascular lesions. Due to insufficient file documentation, the analysis of the VAS 
scores, microcirculation and ABI measurements of another patient could not be 
performed.
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Secondary outcomes regarding treatment characteristics and results are 
summarized in Table 4. Median time until return to flow at duplex ultrasound 
was established after 23.1 hours (range 3.1-46.5 hours). In nine patients (50%), 
return to flow at duplex ultrasound was achieved within 24 hours. Median time 
until revascularisation at angiography was established within 25.5 hours (range 
6.0-81.0 hours). Median duration of total thrombolytic therapy was 47.5 hours 
(range 6.0-81.0 hours).
Angiographic patency was reached in all cases. In 74% of all cases (n=14) additional 
percutaneous interventions were required to treat underlying stenotic lesions (e.g., 
Percutaneous Transluminal Angioplasty (PTA) with or without stent placement). 
In four cases additional surgical interventions were performed, in one case a 
femoral-popliteal bypass and in three cases thromboembolectomy. All patients 
were discharged with a patent treated native artery or bypass graft after additional 
procedures. After thrombolysis, clinical improvement was observed in 85% (n=17) 
of all cases. One case in the UK group had mildly worsened in clinical status due 
to a poor distal run-off which resulted in an early reocclusion of the target artery.
Although no major bleeding complications occurred in any of the groups, minor 
bleeding at the sheath insertion site or groin hematoma was noted in three cases 
(16%). None of these patients required volume substitution or surgical evacuation. 
All cases with minor bleeding complications showed APTT and fibrinogen values 
within normal ranges, whereas in one patient the INR was slightly elevated 1.25 
g/dL on the day of the bleeding complication.
Ankle branchial index increased significantly after treatment in 89% of all patients 
(.27 mL/min (range .0 - .81) vs .82 mL/min (range .29 - 1.20), p=.00; Fig. 2). A non-
significant increase in microcirculation was observed in 61% of all patients (p=.732). 
VAS-scores were significantly lower after treatment in the whole group (p=.005).
Outcomes during follow-up
Median duration of follow-up was 12-months (range 8.9 – 12). One patient died at 
8-months due to (pre-existent) cardiac failure and a concomitant refusal of further 
therapy. The median ABI at discharge was .82 mL/min (range .29-1.20), increased 
to .94 mL/min (range .29-1.23) 6-weeks after the intervention and decreased to 
.84 mL/min (range .46-1.16) at 12-months follow-up (Fig. 2).
During the 12-months follow-up, 11 patients experienced re-occlusions and 2 
stenosis. The primary patency rates at 3-, 6- and 12-months were 75%, 60% and 
55%, respectively (Fig. 3). Among the patients suffering from re-occlusions, 8 
patients underwent thrombolysis with additional percutaneous interventions in 




surgery; n=1, thromboembolectomy). Percutaneous interventions were performed 
on the 2 limbs suffering from in-stent or in-bypass-stenosis.
Two patients received at least 2 reinterventions during the follow-up period 
of which one patient who was initially treated by a hybrid approach containing 
CDT and surgical tromboembolectomy and eventually needed a transtibial leg 
amputation. The assisted primary patency rates at 3, 6 and 12 months were 100%, 
95% and 80%, respectively (Fig. 2).
After 1-year follow-up, a significant improvement was observed in the following 
dimensions of the SF-36 questionaries: physical function, role physical, vitality, 
mental health, social functioning and bodily pain (Table 5). However, role emotional 
showed no statistically significant change over time (p=.09), whereas general 
health remained unchanged at 6-months but increased over 1-year of follow-up 
(p=.02). The results of the PCS and its subscales showed a significant decrease after 
6-months which stayed statistically significant after 1-year follow-up.
Discussion
The Microbubbles and UltraSound-accelerated Thrombolysis (MUST) trial is a 
single-arm phase II trial. This is the first study that shows the safety and technical 
feasibility of CEST for acute peripheral arterial occlusion of native arteries and 
bypass grafts.
CDT showed to be an effective treatment in restoring arterial patency and reducing 
symptoms of acute lower limb ischemia. However, according to the recently 
published European Society of Cardiology/European Society for Vascular Surgery 
guideline on peripheral arterial disease, acute lower limb ischemia is still afflicted 
with a high rate of systemic complications and mortality, even after successful 
revascularisation(1). Several endovascular techniques have been addressed to 
enhance the effects of CDT. The first randomized trial comparing endoluminal 
ultrasound accelerated thrombolysis to standard catheter directed thrombolysis 
showed a reduction in therapy duration and administered fibrinolytics agents(11). 
Nevertheless, the ultrasound accelerated thrombolysis did not seem superior to 
the conventional therapy with respect to the rate of major bleeding complications 
(11% vs. 6%, respectively).
A potential accelerator of the current thrombolytic therapy is the application 
of ultrasound with intravenous microbubbles, which has already shown its 
therapeutic effect in animal studies with large peripheral arterial occlusions(8). 
There is, however, relatively little data on the use of CEST in patients, mostly limited 
to small occluded vessels as in myocardial infarction. A recent randomized trial in 
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ST-segment elevation myocardial infarction comparing low mechanical impulses to 
high mechanical impulses showed beneficial effects on infarct size with sustained 
improvements in systolic function at follow-up (12).
The present data demonstrates that this novel treatment is feasible and provides 
evidence of its safety without any occurrence of side-effects related to the 
microbubbles, as well as significant improvement in both arterial flow and pain 
scores. Interestingly, the arterial flow measurements further increased at 6 weeks 
after the intervention, which may be attributed to successful revascularisation as 
well as a greater adherence to walking training.
Our results differ from earlier research on the considerably shorter therapy time 
of 51 hours in the UK-group, while the duration of therapy in the rtPA-group did 
not differ (UK: 51h (6-81) vs. 67h (4-304), rtPA: 25h (20-73) vs. 20h (2.0-46.0)). 
The relatively long duration of therapy in the rtPA-group might be explained by the 
low-dose protocol as well as the long interval between follow-up angiographies. 
It should be noted that a thorough assessment of the duration of therapy of the 
rtPA-group is difficult due to the large variation in treatment protocols between 
previous studies(13).
Lower rates of bleeding complications were observed in this small series of patients 
when compared to the literature. The overall 1-year amputation and mortality rates 
in this study were both 2%, considerably lower than the 25% mortality rate and 
13% amputation rate reported by Koraen et al(14). Considering the study design 
and sample size, the findings on adverse events of this study should nevertheless 
be interpreted with caution.
Up until this day the measurements of fibrinogen depletion during thrombolysis 
are used to predict bleeding complications or guide in fibrinolytic protocols. Recent 
studies, however, found no association between a drop in or low level of fibrinogen 
levels and haemorrhagic complications(1). In this study, the levels of plasma 
fibrinogen reached levels < 1.0 g/L in two patients without facing any bleeding 
complications, whereas in the three patients with minor bleedings the fibrinogen 
levels (>1.5 g/L) were all within normal limits on the day of occurrence.
It has been reported that the severity of ischemia might influence success of 
thrombolysis as well as mortality and morbidity rates. Korn et al. found a relief of 
ischemia rate of 43% at 2-years and a combined 30-day mortality and morbidity 
rate of 18% in the group presenting with acute onset claudication. However, in the 
group of limb-threatening ischemia a significant higher morbidity and mortality rate 
was seen (p=.02)(15). This resulted in guidelines advising conservative treatment 




limbs were successfully treated with thrombolysis and maintained patency during 
the follow-up. One patient, however, developed a groin haematoma 14 days after 
discharge, which did not require any surgical intervention. Further research 
should try to eliminate the appropriate treatment indications of patients with non-
threatened limb ischemia.
Shortly after the manufactory difficulties in the production of UK in 2018, we were 
obliged to alter the thrombolytic agent to rtPA. Even though it has been established 
that UK and rtPA are equally effective and complication rates do not differ, we still 
recognize the sample size as a limitation of our study for further analysis of the 
secondary outcomes. We believe nonetheless that the patient numbers are large 
enough to provide conclusions regarding the safety of this treatment, which may 
be of use for the design of future studies.
Since the scope of this study was to demonstrate the safety and feasibility of CEST 
in a relatively small patient cohort, no global assertions on the efficacy of CEST 
can be made. To further validate evidence of benefit for CEST it is paramount to 
perform a large randomized controlled trial with a comparative group. Another 
promising line of research would be non-invasive thrombolysis with thrombolytic-
entrapped microbubbles for targeted thrombolytic delivery(16). Theoretically, this 
so-called ultrasound-facilitated thrombolysis could increase thrombus dissolution 
by fibrin targeted microbubble adhesion combined with high-intensity ultrasound 
leading to a local release of the preloaded thrombolytic agents(17). Whilst some 
studies provide proof of concept, additional preclinical studies are necessary to 
further illuminate the clinical potential of accelerate drug delivery.
Conclusions
In conclusion, the findings of this first-in-human trial show promising results 
regarding its safety and technical feasibility with respect to an experimental 
contrast-enhanced ultrasound technique in patients with large peripheral arterial 
occlusions. Contrast enhanced sonothrombolysis has the potential to improve CDT. 
The results of this study suggest further research on technical innovations focused 
on the optimization of CDT in order to both increase efficacy and lower risks of 
haemorrhagic complication to eventually decrease length of in-hospital-stay.
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Acute limb ischemia is a serious condition where the blood flow to the affected 
limb is insufficient for its need. The condition is both limb and life threatening and 
requires urgent intervention. Currently the most commonly used treatment for 
acute limb ischemia is catheter directed intra-arterial thrombolysis. It is a minimally 
invasive therapy, but it has the drawback of being time consuming and it carries a 
risk of (major) bleeding. This thesis focuses on contrast enhanced sonothrombolysis 
(CEST) for acute peripheral arterial thrombosis. CEST is a form of thrombolysis 
where ultrasound contrast agents (a.k.a. microbubbles) and ultrasound are used 
to enhance thrombolysis.
Part I of this thesis is focused on results of current clinical practice and on 
what we know about CEST for peripheral arterial thrombosis. In chapter 2, we 
retrospectively reviewed the results of 2 thrombolytic protocols (low- vs high-
dose urokinase) administered on a regular surgical ward. Although we found no 
difference in technical success rate or 6 months amputation-free survival, there was 
a significantly lower rate of major bleeding complications in the low-dose group. A 
systematic review of all in vivo studies on contrast-enhanced sonothrombolysis in 
a setting of arterial thrombosis is given in chapter 3. A total of 26 preclinical and 
9 clinical trials were included in the review, most of these were done in a setting 
of ischemic stroke or myocardial infarction. Due to high heterogeneity it was 
not possible to perform a meta-analysis, but almost all studies showed a higher 
recanalization rate of the affected artery in the group that received a form of CEST.
Part II of this thesis focuses on the results of our preclinical trials. Based on several 
studies that investigated the benefit of CEST in a setting of ischemic stroke or 
myocardial infarction, we developed a porcine model for investigating these 
in acute peripheral arterial occlusion. In chapter 4 we present this model and 
how to prevent possible allergic reactions of the pigs to the ultrasound contrast 
agents. This model is implemented in chapters 5, 6 and 7, where we used it to 
investigate different aspects of microbubbles and with it different protocols for 
CEST . In chapter 5 we investigated the effect of intravenous microbubbles and 
local ultrasound added to standard intra-arterial catheter directed thrombolysis 
(sCDT) and compared this with sCDT. We found a higher arterial blood flow and a 
significant lower thrombus weight at the end of the procedure in the CEST group 
compared to the sCDT group. In chapter 6, we explored the possibility of using 
microbubbles as a carrier for the thrombolytic agent. Microbubbles, loaded with 
Urokinase and modified to adhere to thrombus, were administered intravenously 
and destroyed with high mechanical index ultrasound at the site of the thrombus. 
As control group we administered intravenous Urokinase alone, combined with 
the same regiment of ultrasound. We found a significantly lower thrombus weight 
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in the CEST group at the end of the experiment and 2 out of 5 pigs in the CEST 
group had a complete or nearly complete return to the baseline arterial blood 
flow in the affected artery compared to none in the control group. In chapter 7 
we evaluate the feasibility of administering microbubbles intra-arterially via an 
ultrasound-emitting catheter. In an in vitro set-up we tested if the destruction of 
the microbubbles, in turn leading to destruction of thrombus, could be achieved 
by the ultrasound-emitting catheter and whether there was a difference when 
the microbubbles were administered directly through the catheter versus via the 
blood stream. We found that microbubbles did get destroyed by the ultrasound 
of the catheter and that this was not influenced by the mode of administration of 
the microbubbles. We tested the lytic effect of this combination in an in vivo model 
and found a significant lower thrombus weight in this group when compared to our 
historical controls.
In part III of this thesis we present the protocol for the first clinical trial testing 
the safety and feasibility of CEST in acute peripheral arterial occlusion (chapter 
8) and the results of this trial (chapter 9). A total of 20 patients were treated with 
CEST on a regular surgical ward. We found CEST to be feasible in a clinical setting 
and there were no serious adverse events related to the experimental treatment.
Discussion and future perspectives
In this thesis we investigated several protocols of CEST in order to improve 
standard intra-arterial thrombolytic therapy. Standard catheter-directed intra-
arterial thrombolysis has the benefit of being minimally invasive. Patients don’t 
require general anesthetics and the thrombolytic agent reaches small arteries that 
cannot be reached via surgical thrombectomy, which helps to improve outflow in 
the affected extremity. Drawbacks of sCDT are the intrinsic risk of bleeding that 
comes with the use of a fibrinolytic agent and the time it takes for the thrombus to 
dissolve, i.e. the time it takes to restore direct blood flow to the extremity. Although 
the treatment is minimally invasive, it still requires placement of an intra-arterial 
catheter. Patients have to stay in a supine position during treatment to prevent 
dislodgement of the catheter, which adds to the burden of this form of therapy. In 
the next paragraphs we will discuss possible improvements on sCDT for peripheral 
arterial occlusion as investigated in this thesis.
Minimalizing risk of major bleeding
Thrombolytic therapy carries a risk of major bleeding, the most important of 
which is intracerebral hemorrhage. Thrombolytic protocols vary widely in the 
literature: there are different thrombolytic agents, different modes of delivery, 
different dosages, and different durations of therapy. In our study in a retrospective 
cohort in chapter 2, we found that a protocol with low dose Urokinase gave the 




incidence of major bleeding. Duration of therapy however, did increase with a 
lower administered dosage of the fibrinolytic agent. These findings concur with 
a recent systematic review by Ebben et al.1 They found a longer mean duration 
of therapy (32.7 hours vs 21.9 hours) when low-dose protocols were compared 
with high-dose protocols. In high-dose protocols the pooled mean rate for major 
bleeding was 8.9% versus 6.3% for low-dose protocols. Technical success rates 
were comparable, with pooled mean rates of 74.9% versus 74.1% for high-dose 
versus low-dose protocols. Another interesting finding in this review was a higher 
overall bleeding risk for rt-PA (19.2%) and tPA (18.6%) versus Urokinase (15.1%). 
The authors of this review conclude there is a lack of comparative prospective 
data and heterogeneity of studies made it impossible to perform a meta-analysis. 
For future research it would be interesting to prospectively compare different 
thrombolytic protocols for the most well-known fibrinolytic agents with regards 
to effectiveness and risk of complications.
In chapter 3 we give an overview of all in vivo studies on CEST in arterial 
thrombosis. CEST is a form of thrombolysis where a combination of microbubbles 
and ultrasound is added to the standard thrombolytic regiment. Microbubbles 
are ultrasound contrast agents that have been widely used to enhance duplex 
imaging. They have been shown to be safe as a diagnostic tool and are now under 
investigation for their possible therapeutic properties. They can be influenced by 
ultrasound to either oscillate or cavitate. This causes microstreaming of fluid and 
with it shear stress to the surface of the clot, resulting in a larger clot surface for the 
fibrinolytic agent to interact with. In our systematic review we found 26 preclinical 
and 9 clinical trials on CEST for arterial thrombosis. Of the 26 preclinical trials 
only 1 reported evidence of focal hemorrhage in the cerebral infarct area, but this 
occurred in all treatment arms. The main bleeding complication in the 9 clinical trials 
on CEST was intracranial hemorrhage. Of these trials, 8 were conducted in ischemic 
stroke patients. Overall there were no significant differences in occurrence of 
intracranial hemorrhage between the treatment arms, with the exception of the 
TUCSON trial by Molina et al., published in 20092. This was a randomized double 
blind dose-escalation study using CEST for patients with ischemic stroke. It was 
terminated prematurely due to a higher incidence of intracranial hemorrhage in the 
second tier of the study. The investigators found other likely contributing factors 
that might explain the higher incidence of intracerebral hemorrhage in this group, 
namely a larger infarct area pretreatment and a higher systolic blood pressure. The 
termination of this study had a huge impact on further clinical trials, even though the 
trial was underpowered and there were reasonable explanations for a higher rate 
of intracerebral hemorrhage in the second cohort. We feel this trial shouldn’t stop 
research on CEST for patients with peripheral arterial occlusion, as there are some 
important differences with patients suffering from ischemic stroke and there is a lot 
to gain. Cerebral ischemia carries an intrinsic risk of hemorrhagic transformation 
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with incidences in literature that vary between 15 and 43%3. CEST for patients 
with stroke in these studies invariably contained an intravenous administered 
fibrinolytic agent. In sCDT, the fibrinolytic agent is administered intra-arterially, 
as intravenous administration has been proven to give a higher incidence of major 
bleeding complications4. As the occluded artery in ischemic stroke is a cerebral 
artery, ultrasound directed at the site of occlusion might have a direct effect on 
surrounding brain tissue. These aspects are very different for CEST in peripheral 
arterial occlusion, since the lesion typically lies a considerable distance from the 
cerebrum. The clinical trial conducted in patients with myocardial infarction did not 
report any intracerebral hemorrhaging5. In our trial testing safety and feasibility of 
CEST in 20 patients with acute peripheral arterial occlusion presented in chapter 
9, we did not find any major bleeding complications.
Shortening time to reperfusion
In chapter 2 we found a longer duration of therapy was needed when a lower dose 
of thrombolytic agent was used. The low-dose protocol gave a lower risk of major 
bleeding, but at the cost of a longer time to reperfusion. A short time to reperfusion 
is essential in keeping tissue loss to an absolute minimum. The longer the duration 
of ischemia, the higher both amputation and mortality rate6. A longer duration of 
therapy prolongs the burden for the patient and will also add to a higher radiation 
exposure due to more control angiographies. The overall risk of complications 
also increases with the duration of therapy7. Furthermore a longer duration of 
therapy might add to costs due to a longer hospitalization time. In chapter 5 we 
investigate CEST as a way to improve time to reperfusion. In our short duration 
experiments (3 hours of therapy) we tested the effect of CEST vs sCDT. Even 
in this short amount of time we found significant reperfusion in several of the 
animals in the CEST group versus none in the control group. Thrombus weights 
were significantly higher in the control group versus the CEST group. The addition 
of ultrasound to CDT has already been implemented in clinical practice by ways 
of an ultrasound emitting catheter. In 2007 Motarjeme reported on his clinical 
experience with this catheter using it for ultrasound enhanced thrombolysis in 
both arterial and venous occlusions8. He found a shorter time to reach complete 
clot lysis than historically reported data. These findings were later supported by a 
randomized trial in 2015 comparing sCDT with CDT using an ultrasound emitting 
catheter9. As this ultrasound emitting catheter seems to reduce time to reperfusion, 
we tested the effect of this catheter on microbubbles in vitro and what this form 
of CEST might result to in vivo in chapter 7. We found that the ultrasound emitting 
catheter does destroy the microbubbles, aiding in further erosion of the clot. This 
finding might help for future clinical studies, as this mode of delivering ultrasound 
to the site of the occlusion is already in use in daily practice. Another finding of the 
study in chapter 7 is a significantly lower mean thrombus weight compared to our 




adding microbubbles and ultrasound to sCDT hastens dissolution of the thrombus 
and as such will shorten time to reperfusion.
Little has been reported on CEST in a setting of peripheral arterial thrombosis, 
but there have been some in vivo studies that support our findings in a setting of 
ischemic stroke or myocardial infarction. An overview of these studies is given in 
chapter 3. As was the case with the systematic review on CDT protocols, there is a 
high heterogeneity amongst studies and therefore it was impossible to perform a 
meta-analysis. That said, almost all studies included in this review showed greater 
rates of recanalization of the previously occluded artery in a group where CEST 
was used compared to any other treatment. The two studies that did not show 
greater rate of recanalization, showed similar rates to the best compared group. 
As mentioned before, the TUCSON trial was terminated prematurely due to a 
higher incidence of intracranial hemorrhage in the second tier of the study2. It was 
therefore underpowered, but there was a trend towards a higher recanalization 
rate in CEST group as well as a higher rate of functional independence at 3 months.
Minimalizing burden for the patient
sCDT demands full cooperation from the patient. The intra-arterial catheter is 
placed percutaneously and kept in place during treatment. In order to prevent 
dislodgement of the catheter and with it major bleeding complication and/or failed 
therapy, the patient has to stay in a supine position. As treatment can take up to 3 
days, the patient has to stay in bed and is completely dependent on care during this 
period. Reducing time to reperfusion, and with it therapy duration, would reduce 
the time that a patient is bedridden.
Another possible way to reduce burden for the patient is explored in chapter 
6, where we investigate not only the thrombolytic properties of microbubbles, 
but also their carrier function. In this study we loaded the microbubbles with 
Urokinase. The Urokinase is encapsulated in the microbubble and released locally 
under influence of Ultrasound. While the Urokinase is loaded in the microbubble 
it is less biologically active, theoretically resulting in a lower risk of bleeding 
complications10. We added RGDS, a targeting ligand for thrombus, to the surface 
of the microbubble so the microbubbles would accumulate at the site of the 
occlusion. As the targeted Urokinase loaded microbubbles were administered 
intravenously, we compared them with intravenously administered Urokinase 
without microbubbles and exposed both groups to high-intensity ultrasound. At 
the end of the experiment thrombus weight was significantly lower in the CEST 
group and 2 out of 5 pigs in this group had a (near) complete return of baseline 
arterial blood flow through the previously occluded artery compared to none in the 
Urokinase and ultrasound group. We did not find any adverse events, specifically 
no signs of (intra-cranial) bleeding. Guan et al. recently conducted a similar study 
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in 43 rabbits where different intravenous CEST protocols were applied during 120 
minutes of treatment11. They found that targeted microbubbles combined with 
Urokinase were more effective in achieving recanalization than non-targeted 
microbubbles. This might be explained by a higher concentration of microbubbles at 
the site of the occlusion due to the adherence of the microbubbles to thrombus. As 
these were only short duration experiments in a relatively small amount of subjects, 
this form of therapy needs further investigation on both safety and efficacy before 
it can be applied in a clinical setting.
Other future perspectives
In chapter 9 we present the results of a clinical study investigating CEST in the 
setting of acute peripheral arterial thrombosis. Although the trial was done in 
a small number of patients, results are promising: CEST for peripheral arterial 
thrombosis was feasible in a clinical setting and there were no serious adverse 
events related to the treatment12. It is our intention to conduct a randomized 
multicenter trial to compare effectivity of CEST vs sCDT in the hope of improving 
outcomes for patients with acute peripheral arterial occlusion. Outcomes for this 
trial will include time to reperfusion, limb salvage, overall survival, quality of life 
parameters and long term results.
There is some evidence of beneficial effect of microbubbles on microcirculation and 
with this on outflow13,14. As the ‘no-reflow’ phenomenon is very likely the result of 
loss of outflow, this offers some interesting possibilities for future investigations.
Another aspect of microbubbles that can be further explored is their carrier 
capacity. As mentioned previously we can load medication in the microsphere, 
making it biologically inactive until the microbubble is destroyed at the intended 
site. Adding a targeting ligand to the bubble makes it adhere to the area of interest, 
in our case thrombus surface. A recent development in the area of therapeutic use 
of microbubbles is the magnetic microbubble15. This new form of microbubble can 
be magnetically directed to a focus area. Another interesting recent development 
in the area of CEST, is the use of nanodroplets instead of microbubbles. The smaller 
size of nanodroplets, 100-300nm, allows them to penetrate deeper into a clot. 
Nanodroplets are also more stable than microbubbles, with a longer half-life in the 
circulation. Both the size and the stability of nanodroplets might make them even 
more effective in disrupting a thrombus16. With all these current developments, 
local thrombolysis via a simple intravenous injection might very well be possible 
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Een acuut tekort aan bloed in een ledemaat ontstaat wanneer de slagader (arterie) 
naar dat ledemaat plotseling afgesloten wordt door bijvoorbeeld een stolsel 
(trombus). Een dergelijke acute arteriële afsluiting (occlusie) vormt een gevaar voor 
zowel het aangedane ledemaat als voor het leven en dient zo spoedig mogelijk 
verholpen te worden. De meest gangbare vorm van behandeling heden ten dage 
is trombolyse behandeling via een intra-arteriële katheter. Hierbij wordt de arterie 
aangeprikt en wordt een katheter in het vat opgevoerd naar de plek waar de 
afsluiting zich bevindt. Via de katheter wordt continue een sterk stolsel oplossend 
middel (trombolyticum, bijv. Urokinase of Alteplase) toegediend ter plaatse van 
de trombus. Deze vorm van behandeling is minimaal invasief, maar heeft als 
belangrijke nadelen dat het tijd kost en dat er een risico is op ernstige bloedingen, 
vooral in het hoofd. Vanuit de neurologie en cardiologie kwam een nieuwe techniek 
om trombusmassa sneller op te lossen (lyseren) en mogelijk zo uitkomsten voor 
de patiënt te verbeteren. Bij deze techniek werden echocontrastmiddelen, ook 
wel microbubbels of microbellen genoemd, gebruikt in combinatie met echo 
(ultrageluid) en een trombolyticum. De microbellen trillen en barsten onder invloed 
van ultrageluid, wat resulteert in mechanische disruptie van de trombus. Hierdoor 
kunnen stolsels sneller opgelost worden. We noemen dit contrast-versterkte 
sonotrombolyse (CVST). Dit proefschrift richt zich op verschillende aspecten van 
CVST voor patiënten met een acute arteriële afsluiting, met als uiteindelijk doel 
de uitkomst voor deze patiënten te verbeteren.
Het proefschrift is opgebouwd in 3 delen. In deel I richten we ons op de huidige 
situatie in de kliniek en geven we een overzicht van wat er bekend is over CVST bij 
perifere arteriële trombose. In hoofdstuk 2 bekijken we retrospectief de resultaten 
van 2 trombolyseprotocollen: lage versus hoge dosis Urokinase. Er bleek geen 
verschil in technisch succes of amputatie vrije overleving na 6 maanden tussen 
de beide groepen, maar er werden wel significant minder ernstige bloedingen 
gevonden in de groep die een lage dosis Urokinase toegediend kreeg. In hoofdstuk 
3 presenteren we een systematische review van alle in vivo studies naar het gebruik 
van CVST in arteriële afsluitingen. In totaal konden we 26 preklinische en 9 klinische 
studies includeren in de review. Door de hoge heterogeniteit van de studies was het 
niet mogelijk om een meta-analyse te verrichten, maar vrijwel alle studies toonden 
een hoger rekanalisatiepercentage in de groep die een vorm van CVST kreeg.
Deel II van dit proefschrift richt zich op de resultaten van preklinische studies naar 
CVST. In hoofdstuk 4 presenteren we een varkensmodel voor het onderzoeken van 
deze nieuwe vorm van trombolyse bij acute perifere arteriële trombose en stellen 
we een protocol voor ter voorkoming van allergische reacties op de microbellen 
bij de proefdieren. Bovengenoemd diermodel implementeren we in hoofdstuk 5, 
6 en 7, waarbij verschillende therapeutische mogelijkheden van de microbellen 
worden onderzocht. In hoofdstuk 5 vergelijken we via het infuus (intraveneus) 
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toegediende microbellen gecombineerd met lokaal ultrageluid en standaard intra-
arteriële trombolyse met standaard intra-arteriële trombolyse alleen. We vonden 
een hogere arteriële stroomsnelheid en een significant lager trombusgewicht in de 
groep met de CVST aan het eind van het experiment. In hoofdstuk 6 onderzoeken 
we de mogelijkheid om microbellen als een vervoermiddel voor het trombolyticum 
te gebruiken. Urokinase werd in de microbellen geladen en de bellen werden zo 
geprepareerd dat ze zich zouden binden aan trombusmateriaal. De microbellen 
werden intraveneus toegediend en ter plaatse van de afsluiting met ultrageluid 
kapot gemaakt. De zo behandelde groep werd vergeleken met een groep die alleen 
Urokinase intraveneus kreeg plus ultrageluid. De groep die microbellen toegediend 
kreeg had een significant lager trombusgewicht aan het eind van het experiment 
en 2 van de 5 varkens in deze groep hadden een (vrijwel) complete terugkeer van 
doorstroming in de aangedane arterie. Dit in tegenstelling tot de controle groep 
waar dit in geen van de experimenten het geval was. In hoofdstuk 7 onderzoeken we 
de mogelijkheid om de microbellen intra-arterieel toe te dienen via een ultrageluid 
katheter. In-vitro testten we of de microbellen door de ultrageluid katheter kapot 
gemaakt werden en zo ja, of het uitmaakt op welke wijze ze toegediend werden: 
via de katheter of via het lumen van het vat. We zagen dat de microbellen door 
de katheter kapot gemaakt werden en dat dit niet beïnvloed werd door de wijze 
van toedienen. We testten het lytische effect van deze wijze van toedienen van 
zowel microbellen als ultrageluid in een proefdiersetting en vonden ook hier een 
significant lager trombusgewicht aan het eind van het experiment vergeleken met 
onze eerdere controle groep met standaard intra-arteriële trombolyse.
In het derde deel van dit proefschrift presenteren we de eerste klinische studie naar 
CVST bij mensen. Aan de hand van de resultaten van de studies uit hoofdstuk 5, 6 en 
7 schreven we een protocol voor een studie naar de veiligheid en haalbaarheid van 
CVST bij mensen (hoofdstuk 8). In hoofdstuk 9 presenteren we de resultaten van 
deze studie. In totaal werden 20 patiënten behandeld met CVST. De behandeling 
bleek haalbaar in een klinische setting en er waren geen ernstige complicaties 
gerelateerd aan de experimentele behandeling.
Concluderend lijkt CVST een gunstig effect te hebben op duur en effectiviteit van 
trombolysebehandeling van acute arteriële trombose en lijkt het ook een haalbare, 
veilige therapie te zijn in een klinische setting. Met CVST kunnen lagere doses van het 
trombolyticum geven, ten einde bloedingscomplicaties te verminderen. Daarnaast 
lijkt het mogelijk een snellere trombolyse te verkrijgen zonder patiënten bloot te 
stellen aan additieve risico’s. Een gerandomiseerd trial om dit te onderzoeken is 
momenteel in voorbereiding. Een sneller herstel van bloedtoevoer naar het bedreigde 
ledemaat zal de belasting voor de patiënt verminderen en hopelijk het uiteindelijke 
resultaat verbeteren. Er is echter nog veel onderzoek nodig voor we dit daadwerkelijk 
in een dagelijkse klinische praktijk kunnen implementeren.
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The Road Not Taken
Two roads diverged in a yellow wood,
And sorry I could not travel both
And be one traveler, long I stood
And looked down one as far as I could
To where it bent in the undergrowth;
Then took the other, as just as fair,
And having perhaps the better claim,
Because it was grassy and wanted wear;
Though as for that the passing there
Had worn them really about the same,
And both that morning equally lay
In leaves no step had trodden black.
Oh, I kept the first for another day!
Yet knowing how way leads on to way,
I doubted if I should ever come back.
I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I—
I took the one less traveled by,




Thank you - Dankwoord
Een proefschrift is het product van een vaak lange reis. Eén die je niet alleen aflegt. 
Bij de eerste stappen wordt je koers vaak voor je bepaald. Iemand pakt je hand en 
zet je op het pad: “Kijk, daar is je doel”. En inderdaad, daar is het. Helder zichtbaar, 
goed afgetekend tegen de horizon, je kan het bijna aanraken. Maar de tijd en het 
leven oefenen onherroepelijk hun invloed uit. Het doel flikkert, je twijfelt. Fata 
Morgana? Het pad kronkelt en slingert, vertakt. Wordt beïnvloed door bagage, 
wandelstok, weer, gezelschap. En dan ben je waar ooit je doel lag en weet je: je moet 
nog een stukje verder. Misschien maar goed ook. Voor de mensen die me gezelschap 
hielden en houden op deze reis: jullie hebben de reis verlicht, het avontuur vergroot 
en me gebracht tot waar ik nu ben. En we zijn er nog niet, reis je nog wat langer mee?
[TL;DR] (Voor de mensen die het dankwoord wat lang vinden): dank je wel en sorry 
als ik je vergeten ben!
In 2019 zat ik in de aula, terwijl Harm Ebben - met wie ik meerdere van mijn 
onderzoeken verrichtte - zijn proefschrift verdedigde. Na de verdediging en 
het verkrijgen van de graad van doctor, richtte zijn promotor, professor Willem 
Wisselink, het woord tot hem: ‘Beste Harm, het valt me op dat je in je dankwoord 
een essentiële groep bent vergeten!’ Harms blik hield ergens het midden tussen 
beduusdheid en ongerustheid. Op wie kon de professor doelen? ‘Je besteedt geen 
enkele aandacht aan de roze wezentjes die jouw onderzoek mogelijk hebben 
gemaakt!’ Ik wist meteen, deze vergissing zal ik niet begaan. Dus Willem, slechts 
een tweede plek voor jou in dit dankwoord. Want die roze viervoeters, die waren 
er ook voor mij.
Mooie, warme, roze dames, onze pink ladies. Jullie hebben al slapend dit onderzoek 
en alles wat daar nog uit zal voortkomen mogelijk gemaakt. Na een klein prikje 
werden jullie suf en kregen jullie gelukkig niets meer mee van alles. En toch. ‘I 
dub thee spiderpig’, schreef een student in hanepoterige letters op 1 van onze 
onderzoekspapieren. Ook ik zag persoonlijkheid en karakter in jullie, nieuwsgierige 
knorders. Het voelt gek om iemand te bedanken die geen keuze had. Toch ben 
ik dankbaar dat jullie er waren. Ik hoop dat we de kennis waar jullie aan hebben 
bijgedragen binnenkort kunnen toepassen in de kliniek en daarmee het leed voor 
onze patiënten zullen verminderen. En voor jullie wens ik veel modderpoeltjes in 
knorretjeshemel.
Prof dr Wisselink, beste Willem. Als de dag van gister herinner ik mij het telefoontje 
dat ik kreeg, waarop ik de hele dag had liggen wachten. Het was 8 uur ’s avonds en 
ik was me klaar aan het maken voor een van mijn laatste nachtdiensten als AIOS 
in het VUmc. Vol spanning nam ik je telefoontje aan: Ik had de plek als CHIVO! 
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Blijer kon je me niet maken. In die periode werden ook mijn eerste schreden op 
het gebied van deze promotie gezet. Het duurde even voor ik een onderwerp had 
en het boekje heeft daarna ook een tijdje op zich laten wachten. Dank voor het 
vertrouwen dat je altijd in me hebt getoond. Dank ook voor het grote voorbeeld dat 
je door de jaren heen steeds voor me bent geweest: als bijzonder kundig chirurg en 
bevlogen dokter, als relativerende wetenschapper en als warm mens. Ik hoop dat 
we nog veel samen zullen opereren het komend jaar en dat ik ook na je aankomend 
pensioen nog veel van je mag blijven leren. Dank dat je mijn promotor wilde zijn en 
me wilde begeleiden gedurende dit traject.
Dr Kak Khee Yeung, lieve Kiki. Dank voor het niet aflatende enthousiasme dat 
jij als wetenschapper steeds weet uit te dragen. Je trekt hierin iedereen met je 
mee. Met je tomeloze energie, je positiviteit en je creativiteit heb je een essentieel 
aandeel aan dit boekje gehad. Bedankt dat je me (subtiel) bent blijven pushen. 
Ik heb je de afgelopen jaren zien uitgroeien van een jonge enthousiaste student, 
naar een prachtige, slimme, invoelende vrouw. Iemand die weet wat ze wil en zich 
niet meer zo makkelijk uit evenwicht laat brengen door haar omgeving. Steeds 
weer bewonder ik hoeveel ballen jij tegelijk omhoog kunt houden en de kwaliteit 
waarmee je dat doet. Ik ben benieuwd waar het leven jou gaat brengen en hoop 
nog heel lang mee te mogen genieten van jou en je interessante levenspad.
Dr René Musters, beste René. Het is al weer een paar jaar geleden dat we begonnen 
met de eerste studies uit dit proefschrift. Ik heb vooral goede herinneringen aan 
de overleggen van tevoren en jouw rustige en nuchtere inbreng hierbij. Ook je 
ondersteuning van Kak Khee en mij in die tijd was van groot belang voor het slagen 
van de studies en is essentieel geweest voor het werk dat ik hier vandaag verdedig. 
Bij de operaties in het lab kwam je regelmatig even kijken, even zien wat we allemaal 
aan het uithalen waren en waar je apparatuur voor werd gebruikt. Beste René, 
dank voor je ondersteuning door de jaren heen, maar vooral ook in die beginfase!
Lieve Nienke, we zijn al meer dan 15 jaar vriendinnen. Af en toe ruzie ik met Pauli 
over wie zijn vrienden erft, mochten we ooit uit elkaar gaan. Dan komen we steeds 
tot de conclusie dat we nog maar even samen moeten blijven :) We hebben verdriet 
gedeeld de afgelopen jaren, maar gelukkig vooral ook veel feestjes. Je bent een 
gevoelsmens, met een helder verstand en een sterk analyserend vermogen. Het 
kan dan ook niet anders dan dat je super goed bent in het werk dat je nu doet als 
coach. Ik leer elke keer weer van je inzichten en geniet van die momenten dat we de 
diepte in kunnen duiken onder het genot van een goed glas wijn. Ik ben ontzettend 
blij dat jij in mijn leven bent en dat jij vandaag naast me staat. En vanavond drinken 




Lieve Barbara, Barbs. Wat een raar spelletje op de telefoon al niet teweeg kan 
brengen! We kennen elkaar nu 6 jaar, maar wat hebben we veel meegemaakt in 
die tijd. De vele ops in en rondom Amsterdam, de beergresses en de banners in 
andere steden, de anomalies en natuurlijk samen een anomaly organiseren. Ook 
dat laatste is onze vriendschap zonder enige kleerscheur doorheen gekomen, dat 
zegt wel wat. Datzelfde geldt overigens voor samen naar Burning Man gaan. Bizar 
hoe goed dat ook ging. Ik ben dankbaar dat jij mijn, ons leven verrijkt. En met ‘ons’ 
bedoel ik uiteraard niet alleen Paul en mezelf, maar ook onze 3 pluizige huisgenoten.
Geachte leden van de promotiecommissie, beste prof. dr. M.R. Meijerink, prof. dr. 
C.J.A.M. Zeebregts, prof. dr. D.A. Legemate, prof.dr. J.F. Hamming, dr. C.S.P. van 
Rijswijk, dr. P.J. van den Akker en dr. A.M. Wiersema. Hartelijk dank voor het lezen 
van dit werk. Tijd is voor ons allen een kostbaar goed. Dank dat u een deel daarvan 
hebt willen besteden aan het inhoudelijk beoordelen van dit manuscript. Dank ook 
voor uw kritische toetsing, die dit werk in perspectief heeft weten plaatsen. Een 
paar leden van de promotiecommissie hebben me een stukje van de reis vergezeld: 
Prof. dr. Meijerink, Martijn, wie had jaren geleden tijdens de borrels in Vak Zuid ooit 
gedacht dat we nu hier zouden staan? Of toen je zelf opgenomen lag en een patiënt 
naast jou over mij hoorde klagen? Ik vind het prachtig dat we beiden zijn gekomen 
waar we zijn en nog altijd met enige regelmaat samen werken. Dr Wiersema, 
Arno, je was 1 van mijn eerste opleiders binnen de chirurgie. Van jou leerde ik 
dat opereren altijd leuker is dan niet opereren. En ook ‘the only way to heal is cold 
steal’. Was ‘where there is a bobble, there should be a hobble’ nou ook van jou? Wat 
bijzonder dat je er vandaag bij bent! Dr van den Akker, Peter, Akkie. Onder jouw 
bezielende vleugels (en die van Robin Hulsebos en Rob Meijer), vond ik de weg 
naar de vaatchirurgie. Opleiden vond jij geen enkel probleem: ‘jullie houden dan 
wel het mes vast, maar ik beweeg de tafel onder jullie’. Je was altijd een begenadigd 
chirurg en ook een heerlijke partner op de dansvloer tijdens de chirurgendagen. 
Wat een eer dat je er bij bent vandaag. Prof. dr. Legemate, Dink, ik ben blij dat ik in 
de laatste jaren van je carrière bij het AUMC nog met je heb mogen samenwerken. 
Ik heb je leren kennen als een integer mens met een wetenschappelijke visie op de 
patiëntenzorg, zonder daarbij het hart uit het oog te verliezen. Stuur je ons af en 
toe foto’s van je mooie zeilreis, als die eindelijk doorgang kan vinden?
Beste collegae met wie ik de vele uren van onderzoek gedeeld heb: prof. dr. Geert-
Jan Tangelder, dr. Harm Ebben, dr. Jeroen Slikkerveer, dr. Menno Groeneveld, 
Klaas Meyer, Paul Sinnige, dr. Sebastiaan Roos, veel verschillende ‘studenten 
van Kakkhee’: dank voor de koffie, het vasthouden van de haken, het geduld, de 
lunches, de administratie, de wetenschappelijke input en vooral voor de humor en 
gezelligheid. @Harm, met jou heb ik nog de meeste uren van onderzoek gedeeld 
en steeds met veel plezier. Dank voor je inzet en enthousiasme, ik kijk er naar uit 
ook in de kliniek met je te gaan samenwerken.
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Beste vaatcollegae van voormalig VUmc, lieve Jan, Arjan en Vincent (en natuurlijk 
ook Kakkhee en Willem). Dank voor de collegialiteit waarmee we al jaren zo fijn 
samenwerken. Ik heb bewondering voor hoe goed jullie zijn in dit vak dat we met 
elkaar delen en ben blij dat ik dagelijks met jullie mag sparren, dat ik weet dat ik 
altijd kan bellen als er iets is en dat jullie er voor me zijn als iets niet goed gaat of is 
gegaan. Hoks, je heldere, nuchtere klinische blik en je rotsvaste vertrouwen in jezelf 
zijn heerlijk om af en toe tegen aan te leunen. Maar het meest waardeer ik je zachte 
kant, die je maakt tot de fantastische dokter die je bent. Jan, je tegendraadse, bijna 
wiskundige blik zorgt regelmatig voor een compleet origineel perspectief op een 
dilemma. Je bent een warm mens met een gezonde dosis humor en ik ben blij dat we 
nog een paar jaar samen mogen werken. Vincent, je jonge-honden-enthousiasme 
van alles met beide handen aangrijpen en je eigenschap je vooral niet te druk te 
maken over dingen zijn inspirerend en vaak een goed voorbeeld voor me. Ik ben 
blij dat je de overstap naar ons hebt gemaakt, je versterkt ons team als geen ander 
zou kunnen.
Beste vaatcollegae van voormalig AMC, lieve Dink, Laurens, Mare, Mark, Martine, 
Mirza en Ron. De fusie van onze 2 ziekenhuizen zorgt voor woelige tijden voor ons 
allemaal. Dat het samensmelten van onze 2 afdelingen een wereldwijde pandemie 
zou veroorzaken kon natuurlijk niemand bevroeden. (Of zie ik nu verbanden die 
er niet zijn?) Ondanks het gebrek aan teambuilding door Corona en ondanks alle 
logistieke frustraties, ondanks dat de lateralisatie met gesloten beurs moest en 
we zelf onze eigen faciliteiten moeten financieren, ondanks alles wat tegen zat, 
hebben jullie ruimte voor ons gemaakt en ons warm en persoonlijk ontvangen. 
Dank hiervoor! Jullie geven mij vertrouwen in de toekomst. Samen zullen we 
weer groeien in waar we goed in zijn en waar we blij van worden: patiëntenzorg, 
onderwijs, onderzoek en innovatie.
Sommige mensen zijn essentieel om een bedrijf te runnen, maar staan tegelijk 
vaak in de schaduw. Zij zijn de olie in onze machine, de trapondersteuning bij 
tegenwind, de google maps als je verdwaald raakt in de jungle die ziekenhuis heet. 
Lieve ondersteunende collegae van de stafgang heelkunde: Laura, Karin, Ilse, 
Wendy, Els K., Els J., Femke, Yvonne, Ron de H. en alle dames en heren die ik nu 
- schandaliger wijze- mogelijk vergeet: dit bedrijf zou niet zonder jullie kunnen en 
ik ook niet! Dank voor jullie steun door de jaren heen, voor het wegvangen van 
vragen, het beantwoorden van brieven, het regelen van computers en sleutels en 
toegang tot systemen, het beheren van agenda’s, het achter de broek zitten waar 
nodig, het (op verzoek) niet meer opruimen van mijn bureau, het niet aflatende 
enthousiasme voor onderwijs, het altijd mee willen denken. Dank ook voor de 
lunches samen, het heelkundefeest + de voorpret daarvan, de borrels als jullie 




reageert, ik hoop voor jou dat je ooit nog eens op vakantie gaat zonder toegang 
tot email en navenante werkzaken. Je bent een topper! ;-*
Lieve Twan (en Nienke), Pien, Sieb, Jelle, Sander, Suus†, Sílvia, Tim, Ella, Aïna, 
Caspar en Hellen, lieve vrienden, bedankt voor alle prachtige momenten die 
we samen hebben gedeeld de afgelopen jaren. De etentjes, de weekendjes weg, 
de alcohol, geboortes, het alcoholvrije bier, verjaardagen, voetbal, ontelbare 
barbecues, verhuizingen, vakanties, boottochtjes, taartjes, werken in de tuin. 
Bedankt ook voor de verdrietige momenten die we samen deelden, waardoor het 
allemaal net wat lichter was. Zonder jullie was het leven een stuk minder rijk en 
kleurig en ook een stuk minder geborgen.
Lieve Wilma, Jan Fredrik, Jochem, Inge, Tasja, Frits-Jan, Floris, mijn vrienden uit 
de studietijd. Goede herinneringen aan lang vervlogen tijden. De introductieweek. 
Mentorschap. (Ik zie helemaal geen krokodil). Bierproefavonden, spelletjes (het vals 
spelen van Wilma), vakanties (Aus Triër im Polen), practica, met smerige koffie in de 
hand doorstuderen tot ’s avonds laat voor tentamens, de biertjes na de tentamens, 
de kroeg in het hoofdgebouw, Captain Jack en Dr Dick, gala’s met of zonder blind 
date, de Riks, de Falafelkoning, sneak preview in Kriterion, Ceintuurbaan 175 (arme 
Abel). We waren Dead Poets Society. Captain, my Captain. We zien elkaar weinig. 
Te weinig. Maar die studietijd hebben jullie zo mooi gemaakt en dat raak ik nooit 
meer kwijt. Dank voor die prachtige jaren! Ik hoop dat we elkaar in komende jaren 
vaker zullen zien, nu we wat meer zijn waar we wilden komen. Dat onze paden ons 
weer naar elkaar toe zullen leiden en er nog vele mooie herinneringen bij zullen 
komen.
Voor mijn schoonfamilie, lieve Wim en Marjan†, Erik, Vroni en Mijntje. Dank dat 
jullie Paul zo goed hebben groot gebracht. Dank voor het weekendje in de Moezel, 
waar ik nog altijd super goede herinneringen aan heb. Dank ook voor de vele malen 
dat we bij jullie, Wim, mochten overnachten en samen konden genieten van de 
Venlose Vastelaovend. Marjan, dank voor je gulle lach en je warme liefde. Dank 
allen voor de vele gezellige momenten en ik hoop dat er ook nog velen zullen volgen! 
En Mijntje, lieve slimme meid, wanneer kom je weer eens logeren?
Voor mijn familie. Mijn lieve, bescheiden ouders. Papsie, ruwe bolster, blanke pit. 
Van jou heb ik nuchterheid en handige handen. Mamsie, empathische stille leider, 
avonturier. Van jou heb ik liefde voor dansen en muziek. Wat kan ik meer zeggen 
dan dat ik heel veel van jullie hou en super trots ben dat jullie mijn ouders zijn? Ik 
ben jullie diep dankbaar voor de prachtige jeugd die jullie mij, Frank en Margreet, 
hebben gegeven. Jullie waren (en zijn) er altijd voor ons, zowel met liefde, steun, 
wijze raad en praktische hulp, als met de regels die kinderen ook nodig hebben. De 
uithoeken van de aarde waar we samen zijn geweest hebben mijn blik op de wereld 
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en op onze samenleving verruimd. Ook daar ben ik heel dankbaar voor. Ik hoop 
dat ik nog jaren van jullie mag genieten en dat we nog heel veel mooie avonturen 
samen mogen meemaken. Lief zussie, je bent allang niet meer alleen mijn kleine 
zusje. Je bent een prachtige, intelligente, volwassen vrouw die de wereld heeft 
gezien en waar ik elke keer weer van leer. We kunnen samen lachen en huilen. We 
mopperen graag over het leven, filosoferen over zingeving en delen passies zoals 
voor koken. Je onderschat jezelf chronisch, maar ik doe dat zeker niet. Ook op jou 
ben ik uiteraard apetrots! Je smaak in mannen is nog iets wat ik in je waardeer, want 
een fijnere, slimmere, humoristischere, relativerendere, lievere zwager had ik me 
niet voor kunnen stellen. Lieve Gerard, je bent een aanwinst voor onze familie! 
Zeker meer dan een bitterbal ;-) Het is dan ook geen wonder dat jullie samen 3 zulke 
briljante kinderen hebben weten te produceren. Lieve Rafael, Camiel, Fedor, wat 
een lieve, interessante, mooie mensen zijn jullie. Wat fijn dat jullie later mijn billen 
zullen wassen, als ik oud en dement ben (hahaha). Voor mijn grote broer, zo maar 
wat dingen die in me opkomen. Hee broertje, wat jammer dat je er niet bij kon zijn. 
Maar ja, die gedachte heb ik al zo vaak gehad. En ook…nu zal je me wel helemaal 
een studiebol vinden he? Als we vanavond goed uit eten gaan, denk ik aan je. Zoals 
altijd, bij elk goed restaurant waar we eten. En soms, heel soms, lik ik ter ere van 
jou mijn bord af. Misschien vanavond ook wel. Dag broertje, ik hoop dat het je goed 
gaat, waar je dan ook bent.
Pauli
….
Jungske leef, nôw luuster,
zag ik in d’n duuster,
de kins mich dao aan haIde wat ik nôw verklaor:
as mich is gegaeve
dén te meuge laeve,
zal ik nog van dich halde euver vieftig jaor.
..*
Het zijn ‘golde jaore’ en ik ben intens dankbaar dat jij er bent. Jij staat in het centrum 
van alles, alle paden leiden naar jou: kompas, tegenwicht, steunpilaar, warmte, 
geluk. Wat hebben we veel meegemaakt samen en wat hoop ik dat we nog heel 
lang heel veel mee zullen maken samen. We worden 115 en sterven tegelijk doordat 
er een koe op onze hoofden valt. (De koe loopt natuurlijk ongedeerd weg.) Hald 
mich nog maar efkes vas en luets mich pas as ik alles vergaete bin los, dan doon ik 
dat auk mit dich.
* Wengske aan wengske, De Vrijbuiters, 1980
12
…
Straks aan d’n euverkant van de nach dao wach de veurjaorszôn.
Achter de nach dao wach op os de zon.
Frans Pollux, 2013
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